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Abstract 
Background:  The neonatal mammalian heart has a transient capacity for regeneration, which is 
lost shortly after birth. A series of critical developmental transitions including a switch from 
hyperplastic to hypertrophic growth occur during this postnatal regenerative window, preparing the 
heart for the increased contractile demands of postnatal life. Postnatal cardiomyocyte maturation 
and loss of regenerative capacity are associated with expression alterations of thousands of genes 
embedded within tightly controlled transcriptional networks, which remain poorly understood. 
Interestingly, although mitogenic stimulation of neonatal cardiomyocytes results in proliferation, 
the same stimuli induce hypertrophy in adult cardiomyocytes by activating different transcriptional 
pathways, indicating that cardiomyocyte maturation may result from epigenetic modifications 
during development. Notably, DNA methylation and chromatin compaction are both important 
epigenetic modifications associated with a decrease in transcription factor (TF) accessibility to 
DNA. However, the role of both DNA methylation and chromatin compaction during postnatal 
cardiac maturation remain largely unknown.  
Hypothesis: Postnatal changes in DNA methylation and chromatin compaction silence 
transcriptional networks required for cardiomyocyte proliferation during postnatal heart 
development.  
Aims:  This PhD Thesis focuses on characterising the role of DNA methylation and chromatin 
dynamics during postnatal cardiac development and maturation using in vitro and in vivo model 
systems. Three major Aims are addressed: 
 Aim 1: To characterize transcription and DNA methylation dynamics during postnatal 
rodent cardiac development (Chapter 3). 
 Aim 2: To determine the role of DNA methylation in regulating the expression of cell cycle 
related genes in mouse and human cardiomyocytes (Chapter 4). 
 Aim 3: To understand the relationship between chromatin accessibility and transcription 
during mouse and human cardiomyocyte development (Chapter 5). 
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Results: In Aim 1, global DNA methylation changes were characterized during postnatal 
development. Marked changes in the expression levels of key DNA methylation enzymes were 
observed during the first month of postnatal heart development. Postnatal inhibition of DNA 
methylation using 5-aza-2’-deoxycytidine (5aza-dC; 1mg/kg/day) reduced global DNA methylation 
levels in the heart in vivo and was associated with a marked increase in cardiomyocyte proliferation 
(~3-fold) and ~50% reduction in binucleated cardiomyocytes compared to saline-treated controls, 
suggesting DNA methylation is required for postnatal cardiomyocyte cell cycle arrest. Next-
generation mRNA sequencing (RNA-seq) and genome-wide sequencing of methylated DNA 
(methyl-CpG binding domain enrichment and sequencing (MBD-seq)) identified dynamic changes 
in the cardiac methylome during postnatal development (2545 differentially methylated regions 
(DMRs) from postnatal day (P) 1 to P14 in the mouse). ~80% of DMRs were hypermethylated and 
these DMRs were associated with transcriptional shut down of important developmental signalling 
pathways.  
In Aim 2, a specific subset of cell cycle genes displaying differentially regulated gene expression 
and DNA methylation patterns were profiled to understand how DNA methylation is involved in 
regulating cardiomyocyte proliferation. Gene expression profiling of these cell cycle genes during 
development and following 5aza-dC treatment in mouse hearts, as well as 3D human cardiac 
organoids (hCOs), verified that DNA methylation was required for transcriptional regulation of a 
small group of cell cycle genes. Interestingly, 5aza-dC (10µM) also induced ~2-fold increase in 
cardiomyocyte proliferation in hCOs. These findings suggest that DNA methylation has a direct 
role in the regulation of a subset of genes required for cardiomyocyte proliferation in both mice and 
humans. 
Chromatin accessibility results from the integrated action of multiple epigenetic marks. In Aim 3, 
cardiomyocyte nuclei were isolated from both human and mouse developmental heart samples for 
RNA-seq and for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) 
to profile changes in transcription and chromatin accessibility during cardiomyocyte development 
in mice (P1 to P56) and humans (foetal (14-19 weeks (wks)), 0-10 years (yrs), 10-30 yrs and 30+ 
yrs). RNA-seq confirmed that cardiomyocyte cell cycle arrest occurs between P1 and P14 in the 
mouse. Moreover, ATAC-seq identified open chromatin signatures at various genomic features, 
including CG islands, transcription start sites (TSSs), enhancers, TF binding sites and protein 
coding regions, while intergenic regions were associated with compact chromatin. Integration of 
RNA-seq and ATAC-seq data demonstrated a strong correlation between transcription and 
chromatin accessibility at the different stages of cardiomyocyte development. TF motif analysis 
 
iii 
identified E2F transcription factor 4 (E2f4) and Forkhead box M1 (Foxm1) sites as being 
transcriptionally repressed and undergoing chromatin compaction from P1 to P56. E2f4 and Foxm1 
are well known TFs that regulate cell cycle, thus suggesting that cell cycle genes are epigenetically 
silenced during cardiomyocyte maturation.  
Conclusion:  This PhD Thesis provides novel evidence for widespread alterations in DNA 
methylation during postnatal heart maturation and suggests that cardiomyocyte cell cycle arrest 
during the neonatal period is subject to regulation by DNA methylation and chromatin compaction. 
Together, this PhD Thesis provides new insights into the role of DNA methylation and chromatin 
dynamics during cardiac development. This Thesis provides a new framework for the epigenetic 
regulation of transcription during postnatal cardiomyocyte maturation and points towards an 
epigenetic mechanism for cardiomyocyte terminal differentiation during the neonatal period. 
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Chapter 1. A Review of the Literature 
In contrast to adults, recent evidence suggests that neonatal mice are able to regenerate following 
cardiac injury. This regenerative capacity is reliant on robust induction of cardiomyocyte 
proliferation, which is required for faithful regeneration of the heart following injury. However, 
cardiac regenerative potential is lost as cardiomyocytes mature and permanently withdraw from the 
cell cycle shortly after birth. Recently, a handful of factors responsible for the regenerative disparity 
between the adult and neonatal heart have been identified, but the proliferative response of adult 
cardiomyocytes following modulation of these factors rarely reaches neonatal levels. The inefficient 
re-induction of proliferation in adult cardiomyocytes may be due to the epigenetic landscape, which 
drastically changes during cardiac development and maturation. This review provides an overview 
of heart development, maturation and the role of epigenetic modifiers in developmental processes 
related to cardiac regeneration. An epigenetic framework is proposed for heart regeneration 
whereby adult cardiomyocyte identity requires resetting to a neonatal-like state to facilitate cell 
cycle re-entry and regeneration following cardiac injury. 
1.1. Cardiac diseases and the need for regeneration therapy 
More than 15 million people die from cardiovascular disease (CVD) each year, which contributes to 
30% of the overall mortality rate and is anticipated to grow to more than 23 million by 2030 
(Mathers and Loncar, 2006; World Health Organization., 2011). Among all CVD cases each year, 
more than half are attributed to coronary heart disease (CHD), also known as ischemic heart disease. 
CHD is one of the most important causes of coronary events, such as acute myocardial infarction 
(MI, also known as heart attack). MI is caused by insufficient blood flow to the heart, which can 
lead to up to 25% loss of cardiomyocytes within a few hours (Laflamme and Murry, 2011). After 
suffering from MI and massive cell death, the heart, as a post-mitotic organ, instead of repairing and 
regenerating the impaired tissue, forms a fibrotic scar with no contractile ability at the site of injury. 
Although a scar might be a sufficient temporary fix, the lack of regenerative capacity causes the 
surviving cardiomyocytes to become hypertrophic in order to compensate for the loss of functional 
cardiomyocytes. This process may lead to contractile dysfunction, arrhythmia and often culminates 
in heart failure or sudden cardiac death (Olson, 2004). Therefore, there is a need for regenerative 
therapies for ischemic heart disease. This section will focus on introducing the therapeutic 
approaches that are currently used in the clinic, as well as current research efforts towards the 
development of regenerative therapeutics for heart disease (Figure 1.1). 
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1.1.1. Current clinical therapeutic approaches 
The current clinical therapeutic approaches for patients suffering a heart attack include 
pharmacological treatments, medical procedures or mechanical support devices (Canseco et al., 
2015; Gerbin and Murry, 2015; Olson, 2004). Pharmacological treatments such as statins, ACE 
inhibitors and beta blockers reduce blood pressure and hypertrophic signalling (Canseco et al., 2015; 
Gerbin and Murry, 2015; Olson, 2004). Medical procedures, such as percutaneous coronary 
intervention and coronary artery bypass grafting can restore perfusion to the heart to improve 
cardiac function (Canseco et al., 2015; Gerbin and Murry, 2015; Olson, 2004). Mechanical support 
with left ventricular assist devices (LVAD) mechanically assists the failing left ventricle (Canseco 
et al., 2015; Gerbin and Murry, 2015; Olson, 2004). However, none of these treatments target the 
underlying problem, which is the loss of contractile units – cardiomyocytes. Therefore, these 
treatments cannot prevent the progression to end stage heart failure in many patients for which the 
only treatment option is heart transplantation (Tousoulis et al., 2008). With the scarcity of 
histocompatible donors for heart transplantation, the restoration of functional cardiomyocytes 
following injury through regeneration of cardiomyocytes remains a central goal in cardiology. 
1.1.2. Cell therapy 
Given the limitation of current clinical therapeutic tactics, various approaches to improve heart 
function have been investigated over the decades. This includes gene therapy, direct cell 
reprogramming, cell therapy and delivery of engineered tissues (Figure 1.1). As the adult heart is a 
post-mitotic organ and lacks robust regenerative capacity, cell therapies have become one of the 
most popular methods for induction of tissue regeneration. A considerable amount of mammalian 
cardiac regenerative and cell transplantation processes have been illuminated by the work of 
developmental biologists, stem cell biologists and cardiologists over the past decade (Choi and Poss, 
2012; Gerbin and Murry, 2015; Xin et al., 2013b). Several cell types including cardiac progenitor 
cells (CPCs), cardiac stem cells (CSCs), embryonic stem cells (ESCs), skeletal myoblasts (SMs) 
and bone marrow cells (BMCs) have been used in transplantation studies for their potential 
myocardial regenerative ability (Choi and Poss, 2012; Gerbin and Murry, 2015; Mazhari and Hare, 
2007; Tousoulis et al., 2008). Current approaches for cell therapy will be discussed in this section. 
Non-cardiac cells Non-cardiac cells such as SMs and BMCs were the initial objects of interest 
for cardiac cell therapy studies. SMs were one of the earliest choices for cardiac cell therapy studies. 
While SMs were shown to improve ventricular function post-MI, the mechanism remains unclear 
(Hagege et al., 2003; Leobon et al., 2003; Seidel et al., 2009). Moreover, subsequent Phase I 
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clinical trials of SMs in humans failed on efficacy and were also associated with increased risk of 
cardiac arrhythmias (Menasche et al., 2008), which subsequently refocused efforts in the field on 
alternative approaches and other cell types (Garbern and Lee, 2013). 
Some of the earliest studies of BMCs were performed by transplanting green fluorescent protein-
labelled BMCs into the border region of the infarcted heart (Orlic et al., 2001). Up to 50% of the 
newly formed myocardium was green fluorescent protein (GFP) labelled, suggesting a 
transdifferentiation of transplanted BMCs into cardiomyocytes that facilitated functional 
regeneration of the rodent heart after MI. However, subsequent studies using cardiac-specific 
reporters to track the fate of transplanted BMCs contradicted the theory of transdifferentiation, 
despite the ability of BMCs to exert some functional benefits even though transplanted cells died 
after 1-2 weeks (Murry et al., 2004). Intriguingly, several related lineage tracing studies also 
showed that the injection of bone marrow derived cells promoted endogenous cardiomyocyte 
proliferation following injury, suggesting that functional improvements occur through beneficial 
paracrine effects (Garbern and Lee, 2013; Hatzistergos et al., 2010; Mirotsou et al., 2007). Also, 
while two clinical trials BOOST and REPAIR-AMI showed that injection of BMCs promotes 
cardiac function of patients presenting with ST-segment elevation MI, subsequent larger and more 
well-controlled double-blinded clinical trials such as FOCUS-CCTRN, TIME and LateTIME did 
not replicate the encouraging results from previous clinical trials, further questioning the efficacy of 
BMCs (Assmus et al., 2002; Leistner et al., 2011; Perin et al., 2012; Schachinger et al., 2004; 
Schachinger et al., 2006a; Schachinger et al., 2006b; Traverse et al., 2012; Traverse et al., 2010; 
Wollert et al., 2004).  
CPCs and CSCs Several methodologies have been used to identify resident cardiac stem cell 
populations in the adult heart, and the expression of specific cell surface markers is one of the most 
popular methods. Through well-developed stem cell studies, several cell surface expression markers 
have been characterized such as c-kit, Sca1 and Abcg2 and, also, TFs such as Nkx2.5, Gata4, Islet1 
and Wt1 which have been used to identify CPCs and stem cells from different developmental stages 
(embryonic, neonatal and adult) (Arceci et al., 1993; Beltrami et al., 2003; Laflamme et al., 2007; 
Laugwitz et al., 2008; Martin et al., 2004; Oh et al., 2003; Zhou et al., 2008). A more recent study 
identified adult cardiac-resident colony-forming units – fibroblasts (CFU-Fs) stem-like populations 
that are essential for cardiac development throughout adulthood (Chong et al., 2011). These 
identified progenitor cell populations exist during different developmental time frames, in low 
abundance and are capable of differentiating into cardiomyocytes, smooth muscle cells or 
endothelial cells when cultured in vitro.  
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c-kit positive cells are one of the most intensively studied and controversial cardiac progenitor cell 
populations. A recent study by Ellison et al stated that c-kit
+
 cells regenerated lost cardiomyocytes 
in an acute cardiac failure model (Ellison et al., 2013). By using transgenic ablation of c-kit
+
 cells, 
regenerative capacity and functional repair of the rodent heart was eradicated. Importantly, the c-
kit
+
 cells were also sufficient to restore the regenerative potential of the heart. Also, previous 
studies reported that isolated human c-kit
+
 cardiac cells formed functional myocardium in vivo and 
facilitated the recovery of infarcted rodent hearts when injected into the injured area (Bearzi et al., 
2007). Conversely, Tallini et al discovered that c-kit
+
 cardiac cells did not contribute to cardiac 
myogenesis in the injured adult heart (Tallini et al., 2009). Also, Li et al showed that c-kit functions 
during cardiomyocyte terminal differentiation and is not an exclusive stem cell marker (Li et al., 
2008). Furthermore, Kubin et al demonstrated that the inflammatory cytokine oncostatin M (OSM) 
induced the re-expression of c-kit in de-differentiating cardiomyocytes, challenging the credibility 
c-Kit as cardiac progenitor marker (Kubin et al., 2011; Li et al., 2008). This result is further 
supported by two quantitative genetic fate-mapping studies, which indicate that c-kit
+ 
cells are not 
functionally critical for cardiogenesis and do not provide a meaningful contribution to 
cardiomyocyte formation during development or following MI (Sultana et al., 2015; van Berlo et al., 
2014).  
Despite the abovementioned controversial results on the identity of CPCs, two recent clinical trials, 
SCIPIO and CADUCEUS, have nevertheless shown that injection of CSCs into patients post 
infarction enhanced cardiac function and reduced infarct size, but the cellular mechanisms for these 
benefits are still unclear (Bolli et al., 2011; Makkar et al., 2012). Taken together, although a number 
of cardiac stem cell populations have been identified in the adult heart, these controversial research 
outcomes have clouded the future clinical use of adult progenitor cells for cardiac regeneration. 
ESCs and induced pluripotent stem cells (iPSCs) The first successful case of differentiation of 
human ESCs (hESCs) into cardiomyocytes was achieved in 2001 (Kehat et al., 2001). Since then, 
more defined protocols have been optimized to obtain more mature differentiated cardiomyocytes 
(Laflamme et al., 2007). It has been shown that the engraftment of hESCs derived cardiomyocytes 
enhanced cardiac function in the infarcted rat heart (Laflamme et al., 2007). Shiba et al also showed 
an electrical coupling of injected hESC derived cardiomyocytes in the infarcted guinea-pig heart 
with a reduction in cardiac arrhythmias (Shiba et al., 2012; Shiba et al., 2014). A more recent study 
by Chong et al exhibited that injection of 1 billion hESC derived cardiomyocytes to the infarcted 
myocardial wall of macaque monkeys (Macaca nemestrina - non-human primate) led to 
remuscularization and electrical coupling of myocardial tissue in the infarcted region (Chong et al., 
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2014). However, non-fatal arrhythmias were observed in this non-human primate cardiac injury 
model, which was not previously observed in small rodent models, demonstrating a potential 
biological difference between small and large animal models (Table 1.1). As many previous studies 
were conducted using small animal models, further studies in large animal models, in particular 
large animals that have similar heart rates to humans, such as pigs, sheep and primates, may be 
necessary to understand the function, efficacy and safety of these hESC or iPSC derived 
cardiomyocytes before clinical application.  
Collectively, ESC therapies for heart disease have shown enormous promise and future potential. 
However, major challenges remain as the use of human ESCs is still controversial and there is a 
need for immunosuppression. The different biological effects and safety concerns in primate models 
will need to be resolved prior to clinical translation. On the other hand, iPSCs overcome many of 
the moral and immunosuppression predicaments of human ESCs. Zhang et al have successfully 
differentiated nodal-, atrial-, and ventricular-like cardiomyocytes from human iPSCs (hiPSCs) 
(Zhang et al., 2009). Moreover, recent studies have demonstrated that hiPSCs can differentiate into 
cardiomyocytes, engraft with the injured area and improve cardiac function when injected following 
MI in mice (Citro et al., 2014; Funakoshi et al., 2016). However, the methods for induced-
reprogramming are currently costly, lengthy and potentially carcinogenic, raising concerns 
regarding their potential use in this future therapeutic area (Gerbin and Murry, 2015).  
Engineered heart tissue Similar to previously discussed ESC or iPSC-derived cardiomyocytes, 
engineered cardiac tissues could be considered as a logical extension of the cell-based therapy 
approach. Instead of injecting ESC or iPSC-derived cardiomyocytes to the injured heart, researchers 
have generated 2D or 3D myocardial tissues for transplantation into the injured heart. The 
recapitulation of native tissue architecture using tissue-engineering strategies holds enormous 
promise for regenerative medicine applications including cardiac regeneration. 
In 1997, Eschenhagen and colleagues created the first successful engineered cardiac tissue by 
culturing neonatal rat cardiomyocytes in a collagen matrix (Eschenhagen et al., 1997). A 
subsequent study by Li et al transplanted engineered cardiac tissue generated from foetal rat 
ventricular cells and a gelatine mesh to the adult rat heart following cryoinjury. This study showed 
that the transplanted graft survived and maintained its function following surgery, suggesting a 
potential therapeutic capacity of engineered heart tissue (Li et al., 1999). A subsequent large-scale 
systematic study by Zimmermann et al further validated the engineered heart tissues and 
demonstrated that they were capable of improving cardiac function in a rat heart failure model 
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(Zimmermann et al., 2006). Numerous independent studies have subsequently supported these 
results and confirmed that transplantation of engineered heart tissue improves cardiac function 
following MI (Sekine et al., 2008; Stevens et al., 2009; Tulloch et al., 2011). Tissue engineering 
remains a research hotspot in cardiology with current research efforts focusing on the generation of 
3D human cardiac tissues using ESC or iPSC derived cardiomyocytes. 
Current limitations of cardiac tissue engineering include the high cost of tissue production, labour-
intensive protocols required for tissue production including multiple manual handling steps, limited 
size due to oxygen diffusion limitations, lack of tissue vascularisation, and time taken for 
mechanical and electrical coupling to host myocardium (Coulombe et al., 2014; Hirt et al., 2014). 
Numerous studies have been targeted at addressing these issues. More cost effective and efficient 
protocols for producing tissues are being developed (Hansen et al., 2010), and may help facilitate a 
reduction in cost and labour in the future. In addition, although blood vessels infiltrate the 
implanted tissues at 1 mm/day following implantation (Shimizu et al., 2006), this infiltration rate 
may not be sufficient for larger sized patches and is associated with some necrosis (Shimizu et al., 
2006). In order to address this problem, blood vessels may be pre-formed in the tissues which link 
to the host vasculature and become perfused (Hirt et al., 2014; Tulloch and Murry, 2013). Electro-
mechanical coupling also remains a major concern due to the potential induction of arrhythmias 
prior to coupling, however, over time the tissues do become coupled (Riegler et al., 2015). 
Therefore, strategies that can enhance this process may overcome the issue in the future. 
Overall, while cell therapies hold enormous potential for cardiac regenerative applications in the 
clinic, many limitations still need to be resolved. These include the delivery of consistent research 
outcomes and demonstrations of efficacy, as well as reducing the cost of tissue production and 
immunological rejection of stem cells. Therefore, alternative approaches that bypass the use of cells 
are also a major focus of current research efforts in the field and these will be discussed in the next 
section.  
1.1.3. Cell-free therapy 
Given the limitations of cell therapy, various studies have been conducted to exclude the 
introduction of foreign cells and investigate the stimulation of endogenous regenerations. However, 
given that cardiomyocytes undergo rapid cell cycle shutdown shortly after birth, two of the major 
strategies under investigation for induction of endogenous regeneration are the re-induction of 
cardiomyocyte proliferation and direct reprogramming of resident non-cardiac cell types into 
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cardiomyocytes. This section will focus on the current trend of cell-free therapy and direct cell 
reprogramming research.  
Cell-free therapy As mentioned, cardiomyocytes exit cell cycle shortly postnatally. The roles 
of several cell cycle regulators and cellular signalling pathways have been investigated regarding 
their ability to induce cell cycle re-entry in cardiomyocyte during development and regeneration. 
Several studies have demonstrated that overexpression of core cell cycle regulatory proteins 
enhanced cardiomyocyte proliferation in vitro (Bicknell et al., 2004; Chaudhry et al., 2004; Di 
Stefano et al., 2011). Bicknell et al demonstrated that the overexpression of the developmentally 
regulated G2/M regulatory complex, cyclin (Ccn) B1- cell division cycle 2 kinase (Cdc2) promoted 
adult cardiomyocyte proliferation in vitro (Bicknell et al., 2004). Similarly, overexpression of 
Ccna2 promotes neonatal and adult cardiomyocyte proliferation in vitro (Chaudhry et al., 2004). 
Furthermore, in vitro inhibition of cyclin-dependent kinase (Cdk) inhibitors, p21, p27 and p57 
promotes adult cardiomyocyte proliferation (Di Stefano et al., 2011). However, the rates of 
cardiomyocyte proliferation observed in vivo are much lower. In 1997, Soonpaa et al showed that 
cardiac-specific overexpression of Ccnd1 increased DNA synthesis and caused multinucleation of 
adult cardiomyocytes in transgenic mice (Soonpaa et al., 1997). A subsequent study from the same 
group further showed that cardiomyocyte-specific overexpression of Ccnd2 but not Ccnd1 or Ccnd3 
promoted cardiomyocyte proliferation and reduced infarct size in the adult mouse heart following 
MI injury (Pasumarthi et al., 2005), suggesting that cell cycle activation through manipulation of 
the core cell cycle machinery could be used for cardiac regeneration. Moreover, overexpression of 
Ccna2 promotes cardiomyocyte mitosis and improves cardiac function in infracted adult rat and 
porcine hearts (Shapiro et al., 2014; Woo et al., 2006). The cell cycle TF, E2F2 has also been 
reported to increase cardiomyocyte proliferation in vivo via the promotion of cyclin A and cyclin E 
transcription (Ebelt et al., 2008). Sdek et al also exhibited that double knockout of retinoblastoma 
(Rb) and p130 re-activated the expression of cell cycle genes and promoted cardiomyocyte 
proliferation in adult hearts that underwent trans-aortic constriction injury (Sdek et al., 2011). 
Together, these studies demonstrate the important role of cell cycle genes in stimulating cell cycle 
re-entry of terminally differentiated cardiomyocytes.  
While direct modulation of cell cycle regulators has shown encouraging results with regard to 
stimulating adult cardiomyocyte proliferation, the effects remain modest. Also, many have used 
transgenic promoters to drive overexpression of pro-proliferative genes during development but 
these effects could be due to immature cardiomyocyte proliferation rather than adult myocyte cell 
cycle re-entry (Ahuja et al., 2007). Therefore, several signalling pathways have also been 
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investigated with regards to their ability to control cardiomyocyte proliferation during development 
and regeneration in adult zebrafish and rodents. An important signalling pathway that regulates 
zebrafish cardiomyocyte proliferation and regeneration is retinoic acid (RA) signalling (Kikuchi et 
al., 2011). Kikuchi et al observed a significant up-regulation of retinaldehyde dehydrogenase 2 
(raldh2, an enzyme required for RA synthesis) in the epicardium and endocardium following apical 
resection injury in zebrafish. Genetic inhibition of RA receptor (dn-zrar) or overexpression of RA-
degrading enzyme (Cyp26) decreased cardiac proliferation and regeneration of the heart (Kikuchi et 
al., 2011). Insulin-like growth factor (Igf) signalling, which is required for embryonic rodent heart 
development, also plays an important role in zebrafish regeneration capacity (Huang et al., 2013). 
Inhibition of Igf signalling through expression of a dominant negative form of the Igf1 receptor (dn-
Ig1r) or Igf1r inhibitor impaired cardiac proliferation and regeneration (Huang et al., 2013). In 
rodents, p38 mitogen activated protein kinase (Mapk) inhibitor therapy in the presence of Fgf1 
improved adult murine cardiac function after injury and was associated with a low rate of 
cardiomyocyte cell cycle re-entry (Engel et al., 2006). Furthermore, overexpression of tyrosine 
kinase receptor Erbb4 (receptor for the growth factor neuregulin 1 (Nrg1)) led to ~22.6%±8.5% 
bromodeoxyuridine positive (BrdU
+
, proliferation marker) mononucleated cardiomyocytes 
compared to ~7.2%±5.3% in control at P14. Similarly, injection of recombinant Nrg1 in adult 
mouse detected ~14.3%±6.5% BrdU
+
 mononucleated cardiomyocytes compared to non-detectable 
BrdU
+
 in the adult control with improvement of cardiac function following MI (Bersell et al., 2009). 
However, a subsequent study showed that Nrg1 did not promote adult cardiomyocyte cell cycle re-
entry in either healthy or infarcted adult mice (Reuter et al., 2014). This is further supported by 
another study where they showed that Nrg1 lost its ability to promote cardiomyocyte proliferation 
after P7, concomitant with the postnatal down-regulation of its receptor Erbb2 (D'Uva et al., 2015). 
Interestingly, overexpression of constitutively active Erbb2 promoted neonatal and adult 
cardiomyocyte proliferation as well as adult cardiac function following MI (D'Uva et al., 2015). 
More recently, the Hippo signalling pathway, a major regulator of organ size, has been identified as 
another pathway involved in regulating cardiac proliferation (Heallen et al., 2011; von Gise et al., 
2012; Xin et al., 2013a). An initial study has shown that Hippo signalling negatively regulated 
Wnt/β-catenin signals to control cardiomyocyte proliferation (Heallen et al., 2011). Subsequently, 
Gise et al used gain- and loss-of-function studies to demonstrate that the activation of yes associated 
protein 1 (Yap1), the nuclear effecter of Hippo signalling pathway, is capable of inducing postnatal 
cardiomyocyte proliferation without influencing their physiological hypertrophic growth (von Gise 
et al., 2012). Moreover, a recent study by Xin et al reported that in vivo Yap1 gain of function 
induced cardiomyocyte proliferation in both foetal (~40% 5-ethynyl-2’deoxyuriding positive (EdU+, 
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proliferative marker) cardiomyocyte) and adult (~1.5% EdU
+
 cardiomyocyte) heart (Xin et al., 
2013a; Xin et al., 2013b).  
Beside these well-characterized growth factor signalling pathways, subsets of microRNAs 
(miRNAs) have also been reported to play a role in cardiomyocyte proliferation and cardiac 
regeneration (Eulalio et al., 2012; Porrello et al., 2011a; Porrello et al., 2013). A study by Porrello 
et al has revealed that inhibition of the miR-15 family during postnatal development promoted 
myocyte proliferation and improved ventricular systolic function following MI in adult mice 
(Porrello et al., 2013). Subsequent studies have showed that miR17~92 promoted cardiac 
proliferation in foetal, embryonic and adult hearts (Chen et al., 2013; Wang et al., 2010). Also, the 
overexpression of miR17~92 was capable of protecting the adult heart from MI. Furthermore, 
through high-content functional screening of miRNAs in vitro, Eulalio et al identified 40 miRNAs 
that promoted cell cycle activity in neonatal and adult rodent cardiomyocytes (Eulalio et al., 2012). 
Overexpression of two of the targeted miRNAs, hsa-miR-590 and hsa-miR-199a, promoted 
neonatal (~25-35% EdU
+
 cardiomyocytes) and adult (~6-9% EdU
+
 cardiomyocytes) cardiomyocyte 
proliferation and induced regeneration of the adult heart following MI.  
All of these research outcomes support the idea that induction of adult cardiomyocyte proliferation 
facilitates endogenous cardiac regeneration. However, various factors that induce potent 
cardiomyocyte proliferation in foetal or neonatal cardiomyocytes fail to induce the same degree of 
cardiomyocyte proliferation in adulthood. This critical observation suggests a potential epigenetic 
barrier to cardiomyocyte cell cycle re-entry, which may be established during postnatal 
development. Further studies to interrogate this question would help provide a better understanding 
of the biological processes governing postnatal cardiomyocyte maturation. 
Direct cell reprogramming In 1958, John Gurdon established the concept of reprogramming 
when he discovered that transplantation of somatic cell nuclei into enucleated oocytes was 
sufficient to “reprogram” cells into a pluripotent state (Gurdon et al., 1958). It was subsequently 
demonstrated that delivery of a single myogenic TF, MyoD, could reprogram fibroblasts into a SM 
without reverting to a pluripotent state, in a process now referred to as direct reprogramming (Davis 
et al., 1987).  
As fibroblasts and myofibroblasts are largely responsible for maintenance of the infarct scar after 
MI, transdifferentiation of these cell types into cardiomyocytes represents a potentially useful 
regenerative strategy. Previous studies showed that members of the core cardiogenic gene program 
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Gata4, Mef2c, Tbx5 (and Hand2) reprogrammed cardiac fibroblasts into spontaneously contracting 
cardiac-like myocytes in vitro (Ieda et al., 2010) and in vivo (Song et al., 2012). Recapitulation of 
these studies in human fibroblasts showed that GATA4, TBX5, HAND2 and two MEF2C-regulated 
miRNAs, miR-133 and miR-1, up-regulated the expression of cardiac troponin T (cTnnT) and 
tropomyosin (markers of cardiomyocytes) and created a small subset of spontaneously beating 
cardiomyocytes (Nam et al., 2013).  
Cumulatively, these studies suggest fibroblasts, or indeed other cells types within and surrounding 
the infarct, could represent a viable target for cardiomyogenesis. However, current reprogramming 
of cell identity, in both pluripotency and direct reprogramming approaches, is an inefficient process 
and current strategies result in off-target effects in other cell types within and outside the heart (Ieda 
et al., 2010; Islas et al., 2012; Jayawardena et al., 2012; Nam et al., 2013; Polo et al., 2012). 
Potentially, overcoming the epigenetic roadblock could be an essential improvement for 
reprogramming efficiency and controlling the maturation of reprogrammed cells. 
1.2. Endogenous cardiac regeneration  
Clearly, the impact of the abovementioned therapies for regeneration of the infarcted heart is 
promising. However, some controversial outcomes require further investigation before clinical use. 
Also, further examination regarding cell fate and the mechanisms underlying their functional 
benefits need to be conducted before proposing long term benefit. Moreover, outcomes from cell-
free therapy reveal the importance of endogenous cardiomyocyte proliferation during cardiac 
regeneration. As another avenue for replenishment of cardiomyocytes after injury, it is important to 
consider the mechanisms of activation of endogenous cardiac regenerative capability. In fact, heart 
regeneration has been investigated in depth in the past 50 years in several amphibian, teleost and 
mammalian species (Carvalho and de Carvalho, 2010; Laflamme and Murry, 2011; Uygur and Lee, 
2016). In higher vertebrates, compared to highly regenerative organs such as liver, bone, skeletal 
muscle or skin, the heart is one of the least regenerative organs. Conversely, lower vertebrates 
possess a higher regenerative capacity compared to mammals (Oberpriller and Oberpriller, 1974; 
Poss et al., 2002) (Figure 1.2). However, several recent studies reported that 1-day old neonatal 
rodent heart is capable of regenerating cardiomyocytes to compensate the lost myocardium in 
various cardiac injury models, including apical resection, genetic ablation, cryoinjury and MI, 
suggesting that mammals might retain significant cardiac regenerative potential during early 
postnatal life (Darehzereshki et al., 2015; Haubner et al., 2012; Porrello et al., 2011b; Porrello et al., 
2013; Strungs et al., 2013; Sturzu et al., 2015). This also indicates that the ability of the heart to 
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regenerate may not be due to inherent species differences that confer regenerative capacity, but 
rather due to the developmental maturation of cardiomyocytes and postnatal shutdown of 
regenerative capacity in mammals. In this section, endogenous cardiac regeneration in several 
organisms will be discussed. 
1.2.1. Cardiac regeneration in urodele and anurans amphibian  
Urodele and anurans are both members of the amphibian order, where urodele amphibians retain 
their tail throughout life (such as salamanders and newts) whereas anurans undergo morphogenesis 
to lose their tail and acquire limbs in adulthood (including frogs and toads). The earliest study of 
newt cardiac regeneration capacity was conducted by Oberpriller et al in 1974 (Oberpriller and 
Oberpriller, 1974). Research provided evidence for DNA synthesis and mitosis in adult newt 
cardiomyocytes after ventricular apical resection injury. Repair of cardiac injury started at ten days 
post-injury and involved the formation of blood clot, necrosis, macrophagic activity and 
regeneration of heart muscle, however, only a partial regeneration was observed. Recently, Witman 
et al observed a full regeneration in the adult newt heart following apical resection of a small 
portion of the cardiac ventricles, suggesting the newt heart can recover completely following injury 
under certain experimental conditions (Witman et al., 2011). A parallel experiment in axolotl also 
reported a full recovery of the injured heart within 90 days (Flink, 2002). Interestingly, studies 
reported that matrix deposition acted as the imminent response following injury to provide support 
at the injured site (Piatkowski et al., 2013). However, the deposited matrix started to be removed 
after 50 days and was replaced with cardiomyocytes (Piatkowski et al., 2013; Witman et al., 2011). 
Overall, it is now well accepted that urodele amphibian hearts are capable of regeneration following 
injury.  
In 1973, Rumyantsev and colleagues studied the regenerative capacity of the anuran heart 
(Rumyantsev, 1973). Unlike the urodele amphibians discussed in the previous section, adult anuran 
amphibians exhibited a different regenerative response (Rumyantsev, 1973; Uygur and Lee, 2016). 
Studies observed cardiomyocyte dedifferentiation and cell cycle reactivation following injury in the 
adult frog heart (Rumyantsev, 1973). Using 
3
H-thymidine (
3
HTdr) tracing study, Rumyantsev et al 
observed up to 13% of myocytes entered into mitosis within the first two weeks after local injury in 
the adult frog heart, with these mitotic events peaking at 3 weeks after injury (Rumyantsev, 1973). 
However, the adult frog heart failed to undergo full regeneration, leaving a partially regenerated and 
partially scarred heart tissue (Rumyantsev, 1973; Uygur and Lee, 2016).  
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1.2.2. Cardiac regeneration in zebrafish 
Apical resection Poss et al subsequently used similar techniques to investigate whether 
zebrafish possess cardiac regenerative capacity (Poss et al., 2002). Heart tissue structure and 
function was fully restored within two months after 20% of ventricular myocardium was excised in 
1-2 year old adult zebrafish. Cardiomyocyte proliferation was histologically observed by staining 
BrdU
+
 cells at 7 days after the resection. Similar to amphibians, a blood clot was formed after tissue 
resection to prevent blood loss. Two to four days after amputation, fibrin deposits replaced the 
erythrocytes. However, unlike amphibians, which had a large area of fibrin deposition, zebrafish 
suffered only a small extent of fibrosis and they were capable of overcoming the fibrotic response 
in 60 days to achieve a 100% restoration of myocardial function (Poss et al., 2002). Interestingly, 
sarcomeric structural re-organization was observed during the restoration of the myocardium. 
Notably, cell fate tracking studies established that cardiac regeneration was accompanied with the 
dedifferentiation and division of pre-existing cardiomyocytes (Jopling et al., 2010; Kikuchi et al., 
2010). The source of regenerated cardiomyocytes will be further discussed in the upcoming section. 
Cryoinjury Using cardiac resection, which involves removal of a large portion of tissue, may not 
be the optimal model for studying cardiac regeneration, because MI involves localized 
cardiomyocyte cell death and inflammation. Interestingly, several groups have established 
cryoinjury models, which are believed to be a closer model to MI (Chablais et al., 2011; Gonzalez-
Rosa et al., 2011). Research groups have used liquid nitrogen pre-cooled stainless cryoprobes to 
injure the adult zebrafish myocardium, which leads to mortality of 25% of the cardiac tissue in the 
injured area. Using transgenic fish with cardiac-specific cardiac myosin light chain 2 (cmlc2) 
promoter driven GFP protein or nuclear DsRed 2, the whole reparative process following cryoinjury 
was observed (Chablais et al., 2011). Similar to apical resection, cryoinjury also triggered an instant 
blood clot formation followed by fibrin deposition at 4 days post cryoinjury (dpci), collagen 
network introduction at 7 dpci to form a fibrotic scar and recovery beginning at 14 dpci. By the time 
of 60 dpci, the injured area was almost completely replenished with nascent cardiomyocytes. 
Electrocardiograms (ECG) showed the functional recovery of original electrical properties, proving 
that newly formed myocardium functionally integrated with the pre-existing myocardium (Chablais 
et al., 2011). Remarkably, although a massive fibrotic scar was formed after cryoinjury in zebrafish, 
which is similar to the response of mammalian heart after suffering from infarction, zebrafish 
managed to overcome the obstacles and replaced the scar with regenerated cardiac tissue, 
suggesting that scar formation after injury is compatible with cardiac regeneration in zebrafish 
(Gonzalez-Rosa et al., 2011).  
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Genetic ablation A recent study conducted by Wang et al using genetic ablation removed more 
than 60% of ventricular myocardium, which caused acute heart failure in zebrafish (Wang et al., 
2011). By crossing cmlc-2 promoter controlled tamoxifen inducible Cre recombinase (CreER) 
transgenic fish line with myocyte specific β-actin 2 driven cytotoxic diptheria toxin A chain (DTA) 
expression in transgenic fish line, Wang et al managed to induce cardiomyocyte specific cell death 
after 5-7 days of tamoxifen injections. Regeneration started rapidly at 7 days post injection (dpi). 
By 14 dpi, close to 50% of the ablated tissue was replaced by proliferating myocytes and at 30 dpi 
heart muscularisation was completed. Although the massive cardiac cell death decreased exercise 
tolerance and increased mortality following heat stress, it did not influence fish survival, 
demonstrating that the major selective loss of cardiac muscle cells was enough to activate cardiac 
regeneration. This non-surgical, targeted genetic ablation model, which triggered massive 
cardiomyocyte cell death without any surgical intervention, creates a closer approximation to MI 
and provides a more stable platform to study injury and proliferation in other cell types or animals 
(Wang et al., 2011). 
Source of cardiomyocytes Heart regeneration studies in zebrafish show that lower vertebrates 
maintain a greater regenerative capacity compared to higher vertebrates. Presently, an issue of 
intense interest is whether pre-existing cardiomyocytes, non-myocytes or CSCs are the contributory 
cell population in myocardial regeneration. In 2006, Lepilina et al used cardiac specific fluorescent 
reporters and reported that newly regenerated cardiomyocytes were derived from an 
undifferentiated epicardial progenitor cell population (Lepilina et al., 2006). However, a more 
recent study by the same group and Jopling et al showed a converse outcome (Jopling et al., 2010; 
Kikuchi et al., 2010). Using the Cre/lox genetic fate-mapping system, they revealed that de-
differentiation and proliferation of pre-existing cardiomyocytes after amputation was the 
predominant mechanism driving cardiomyocyte regeneration following injury. Similarly, Wang et 
al observed the phenomenon of massive sarcomere disorganization in existing cardiomyocytes 
concomitant with cardiac regeneration at 7 and 14 dpi in the genetic ablation injury model (Wang et 
al., 2011). Kikuchi et al reported apical resection of zebrafish initiated cardiac specific expression 
of the TF gata4 in the subepicardial ventricular layer within 7 dpa and gata4
+
 cells subsequently 
migrated into the injury sites (Kikuchi et al., 2010). gata4
+
 cells were co-labelled with BrdU at 
edges of the wound and inside of the injury site at 7 and 14 dpa, respectively, suggesting DNA 
synthesis in gata4
+
 cells contributes to heart regeneration. In fact, gata4 is an embryonic 
cardiogenesis gene, which is necessary for embryonic cardiac development and vascularisation 
(Choi and Poss, 2012). The re-expression of gata4 in subepicardial cells proposed a re-activation of 
the embryonic gene program in adult cardiomyocytes. Together, current research suggests that the 
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regeneration of zebrafish heart following injury is accomplished by pre-existing cardiomyocytes 
through de-differentiation and cell cycle re-entry. 
1.2.3. Cardiac regeneration in embryonic and neonatal rodents 
Genetic knockout Compared to the high regenerative capacity of lower vertebrates, adult 
mammalian hearts possess a remarkably low rate of cardiac regeneration. However, a study by 
Drenckhahn et al reported that the foetal mouse heart retains some regenerative capacity 
(Drenckhahn et al., 2008). The mitochondrial enzyme Holocytochrome c synthase (Hccs) is 
involved in generating energy for cells. Cardiac specific knockout of the X-linked gene encoding 
Hccs caused 50% deficient cells in female embryonic hearts during mid-gestation. Unlike the 
embryonic lethality in males, heterozygous females survived until birth with no significant 
morbidity, with only 10% of cells appearing diseased, suggesting that regeneration of diseased cells 
compensated for this genetic deficiency during embryonic foetal heart development. This research 
outcome suggested a potential for regeneration in the embryonic mammalian heart. 
Apical resection In order to determine whether cardiac regenerative capacity extends into the 
early neonatal period, Porrello et al repeated the zebrafish apical resection model in neonatal mice 
(Porrello et al., 2011b). While P1 mice were capable of regenerating after trauma, the regenerative 
capacity was lost in 7-day old mice. The results implicated a developmental window for 
regeneration arrest within 7 days after birth in mice, which coincides with the timing of cell cycle 
arrest during rodent cardiac development (Li et al., 1996). Similar to the zebrafish injury model, the 
rodent heart showed a large blood clot shortly after resection followed by a significant 
inflammatory response. Full restoration of the resected area occurred within 21 days with normal 
systolic function evidenced by echocardiogram examination. Neonatal heart regeneration was 
associated with proliferation of cardiomyocytes and a full integration of newly formed cardiac 
muscle cells with the existing myocardium. 
MI Following the observation of cardiac regeneration in neonatal mice after apical resection, 
another study was conducted by the same group using MI model (Porrello et al., 2013). Through 
inducing ischemic MI in P1 mice by left anterior descending (LAD) coronary artery ligation, they 
created a necrotic and severely inflammatory environment in the neonatal heart that is more similar 
to MI in adult humans. Similar to the apical resection results, a full functional recovery was 
accomplished by 21 days post-MI in neonatal mice. In contrast to the robust regeneration activity in 
1-day old mice, 7-day and 14-day old mice failed to recover following LAD ligation and instead 
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formed large fibrotic scars, implying a loss of regenerative capacity within a week after birth. Very 
similar results were also obtained in an independent study performed by Haubner et al (Haubner et 
al., 2012).  
Source of cardiomyocytes The fact that rodents possess a regenerative capacity shortly after 
birth opens up the possibility of reactivation of cardiac regeneration mechanisms in adulthood. The 
origin of the regenerated cardiomyocytes, again, becomes a very important issue. In both of the 
apical resection and MI studies of neonatal mice, by using tamoxifen-induced CreER controlled by 
alpha myosin heavy chain (aka myosin heavy chain 6, αMHC/ Myh6) to track the cardiomyocyte 
lineage, Porrello et al detailed that the newly formed cardiac muscle cells were originated from pre-
existing cardiomyocytes (Porrello et al., 2011b; Porrello et al., 2013). Haubner et al also reported 
that the pre-existing cardiomyocyte population contributed to the cardiac regeneration in the 1-day 
old MI mouse heart (Haubner et al., 2012). These research outcomes are similar to the previously 
reported regeneration event in the zebrafish (Jopling et al., 2010; Kikuchi et al., 2010). Interestingly, 
as previously mentioned about the importance of Hippo signalling, Yap cardiac-specific inhibition 
in neonatal mice replaced the cardiac regenerative response with a fibrotic response, demonstrating 
a requirement for this signalling pathway in neonatal heart regeneration (Figure 1.3) (Xin et al., 
2013a; Xin et al., 2013b).  
1.2.4. Cardiac regeneration in adult rodents 
Unlike the high regeneration capacity of mammalian foetal or neonatal cardiomyocytes, the 
regeneration capacity of adult myocytes is debatable. Previous studies using apical resection and 
induced MI already showed that following development, adult mouse failed to regenerate following 
injury (Porrello et al., 2011b) (Porrello et al., 2013) (Haubner et al., 2012). It is important to notice 
that, while sharing the similar biological processes with neonatal mouse hearts following injury 
which involves initial formation of blood clot, infiltration of immune cells as well as deposition of 
extracellular matrix at the injured region, adult mouse hearts fail to activate the cardiomyocyte 
proliferation to compensate the loss of cardiac tissue, ending with extensive scar formation (Uygur 
and Lee, 2016), suggesting a developmental modification that regulates cardiomyocyte proliferation 
capacity after birth (Figure 1.2). 
Recently, Senyo et al used stable isotope labelling (
15
N) for genetic mapping in the mouse, which 
showed a small regeneration rate (0.76% per year) from pre-existing cardiomyocytes (Senyo et al., 
2013). This study debates the previous study from the same group by Hsieh et al that a stem cell 
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population was responsible for the substitution of adult mammalian cardiomyocytes after injury but 
not during normal aging (Hsieh et al., 2007). Moreover, two genetic fate mapping studies suggested 
that CPCs such as c-kit
+
 are not required for cardiogenesis (Sultana et al., 2015; van Berlo et al., 
2014). Kimura et al also identified a rare cycling cardiomyocyte population in the adult heart 
through hypoxia cell fate mapping (Kimura et al., 2015). Notably, 2 recent studies have performed 
detailed characterization on the cardiomyocyte cycling during development. While Naqvi et al 
demonstrated a proliferative burst of cardiomyocytes at P15 which contributed to an increase in 
cardiomyocyte number by 40% postnatally (Naqvi et al., 2014), Alkass et al recently contested this 
finding and suggested that cardiomyocyte number was established within the first week after birth 
with no significant changes in cardiomyocyte proliferation detected after P11 (Alkass et al., 2015). 
Nevertheless, both studies showed no significant changes in cardiomyocyte proliferation and 
myocyte number in adulthood, suggesting the limited capacity of adult cardiac proliferation.  
Together, the origin of nascent cardiomyocytes being generated from either stem cell populations or 
existing cardiomyocytes remains a contentious issue but the adult heart does appear to have 
measurable, yet extremely limited, capacity for cardiomyocyte replenishment. 
1.2.5. Cardiac proliferation and regeneration in human 
Development Like rodents, it is a well-accepted concept that adult humans have extremely low 
aptitude for cardiac regeneration. A previous study accomplished by Quaini et al in 2002 by 
tracking female transplanted hearts in male recipients using post-mortem fluorescence in situ 
hybridization revealed 10% Y-chromosome positive myocytes in the transplanted female heart 
(Quaini et al., 2002). The result showed a low but still evident proliferation rate in human cardiac 
cells. Interestingly, similar data reported by Bergmann et al in 2009 tracked the integration of 
carbon-14 into genomic DNA after the Cold War nuclear bomb testing (Bergmann et al., 2009). 
The study disclosed a 1% turnover rate in human heart annually, suggesting a less than 50% 
cardiomyocyte replacement within a whole life span. This result was further confirmed by ploidy 
quantification of cardiomyocyte nuclei through immunostaining of the cardiomyocyte markers 
cTnnT and cTnnI, as well as pericentriolar material 1 (PCM1) (Bergmann et al., 2011). While other 
studies have reported much higher rates of cardiomyocyte turnover in the adult human heart 
(complete turnover of the entire cardiomyocyte compartment up to 15 times in females (or 11 times 
in males) aged 20 to 100) (Kajstura et al., 2010), these findings are highly controversial (Porrello 
and Olson, 2010).  
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The developmental timing of cardiomyocyte turnover in humans is also controversial. A study by 
Mollova et al studied the cardiomyocyte cell cycle activity in human hearts aged 0-59 years old and 
showed that myocytes from early developmental stages have high cell proliferation capacity and the 
number of cardiomyocytes in the left ventricle increased by 3.4 fold within the first 20 years of life 
(Mollova et al., 2013). However, a recent study by Bergmann et al has reported a detailed 
characterization of cardiomyocyte proliferation during development (Bergmann et al., 2015). The 
study has shown that the total number of cardiomyocyte remains stable from 1 month to 73 years of 
age, suggesting the number of cardiomyocytes is established perinatally and remains unchanged 
into adulthood (Bergmann et al., 2015), similar to their findings in developing rodent hearts (Alkass 
et al., 2015). The study suggested that cardiomyocyte turnover rate peaked within the first 10 years 
of life at ~8% and decreased exponentially into adulthood, remaining less than 1% per annum in 
adulthood. On the other hand, endothelial cells and mesenchymal cells have a much higher turnover 
rate throughout adulthood of 15% and 4% per annum, respectively (Bergmann et al., 2015). 
Currently, the cardiomyocyte proliferation rate and the timing of cell cycle arrest in humans are still 
debatable. However, all of these studies showed that while the postnatal human heart can be largely 
considered a post-mitotic organ, it still possesses a limited ability to proliferate into adulthood.  
Regeneration It is currently unclear whether humans also possess regenerative capacity during 
childhood and infancy but several lines of evidence point towards a similar neonatal regenerative 
window in humans. In 2011, Fratz et al reported a tracing study of 14 patients who underwent 
corrective cardiac surgery in infancy and the report showed either no scarring (28%) or minimal 
scaring (57%) in these patients decades after surgery (Fratz et al., 2011). Moreover, Haubner et al 
recently reported a case study whereby a newborn infant who suffered a severe MI completely 
recovered cardiac functional after 1.5 months (Haubner et al., 2016). These intriguing clinical 
observations suggest the neonatal human heart might also possess substantial regenerative capacity.  
Together, while the actual cardiac proliferative capability of the adult human heart remains 
controversial, these studies suggest that cardiac regenerative potential is developmentally regulated 
in humans. More extensive studies are required to investigate the molecular mechanisms that 
regulate cardiomyocyte maturation and regenerative capacity in the neonatal period. Such studies 
are required to identify much needed strategies to promote or re-introduce cardiomyocyte 
proliferative capability in order to facilitate cardiac regeneration following MI.  
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1.3. Cardiac development, maturation and arrest 
The heart experiences several transitions during postnatal maturation, including increased 
ventricular pressure, changes in hormonal signalling, alterations in metabolic substrate utilization 
(from glycolytic to fatty acid oxidation), switches in sarcomeric isoforms, as well as cell cycle 
arrest (Celine J Vivien, 2016; Girard et al., 1992; Makinde et al., 1998; Uosaki et al., 2015; Yang et 
al., 2014b) (Table 1.2). After fertilization and throughout gestational development, organs 
experience a hyperplastic period, which is required for growth before parturition in all mammals. 
Several studies indicated that murine hearts experienced a rapid transition from hyperplasia to 
hypertrophy shortly after birth (Katzberg et al., 1977; Li et al., 1996; Soonpaa et al., 1996). All 
studies showed that rodent cardiomyocytes went through a rapid growth phase during 
embryogenesis and the proliferation of myocytes dropped shortly before birth. Within the first 3 
days after birth, myocytes still possess the proliferative ability with the capacity to fully 
disassemble sarcomeres in dividing cardiomyocytes (Li et al., 1996). However, rodent cardiac 
muscle cells undergo their last round of DNA synthesis without further cytokinesis, leaving the 
cells binucleated; a process that begins around 4 days after birth and is completed by 14 days-of-age. 
The percentage of binucleated cardiomyocytes peaked at 2 weeks postpartum at more than 90% and 
this level was maintained throughout the life span (Li et al., 1996). This result was subsequently 
supported by an extensive quantitative experiment where it was shown that the number of 
cardiomyocytes is established within the first postnatal week. Additionally, two subsequent waves 
of non-replicative DNA synthesis occur in rodents, which contribute to multinucleation and 
polyploidisation of cardiomyocytes in the postnatal period (Alkass et al., 2015).  
 On the other hand, human ventricles are comprised of 74% mononucleated, 25.5% binucleated, and 
0.5% multinucleated cardiomyocytes, with no change in these percentages during aging, cardiac 
hypertrophy or ischemic cardiomyopathy (Bergmann et al., 2015; Mollova et al., 2013; Olivetti et 
al., 1996) (Table 1.1). Moreover, 90% of newborn human cardiomyocytes are diploid but became 
tetraploid by the time of adulthood with an undetectable cytokinesis rate after 20 years of age 
(Bergmann et al., 2015; Botting et al., 2012; Mollova et al., 2013). Conversely, the majority of fish, 
newt and neonatal cardiomyocytes are mononucleated and diploid, which allow the cells to 
maintain regenerative capacity (Alkass et al., 2015; Matz et al., 1998; Poss, 2007). Thus, it has been 
suggested that the percentage of mononucleated or binucleated cardiomyocytes could account for 
species- and developmental stage-specific differences in the ability to re-enter the cell cycle, 
therefore influencing regenerative capacity (Olivetti et al., 1996; Poss, 2007; Soonpaa et al., 1996).  
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Currently, the mechanisms that control cardiomyocyte binucleation, polyploidy and the transition 
from hyperplastic to hypertrophic growth remain very poorly understood. One potential mechanism 
for the postnatal regulation of cardiomyocyte differentiation involves epigenetic silencing of the 
neonatal gene expression program, which could alter the cardiomyocyte transcriptome for the 
lifespan of the animal. The next section will introduce the concept of epigenetics and how it 
regulates various biological processes through transcriptional regulation. 
1.4. Introduction to epigenetics 
Every cell contains the genetic blueprint for the production of all transcripts and proteins in an 
organism. However, transcription and translation need to be exquisitely controlled in order to give a 
cell its identity and function. The establishment of the cardiac gene program requires the 
deployment and repression of distinct subsets of genes to facilitate cardiac development and 
establish a robust steady-state cell identity. Control of gene expression during development is 
tightly regulated by both TFs and epigenetic modifications. Nucleosomes are the fundamental unit 
of chromatin and the condensation of nucleosomes occludes access of gene regulatory machineries 
to genes and distal regulatory regions to control transcription. How this process is executed relies 
on interplay between three central epigenetic processes: 1) the manipulation of histones and higher 
order chromatin structures by ATP-dependent chromatin remodelling molecules, 2) post-
translational modification (PTM) by covalent labelling of histones or the exchange of canonical 
histones with histone variants, and 3) direct DNA cytosine methylation. PTMs of histones and DNA 
methylation are the basis of the so-called “epigenetic code” and to a large extent appear to program 
cell identity by maintaining open chromatin at cell lineage-specific gene loci and closing chromatin 
at others (Efroni et al., 2008; Meissner et al., 2008; Zhu et al., 2013). 
The adult mammalian heart has an extremely limited capacity for renewal and regeneration. 
Cardiomyocytes transition from hyperplastic to hypertrophic growth during early postnatal life (Li 
et al., 1996), and cardiomyocyte proliferation after cardiac injury in the adult is very low (Senyo et 
al., 2013; Soonpaa and Field, 1997). Comparatively, neonatal hearts are capable of regenerating 
following cardiac injury (Haubner et al., 2012; Porrello et al., 2011b; Porrello et al., 2013), which is 
dependent on the proliferative competency of neonatal cardiomyocytes. The loss of this 
regenerative capacity during early postnatal life coincides with dramatic changes in the 
transcriptional and epigenetic landscape (Gilsbach et al., 2014; Preissl et al., 2015b). Therefore, 
epigenetics may have a decisive role in cardiac maturation and the shutdown of cardiac regenerative 
ability (Figure 1.4). The following section outlines the known epigenetic processes governing 
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cardiac development and maturation, a process that could be harnessed to facilitate regeneration of 
the adult heart following damage. 
1.4.1. Histone tail modification 
An expansive catalogue of histone modifications has been identified, including lysine ubiquitination, 
sumoylation, acetylation and methylation, as well as serine/threonine phosphorylation (Rothbart 
and Strahl, 2014). These histone modifications can directly affect the state of the surrounding 
chromatin, and can also serve as binding sites for chromatin remodelling complexes, which can 
influence gene transcription (please refer to (Rothbart and Strahl, 2014) for a detailed review on this 
topic). This literature review will focus on methylation and acetylation, as these are the most 
extensively studied PTMs during cardiac development. Acetyl or methyl groups can be added by 
histone acetyl transferases (HATs) or histone methyltransferases (HMTs), respectively. These 
PTMs can also be removed by histone deacetylases (HDACs) and histone demethylases. 
Histone acetylation by HATs can lead to relaxed chromatin structure and transcription of genes, as 
acetylation removes the positive charge on the histones, which decreases the electrostatic attraction 
between histone proteins and negatively charged DNA (Bannister and Kouzarides, 2011). There are 
5 families of HATs (Gillette and Hill, 2015), which form part of larger protein complexes, thus 
enabling targeting of different enhancers and promoters. Acetylation (Ac) of histone 3, lysine 27 
(H3K27) is typically correlated with active enhancers (Rothbart and Strahl, 2014) (Table 1.3). On 
the other hand, HDACs erase acetylation marks on histones, which leads to a more compact 
heterochromatin structure and decreased gene expression (Bannister and Kouzarides, 2011).  
Histone methylation is both positively and negatively correlated with gene transcription and is 
dependent on the particular lysine that is methylated and the extent of the methylation (mono-, bi- 
or trimethylation). Some of the most clearly defined methylation sites at gene promoters are H3K4, 
H3K9 and H3K27 (Li et al., 2007). Trimethylation (me3) of H3K4 (H3K4me3) is correlated with 
active promoters, whereas many transcriptionally silent promoters are enriched for H3K27me3 and 
H3K9me3 (Table 1.3) (Li et al., 2007). Some histone methylation marks can also delineate 
enhancer regions (H3K4me1) or actively transcribed gene bodies (H3K36me3) (Chen and Dent, 
2014). Some genes can also have a “poised” status where bivalent histone modifications are present. 
For example, in ESCs (ESCs), the promoters of some lineage-specific TFs are labelled with both 
active (H3K4me3) and repressive (H3K27me3) marks, which repress their expression, but also 
poise them for rapid activation upon demethylation of H3K27me3 (Bernstein et al., 2006). However, 
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this bivalency phenomenon ideally requires single cell analysis to exclude the possibility of 
artefacts due to heterogeneous cell populations (Hong et al., 2011).  
1.4.2. DNA methylation  
DNA methylation is one of the most well characterized epigenetic modifications and is involved in 
multiple gene regulatory functions and developmental processes (Smith and Meissner, 2013). DNA 
methylation occurs at the fifth position of cytosine of DNA is one of the most mechanistically 
studied epigenetic regulation and is regulated via DNA methyltransferases (Dnmts). Three major 
DNMTs are required for DNA methylation, DNMT1, DNMT3A and DNMT3B (Smith and 
Meissner, 2013). DNMT1 methylates the newly synthesized DNA strand during DNA replication to 
ensure transfer of methylation marks during cell division (Smith and Meissner, 2013). On the other 
hand, DNMT3A and DNMT3B operate as the machinery for de novo DNA methylation (Smith and 
Meissner, 2013). The three Dnmts work in concert to dynamically regulate epigenetic processing of 
the genome.  
On the other hand, DNA can also be actively demethylated by the ten-eleven translocation (TET) 
family of enzymes comprising TET1, TET2 and TET3. These enzymes actively remove DNA 
methylation marks through progressive oxidation of the methyl group together with thymine DNA 
glycosylase (TDG) mediated DNA base excision repair mechanisms (Kohli and Zhang, 2013).  
In mammalian cells, methylation normally occurs at CpG dinucleotides. However, methylation at 
non-CpG sites has also been reported in pluripotent stem cells (PSCs) (Ramsahoye et al., 2000), as 
well as some mouse and human tissues, including brain (Lister et al., 2013). The majority (60-80%) 
of CpG sites in the mammalian genome are methylated. However, less than 10% of the CpG sites 
are present in CG rich islands in the promoters of actively transcribed genes (Smith and Meissner, 
2013). In these CpG islands (CGIs), promoter methylation is typically associated with silencing of 
gene transcription (Chen and Dent, 2014). This evolutionarily conserved silencing mechanism is 
employed during multiple stages of development (Laurent et al., 2010; Lister et al., 2009). 
Additionally, CpGs in gene bodies can also be methylated and this may play a role in transcription 
or splicing regulation (Jones, 2012). 
1.4.3. ATP-dependent chromatin modifications  
In addition to histone and DNA modifications, the epigenetic state is also influenced by ATP-
dependent chromatin remodelling complexes. These complexes can be subcategorized into five 
main families: switch/sucrose non-fermentable (SWI/SNF), imitation SWI (ISWI), chromodomain-
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helicase DNA-binding protein, INO80 and α-thalassemia mental retardation syndrome X-linked 
(ATRX) (Bartholomew, 2014). Interestingly, the number of complexes in each family increases 
with increasing organismal complexity (Bartholomew, 2014). In more complex mammalian 
organisms, specific complexes are expressed in a cell-type specific manner and are essential for 
normal development (Lickert et al., 2004).  
1.4.4.  TFs  
TFs are proteins that typically bind 6-12 nucleotide sites of gene promoters and distal regulatory 
elements to regulate transcription. In many cases, these 6-12 nucleotide sequences repeat millions 
of times throughout the genome and exhibit strict spatiotemporal transcriptional control. However, 
chromatin immunoprecipitation sequencing (ChIP-seq) experiments have revealed two different 
binding behaviours: 1) widespread, seemingly stochastic, binding of TFs to genomic regions that do 
not appear to have transcriptional activity, or 2) TFs occupying distinct suites of genes in different 
cell types (Cao et al., 2010; Pilon et al., 2011). There are four mechanisms that dictate the binding 
of TFs to DNA: the DNA consensus sequence for TF binding, epigenetics, TF complexes (e.g. co-
factors) (Bouveret et al., 2015), and TF PTMs (Filtz et al., 2014). Importantly, even if the required 
TF complexes and PTMs are present, epigenetics can still dictate which genes are transcribed 
(Wohrle et al., 2007), as TFs preferentially drive the expression of genes from regions of open 
chromatin (Beato and Eisfeld, 1997).  
Interestingly, not all TFs are limited to euchromatic regions and some “pioneering factors” can bind 
to DNA and activate transcription irrespective of chromatin state (Zaret and Carroll, 2011). 
Pioneering TFs coordinate the recruitment of chromatin modifiers and facilitate the relaxation of 
chromatin (Zaret and Carroll, 2011). Rewiring of the epigenetic landscape by pioneer factors then 
allows “signal-dependent” TFs to drive tissue specific gene networks, such as the case with the 
pioneering TF FOXA1 and GATA factors (Carroll et al., 2005; Stefanovic and Christoffels, 2015; 
Zaret and Carroll, 2011; Zhou et al., 2012). Therefore, some TFs are capable of establishing an 
epigenetic framework upon which signal-dependent and tissue-specific TFs work upon to 
consolidate gene expression signatures and program cellular identity.  
1.4.5. Non-coding RNAs  
One of the greatest surprises of the Human Genome Project was the finding that only 2% of the 
human genome codes for protein (Carninci et al., 2005; Lander et al., 2001). In recent years, next 
generation sequencing studies have revealed that up to 75% of the genome is actively transcribed 
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(Djebali et al., 2012). The majority of non-coding RNAs have unknown biological functions and 
comprise a number of different classes of RNA, including long non-coding RNAs (lncRNAs) and 
small non-coding RNAs, such as miRNAs. 
LncRNAs are defined as being >200 nucleotides long, can be either polyadenylated or non-
polyadenylated, exhibit mostly nuclear expression, and appear to contain functional intramolecular 
domains (Djebali et al., 2012; Quinn et al., 2014). LncRNA expression is often cell-type specific 
(Derrien et al., 2012) and their expression concords closely with cardiac developmental and disease 
states (Yang et al., 2014a). Although the existence of lncRNAs has been recognized since 1991 
(Bartolomei et al., 1991), little is known about their functions. Globally, evolutionarily conserved 
lncRNAs are negatively correlated with protein-coding gene expression and it has been postulated 
that they largely function to suppress the expression of other lncRNAs and protein-coding genes 
(Necsulea et al., 2014). For the purposes of epigenetic control, however, one of the more interesting 
properties of lncRNAs is their ability to act as scaffolds for the chromatin modifying machinery. 
For example, the lncRNA HOTAIR colocalises with PRC2 components and directs PRC2-mediated 
transcriptional silencing at the HOXD locus (Rinn et al., 2007). In fact, lncRNAs have been shown 
to interact with not only PRC2 but also ATP-dependent chromatin remodellers (Han et al., 2011), 
H3K4 HMTs (Grote et al., 2013), and DNMTs (Di Ruscio et al., 2013; Wang et al., 2015).  
A specific class of lncRNAs, known as enhancer RNAs (eRNAs), are transcribed from enhancer 
regions and are thought to denote active enhancers (Arner et al., 2015). Indeed, eRNA transcription 
may precede and drive H3K4 methylation at enhancer loci, thus establishing de novo gene networks 
(Kaikkonen et al., 2013; Li et al., 2013). A paradigm whereby eRNAs cement tissue-specific 
enhancer-promoter interactions is supported by the fact that enhancer usage transitions during 
development (Arner et al., 2015), enhancer usage is highly cell type-specific (Kieffer-Kwon et al., 
2013), and eRNAs are involved in enhancer-promoter chromatin interactions (Lai et al., 2013) 
(Figure 1.4).  
It is therefore tempting to suggest that scaffolding RNAs could have key roles in not only chromatin 
organization but also epigenetic patterning, by targeting diverse epigenetic modifiers to specific loci. 
Hence, lncRNAs are emerging as important regulators of epigenetic processes and are the focus of 
continuing research.  
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1.4.6. Nutrition and Metabolism 
Many epigenetic regulators require metabolically-derived intermediates to perform their functions 
(Keating and El-Osta, 2015). Recent studies have shown that folate, vitamin B12, choline and other 
vitamin B derivatives produce S-adenosylmethionine (SAM, methyl donor in methyltranfer process) 
and S-adenosylhomocysteine (SAH, product inhibitor of SAM), which are critical for DNA 
methylation and histone methylation via 1-carbon metabolism to provide the required substrates for 
epigenetic modifications (Choi and Friso, 2010; Keating and El-Osta, 2015). Moreover, Acetyl-
CoA is used as a substrate for HATs, α-ketoglutarate and flavin adenine dinucleotide are TET and 
histone lysine demethylase (KDM) co-factors, and nicotinamide adenine dinucleotide (NAD) is 
required for SIRT-dependent histone deacetylation (Keating and El-Osta, 2015). This suggests that 
nutrition and the metabolism have impact epigenetic modifications. Moreover, in skeletal muscle, 
satellite cells transition from fatty acid oxidation to glycolysis during activation, leading to 
decreased NAD+ and reduced SIRT1 deacetylase activity (Ryall et al., 2015). Furthermore, changes 
in H4K16ac then lead to the regulation of 100s of genes that promote differentiation of satellite 
cells into skeletal muscle (Ryall et al., 2015). In addition, previous studies have shown that during 
postnatal switching of cardiac metabolic events, the expression activity of FoxO1 is under the 
control of the metabolic monitor 5’ adenosine monophosphate-activated protein kinase (AMPK), 
which modulates downstream effectors and leads to postnatal cell cycle shutdown, providing a 
direct transcriptional regulatory link to cellular metabolism (Evans-Anderson et al., 2008; Sengupta 
et al., 2013). Collectively, these studies have indicated that epigenetic modifications are 
intrinsically linked with nutrition and metabolism, which impact transcriptional regulation during 
various biological processes. 
1.5. Epigenetic regulation of cardiac development 
1.5.1. Dynamic changes in the epigenome during cardiomyocyte differentiation 
and maturation 
Chromatin landscape Epigenetic marks are established during cardiac development as cells 
pass through distinct stages (e.g. pluripotency > mesoderm > cardiac progenitors > cardiomyocytes) 
(Paige et al., 2012; Wamstad et al., 2012). There is a progressive compaction of nucleic material 
during differentiation of ESCs (Gifford et al., 2013) and also during cardiomyocyte maturation 
(Sdek et al., 2011). Chromatin compaction and gene silencing are particularly prevalent at 
pluripotency loci and are coupled with a global shutdown of pluripotency in somatic cells (Gifford 
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et al., 2013). This intimates a role of chromatin in not only controlling transcriptional output by TFs, 
but in a wider context, in controlling cellular differentiation and cell-lineage specification.  
Global epigenetic modification Epigenetic changes have been associated with many processes 
during cardiac development. Recent studies by the Bruneau and Murry labs have provided a 
comprehensive map of changes in the epigenomic landscape during cardiac lineage specification 
and differentiation (Paige et al., 2012; Wamstad et al., 2012). During cardiomyocyte differentiation, 
chromatin patterns exhibit distinct modifications in gene sets associated with similar biological 
functions (Wamstad et al., 2012). This is exemplified by the existence of a distinct chromatin 
signature around genes related to sarcomere structure, contraction or metabolism, which share a 
similar expression profile in differentiated cardiomyocytes (Wamstad et al., 2012). Interestingly, 
there is also evidence for the acquisition of repressive histone marks at the promoters of several cell 
cycle genes as cardiomyocytes mature from foetal to adult stages (Sdek et al., 2011). These 
chromatin modification patterns could provide a fine-tuning system to guarantee the coordinated 
regulation of functionally comparable genes in response to differentiation signals during cardiac 
development.  
DNA methylation patterns also exhibit dynamic signatures during cardiac development and 
cardiomyocyte maturation. In ESCs, TF binding sites for Oct4 and Nanog are unmethylated, while 
cardiac TF binding sites for Gata1-4 and Mef2c are methylated (Gilsbach et al., 2014). However, 
this pattern switches during development as ESC TF binding sites are highly methylated in neonatal 
and adult cardiomyocytes but, conversely, cardiogenic TF binding sites are demethylated in 
neonates and adults (Gilsbach et al., 2014). Furthermore, Gilsbach et al. reported the transcriptional 
shut down of several genes encoding foetal isoforms of sarcomeric proteins during differentiation, 
which was associated with an acquisition of repressive histone marks and DNA methylation from 
embryonic life to adulthood (Gilsbach et al., 2014). In contrast, genes involved in calcium handling 
and contraction were demethylated from embryonic to adult stages, which was associated with 
transcriptional activation of these genes during cardiac development (Gilsbach et al., 2014). While 
some cell cycle genes are directly methylated during cardiac maturation (Gilsbach et al., 2014), this 
appears to be an exception, rather than a general rule, as a clear relationship between DNA 
methylation and cell cycle gene transcription in cardiomyocytes is yet to emerge.  
These studies have identified the acquisition of an epigenetic signature during cardiomyocyte 
maturation, whereby some developmental genes are silenced and others have open chromatin 
conformations (Figure 1.5). There is growing interest in the potential for induction of adult 
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cardiomyocyte proliferation as a strategy for promoting cardiac regeneration following MI and a 
recent study suggests that epigenetics plays a key role in this process. Notch stimulation was shown 
to induce proliferation of neonatal cardiomyocytes, but not adult cardiomyocytes (Felician et al., 
2014b). Felician et al. demonstrated that the accumulation of repressive histone marks (H3K27me3) 
and DNA methylation marks at the promoters of Notch-responsive signalling effectors during 
neonatal development prevented Notch ligands from re-inducing proliferation in adult 
cardiomyocytes (Felician et al., 2014b). This indicates that adult cardiomyocytes may need to be 
epigenetically reset for efficient cell cycle re-induction before regeneration can occur (Figure 1.6). 
The following sections will highlight the important functions of epigenetic modifiers during cardiac 
development with a specific focus on their known roles in cardiomyocyte differentiation, 
proliferation and maturation.  
1.5.2. Histone acetyltransferases and deacetylases are required for 
cardiomyocyte proliferation 
HATs HATs can promote transcription by opening chromatin and loosening DNA-histone 
interactions. Two of the most well characterized and extensively studied HATs are p300 and CREB 
binding protein (CBP), which are ubiquitously expressed and cooperate with many different TFs to 
regulate gene transcription in different cell types. In addition to its role in acetylation of histone tails, 
p300 also interacts with and directly acetylates critical cardiac TFs, including Mef2, Gata4 and 
serum response factor (Srf) to enhance DNA binding (Sartorelli et al., 1997; Slepak et al., 2001; 
Takaya et al., 2008). Genetic knockout of p300 is embryonically lethal (Shikama et al., 2003) and 
results in proliferation defects, down-regulation of cardiac structural genes (beta myosin heavy 
chain (aka myosin heavy chain 7, βMhc/ Myh7), α-actinin (Actn)) and cardiac structural defects 
including reduced trabeculation (Yao et al., 1998). Cardiovascular development is also disrupted in 
knock-in mice harbouring a single AT-deficient allele of p300 or Cbp, which leads to myocardial 
hypoplasia and is associated with embryonic or neonatal lethality (Shikama et al., 2003). 
Collectively, these studies suggest that p300/Cbp is required for cardiomyocyte proliferation during 
heart development. However, the effect of conditional, cardiac-specific deletion of p300/Cbp has 
not been reported and a mechanistic framework for their involvement in cardiomyocyte 
proliferation is currently lacking.  
HDACs HDACs remove acetylation marks and repress transcription through promotion of 
chromatin condensation. Class I and Class III HDACs are ubiquitously expressed, however, Class II 
HDACs are enriched in brain, muscle and T cells (Backs and Olson, 2006). HDACs are important 
for cardiac development and disease. This is highlighted by a number of global and heart-specific 
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gene knockout studies. Global deletion of Hdac1 is embryonic lethal at E9.5, whereas Hdac2 
deletion leads to extensive cardiac defects in the perinatal period, including cardiomyocyte 
hyperplasia and apoptosis (Montgomery et al., 2007). Interestingly, Hdac2 functions with a small 
homeodomain factor, Hopx, to deacetylate Gata4. Combined deletion of Hdac2 and Hopx leads to 
hyperacetylation of the Gata4 protein and is associated with a marked increase in cardiomyocyte 
proliferation, up-regulation of Gata4 targets and perinatal lethality (Trivedi et al., 2010). Notably, 
cardiac-specific deletion of either Hdac1 or Hdac2 alone does not result in an overt phenotype, 
which is likely due to redundancy. Deletion of both Hdac1 and Hdac2 in cardiomyocytes results in 
neonatal lethality and severe cardiac malfunction, such as cardiac arrhythmias, dilated 
cardiomyopathy and increased expression of cardiac contractile and calcium handling genes 
(Montgomery et al., 2007). These observations indicate that HDAC1 and HDAC2 play important 
roles in cardiac development and cardiomyocyte proliferation. However, it is unclear whether these 
effects are mediated directly via deacetylation of histone proteins or via deacetylation of non-
histone proteins such as the core cardiogenic TF GATA4.  
Global ablation of Hdac3 is embryonic lethal at E9.5 (Montgomery et al., 2008), but cardiac-
specific deletion of Hdac3 generates viable mice. However, cardiac-specific Hdac3 knockout mice 
die by 3-4 months of age with severe cardiac hypertrophy and abnormalities in fatty acid oxidation 
pathways, suggesting an important role for Hdac3 in cardiomyocyte metabolism during postnatal 
development (Montgomery et al., 2008). Conversely, cardiac-specific overexpression of Hdac3 
leads to ventricular myocardial thickening through excessive cardiomyocyte proliferation (Trivedi 
et al., 2008), and is associated with inhibition of cyclin dependent kinase inhibitors, such as cyclin 
dependent kinase inhibitor (Cdkn) 1a, Cdkn1b, Cdkn1c, Cdkn2b, and Cdkn2c (Trivedi et al., 2008). 
Therefore, HDAC3 is required for physiological maturation of cardiomyocytes through its effects 
on proliferation and metabolism. 
Class II HDACs are known to regulate the nuclear localisation of key cardiac TFs, such as Mef2, 
which is a critical regulator of the cardiac differentiation program and is required for cardiac growth 
under pathological conditions (Lu et al., 2000; Sartorelli et al., 1997). Notably, double knockout of 
Hdac5 and Hdac9 is perinatally lethal with only ~30% of offspring surviving to adulthood (Chang 
et al., 2004). Deletion of both Hdac5 and Hdac9 causes growth retardation, thin-walled 
myocardium and severe ventricular septal defects (Chang et al., 2004). In contrast, cardiac-specific 
deletion of Hdac5 or Hdac9 causes cardiac hypertrophy through derepression of Mef2 targets and 
induction of the foetal hypertrophic gene program (Chang et al., 2004; Zhang et al., 2002). While it 
is clear that Class II HDACs play an important role in regulating the transcriptional response of the 
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adult heart to cardiac stress, specific functions for Class II HDACs in cardiomyocyte proliferation 
have not been described.  
Class III HDACs comprise members of the Sirt family (SIRT1-7). SIRT1 (Cheng et al., 2003), 3 
(Koentges et al., 2015; Sundaresan et al., 2009), 6 (Sundaresan et al., 2012) and 7 (Vakhrusheva et 
al., 2008) are crucial for cardiac development and the response of the adult heart to cardiac stress. 
However, no specific role of Class III HDACs has been reported with respect to cardiac 
proliferation or regeneration. 
In summary, these results suggest that histone acetyltransferases and deacetylases play a critical 
role during heart development. Several HAT and HDAC mutant mice have defects in 
cardiomyocyte proliferation, which implies a key role for histone acetylation in the regulation of the 
cardiac cell cycle. However, HATs and HDACs can modify the acetylation status of both histone 
and non-histone proteins, including key cardiogenic TFs, and our understanding of the mechanistic 
link between histone acetylation and cardiomyocyte proliferation is very limited. Few studies have 
evaluated the genome-wide effects of HAT or HDAC deletion on the cardiac epigenome and this 
remains an important goal for future research.  
1.5.3. Histone methyltransferases are required for cardiomyocyte proliferation 
Ezh2 SET domain-containing methyltransferases are the most studied lysine methyltransferase 
family in the heart. EZH2 is a SET domain-containing H3K27-specific methyltransferase and a 
subunit of the PRC2 complex. Cardiac-specific knockout of Ezh2 under control of the Nkx2.5 
promoter causes lethal congenital heart malformations associated with impaired cardiomyocyte 
proliferation and derepression of Ezh2 targets, including several TFs or genes that are essential for 
cardiac organogenesis (e.g. Pax6, Isl1, Six1 and Bmp10 (Cassano et al., 2012)) and up-regulation of 
the cell cycle inhibitor Cdkn2a and Cdkn2b (Cassano et al., 2012; Chen et al., 2012). In contrast, 
conditional deletion of Ezh2 in anterior heart field progenitor cells does not disrupt cardiac 
specification and development but rather induces cardiomyocyte hypertrophy. Interestingly, these 
effects appear to be dependent on Six1, a cardiac progenitor cell TF that is developmentally shut 
down in differentiated myocytes (Delgado-Olguin et al., 2012). Six1 is normally repressed by Ezh2, 
which functions to stabilize cardiac gene expression upon differentiation and to maintain postnatal 
cardiac homeostasis (Delgado-Olguin et al., 2012; Stergachis et al., 2013). However, deletion of 
Ezh2 in differentiated cardiomyocytes does not cause any overt phenotype, which could be due to 
functional redundancy with Ezh1 at later stages of development (Cassano et al., 2012). Lysine 
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methyltransferase 2D (KMT2D) has also been shown recently to regulate cell cycle activity during 
cardiac development through H3K4 dimethylation (Ang et al., 2016). 
SMYD1 Another important member of the SET domain-containing methyltransferase family 
is SET and MYND domain containing 1 (SMYD1). Early studies of SMYD1 suggested that it was 
critical for cardiac differentiation and development. Homozygous Smyd1 knockout mice are 
embryonic lethal at E10.5 and present with severe ventricular hypoplasia and defects in right 
ventricular formation and trabeculation, associated with transcriptional repression of right 
ventricular-specific TFs, including Hand2 (Gottlieb et al., 2002). Conditional deletion of Smyd1 
using the Nkx2.5-Cre driver resulted in defective expansion of second heart field progenitors and 
reduced cardiomyocyte proliferation (Rasmussen et al., 2015). Smyd1 morpholino knockdown in 
zebrafish embryos also disrupted myofiber maturation (Tan et al., 2006), further suggesting 
SMYD1 is essential for cardiac muscle maturation.  
Dot1l The disruptor of telomeric silencing-1 (DOT1L), an H3K79-specific methyltransferase, is 
the most extensively studied candidate of the non-SET domain containing methyltransferase family 
during cardiac development. Global ablation of Dot1l causes growth retardation, cardiac dilation 
and lethality between E9.5 to E10.5 (Jones et al., 2008). ESCs developed from Dot1l-deficient mice 
display abnormalities in ploidy, telomere elongation and reduced cell proliferation (Jones et al., 
2008). Dot1l-deficient ESCs also exhibit aberrant chromatin structure characterized by a reduction 
in H3K79 methylation suggesting Dot1l has an essential role in guiding chromatin condensation 
during embryonic development (Jones et al., 2008). Cardiac-specific ablation of Dot1l results in 
viable offspring. However, these mice develop cardiac hypertrophy at 6 months of age, associated 
with an increase in the total percentage of proliferating cells in the heart, although specific 
quantification of cardiomyocyte proliferation was not performed (Nguyen et al., 2011). Dot1l also 
regulates cardiac structural proteins through transcriptional regulation of its downstream target 
Dystrophin (Dmd), which could also contribute to the cardiac functional abnormalities observed in 
this model (Nguyen et al., 2011).  
Jumonji (Jmj) The members of the Jmj C family are some of the most well characterized 
KDMs during development. Homozygous knockout of Jmj, which demethylates H3K9me2 or 
H3K27me2, is embryonic lethal around E11.5 with growth retardation and cardiac defects, 
including hyperplasia of trabecular cardiomyocytes (Takeuchi et al., 1999). The repressive effects 
of Jmj on cardiomyocyte proliferation involve direct repression of Ccnd1 (Toyoda et al., 2003) and 
potentiation of the repressive effects of Rb function on E2F activity and cell cycle genes (Jung et al., 
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2005). However, it is unclear whether conditional deletion of Jmj in the adult heart is sufficient to 
drive cardiomyocyte cell cycle re-entry.  
Ubiquitously transcribed tetratricopeptide repeat, X chromosome (Utx) The UTX and 
Jmj domain-containing protein 3 (JMJD3) enzymes are KDMs that specifically target H3K27me3 
(Hong et al., 2007). Studies have shown that Utx histone demethylase function is directed by core 
cardiac specific TFs, such as Nkx2.5, Gata4 and Tbx5, to the enhancer regions of cardiac genes, 
which leads to the transcriptional activation of their target genes during cardiac differentiation (Lee 
et al., 2012). Moreover, Utx deletion results in failure of ESCs to differentiate into the cardiac 
lineage (Lee et al., 2012; Welstead et al., 2012). Similarly, Jmjd3 knockout ESCs fail to 
differentiate into mesoderm and cardiac lineages (Ohtani et al., 2013). Global genetic deletion of 
Utx results in embryonic lethality by E13.5 with developmental abnormalities in cardiac chamber 
formation (Lee et al., 2012; Welstead et al., 2012). Jmjd3 homozygous knockout mice die before 
E6.5 (Ohtani et al., 2013). Taken together, these studies support an important role for UTX/JMJD3 
(and, by inference, H3K27me3) in cardiac differentiation but further studies are required to 
specifically dissect the role of these enzymes in the regulation of cardiac lineage decisions. 
1.5.4. DNA methylation in cardiac development and diseases 
Cardiac development Some of the very first genetic studies of DNA methylation in 
mammals showed that genetic deletion of Dnmt1 in the mouse germ line causes embryonic lethality 
associated with cardiac developmental defects, including ventricular hypoplasia (Li et al., 1992). 
However, despite these early observations, there is a paucity of studies on DNMT1 during cardiac 
development and specific functions for maintenance methylation in the cardiac lineage remain 
largely unexplored. In contrast, global deletion of either Dnmt3a or Dnmt3b has demonstrated 
critical roles for these enzymes during mammalian development, but cardiac development does not 
appear to be overtly impacted in these animals (Okano et al., 1999). Interestingly, a recent study 
exhibited that Dnmt3a but not Dnmt3b is essential for the maintenance of cardiac sarcomeric 
structure and contractile function in an in vitro foetal cardiomyocyte culture system (Fang et al., 
2016). While a recent study identified an important role for Dnmt3b in cardiac valve formation 
during embryogenesis (Chamberlain et al., 2014), another study has demonstrated that Dnmt3a/3b 
are dispensable for postnatal cardiomyocyte function (Nuhrenberg et al., 2015). Cardiac-specific 
double deletion of Dnmt3a/b in cardiomyocytes, in this case driven by the atrial myosin light chain 
(Mlc2a) promoter, does not result in an overt cardiac phenotype under basal conditions or in 
response to cardiac stress (pressure overload) (Nuhrenberg et al., 2015), despite changes in cardiac 
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gene expression (Gilsbach et al., 2014). Further studies are required to assess the impact of DNMT3 
on other aspects of cardiac physiology and pathology but these findings suggest that de novo 
methylation is not required for maintenance of adult cardiac function.  
The lack of an evident cardiac phenotype in Dnmt3a/3b null mice (Nuhrenberg et al., 2015) is 
surprising given several recent reports of dynamic changes in the cardiac methylome during 
development and disease (Gilsbach et al., 2014). A recent genome-wide study has identified 
widespread alterations in cardiac DNA methylation patterns during the transition from foetal to 
adult stages. In isolated neonatal cardiomyocytes, several cardiac-specific TF binding motifs, such 
as Gata1-4 and Mef2c, were enriched in hypomethylated regions of the genome (Gilsbach et al., 
2014). Moreover, as cardiomyocytes mature and establish the adult gene program, several cardiac 
genes, including those involved in calcium handling (Atp2a2) and contraction (Myh6, cardiac type 
troponin T2 (Tnnt2), cardiac type troponin I3 (Tnni3)), become demethylated and acquire active 
histone marks (H3K27ac, H3K4me3 and H3K4me1) (Gilsbach et al., 2014). Interestingly, the foetal 
cardiac gene program (e.g. slow skeletal type troponin I1 (Tnni1)) is down-regulated in adult 
cardiomyocytes and this transition is accompanied by increased methylation and the acquisition of 
repressive histone marks (H3K27me3) (Gilsbach et al., 2014). This result is supported by the 
transcriptome and methylome profiling data of adult cardiomyocytes derived from CPCs (Zhang et 
al., 2015). The study suggested that following dedifferentiation of the adult cardiomyocyte, those 
cells displayed an increase expression level accompanied with decrease DNA methylation in cell 
cycle and proliferation related genes whereas cardiomyocyte structural and functional genes 
obtained DNA methylation marks and decrease in their expression status (Zhang et al., 2015). 
Therefore, DNA methylation undergoes dynamic changes during heart development and this is 
associated with the establishment of the adult gene program during cardiomyocyte maturation.  
Cardiac diseases The changes of DNA methylation level and its mechanism during the 
initiation and progression of heart disease remains largely unknown. A recent clinical research 
showed that the global DNA methylation level of peripheral blood leukocytes is positively 
correlated with CVDs (MI and stroke) (Kim et al., 2010). Moreover, Udali et al recently showed 
that the DNA methylation levels of several genes, such as ESR1, ESR2, ALOX15, HSD11B2, 
NKCC1 and THBS1, is correlated with atherosclerosis, hypertension and stroke (Udali et al., 2013). 
Furthermore, DNA hypomethylation caused by Mthfr (related to methyl donor generation) 
deficiency in the mouse promoted aortic fatty streak formation (Baccarelli et al., 2010). The study 
has reported that DNA methylation level was decreased in the heart of the atherosclerosis-prone 
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gene ApoE knockout mouse, as well as in a model of aorta neointimal thickening in the New 
Zealand white rabbit (Baccarelli et al., 2010). 
In terms of cardiomyopathy, Movassagh et al has demonstrated that dynamic changes in DNA 
methylation levels is correlated with differential expression of at least 3 angiogenesis-related genes 
in cardiomyopathy patients (Movassagh et al., 2010). A subsequent study reported by the same 
group showed similar results with their previous study with a further in vitro experiment 
(Movassagh et al., 2011). The study has shown that siRNA knockdown of Dux1, a molecule that 
was up-regulated after cells were treated with the DNA methylation inhibitor (RG108), led to a 
reduction in cell viability in vitro, suggesting a potential regulation of cell viability through 
methylation of Dux1 (Movassagh et al., 2011). Moreover, profiling of left ventricular DNA 
methylation level of the repeat elements in human heart failure also demonstrated a significant 
decrease of the DNA methylation level of satellite repeat elements associated with increase of 
transcription in end-stage cardiomyopathy patients (Haider et al., 2012). Furthermore, differential 
DNA methylation changes were observed in some heart disease-related signalling pathway 
molecules and identified several novel genes in dilated cardiomyopathy patients (Haas et al., 2013). 
In vivo morpholino inhibition of these novel genes (adenosine A2a receptor (Adora2a) and 
lymphocyte antigen 75 (Ly75)) in zebrafish impaired cardiac contractility and caused heart failure, 
respectively (Haas et al., 2013), suggesting the change in methylation during disease targeted 
cardiac contractile event.  
Demethylating agent 5-azacytidine (5aza)  2 hypomethylating agents, 5aza (commercial 
name – Vidaza) and its derivative 5aza-dC (commercial name – Decitabine or Dacogen) are 
clinically approved drugs for myelodysplastic syndromes and acute myeloid leukaemia. It 
effectively prevents DNA methylation by incorporating into DNA (Vidaza and Dacogen) or RNA 
(Vidaza) as the analogue of cytidine that could not be methylated (Christman, 2002). A previous 
study reported that 5aza-dC rescued the hypertrophic and heart failure phenotype induced by 
norepinephrine (Xiao et al., 2014). This result is subsequently supported by a recent study where 
spontaneous hypertensive rat treated with 5aza showed ameliorated effects in cardiac fibrosis and 
hypertrophy. Moreover, a recent study reported that the 5aza protected cardiac function (ejection 
fraction, contractility and relaxation indices) and attenuation of cardiac fibrosis following MI in the 
rats (Kim et al., 2014), via the shifting of pro-inflammatory to anti-inflammatory macrophage 
phenotype through regulates the sumoylation of interferon regulatory factor-1(Jeong et al., 2015; 
Kim et al., 2014). This suggests that DNA methylation plays a role in regulating cardiac fibrosis 
and hypertrophy and this effect is reversible.  
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Collectively, these results have displayed the deep relationship between DNA methylation and 
normal cardiac development as well as cardiac diseases progression. It is important for future study 
to tear apart the mechanism of DNA methylation in regulating cardiac development and diseases.  
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1.6. Hypothesis and Aims 
What we know One critical concept that can be derived from the current literature review is 
that mammalian cardiomyocytes lose their proliferative and regenerative capacity during postnatal 
development. Many pro-proliferative factors that induce myocyte division during early 
developmental stages fail to induce adult cardiomyocyte cell cycle re-entry to the same extent. This 
phenomenon might be due to the existence of epigenetic roadblocks that are progressively acquired 
during postnatal development, especially at genomic regions involved in regulating the transcription 
of genes required for cardiomyocyte proliferation. Understanding this epigenetic regulation would 
bring important insight to the cardiac maturation mechanism.  
What we do not know As one of the most important and stable epigenetic marks, DNA 
methylation has emerged as a powerful regulator of developmental processes but its role in 
postnatal cardiomyocyte maturation remains elusive. Moreover, a broader conceptual framework 
for understanding how the chromatin landscape shapes cardiac development and, in particular, 
myocyte maturation is lacking.  
Hypothesis The central hypothesis underpinning this PhD thesis is that postnatal alterations in 
DNA methylation and the chromatin landscape establish the mature cardiomyocyte transcriptional 
program associated with loss of proliferative capacity.  
Aims:  To test the hypothesis, this PhD Thesis focuses on characterizing the role of DNA 
methylation and chromatin dynamics during postnatal cardiac development and maturation using in 
vitro and in vivo model systems (Figure 1.7):  
Aim 1: To characterize DNA methylation dynamics and its functional role during postnatal cardiac 
maturation (Chapter 3). 
Aim 2: To determine the role of DNA methylation in regulating the expression of cell cycle related 
genes in mouse and human cardiomyocytes (Chapter 4). 
Aim 3: To understand the relationship between chromatin accessibility and transcription during 
mouse and human cardiomyocyte development (Chapter 5). 
To address the abovementioned aims, a number of classic molecular biology techniques, as well as 
contemporary next-generation sequencing approaches have been employed. These molecular 
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techniques, as well as the animal models and in vitro culture systems they are applied to, are 
described in detail in the following General Methods chapter (Chapter 2). 
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Table 1.1. Comparison of vertebrate models of cardiac development and regeneration. 
 
Newt Zebrafish Mouse Human 
Heart rate 
(beats/minute) 
30 120 300-600 60-90 
Chamber 
3 
(2 atria 
1 ventricle) 
2 
(1 atrium 
1 ventricle) 
4 
(2 atria 
2 ventricles) 
4 
(2 atria 
2 ventricles) 
Circulation Double Single Double Double 
T-tubule system - - Yes Yes 
Ploidy Diploid Diploid Diploid 
Tetraploid or 
higher 
Nuclear of 
cardiomyocytes 
Mononucleated Mononucleated 
Binucleated 
(1 week after 
birth) 
Mononucleated 
Withdraw from 
cell cycle 
- - 
1 week after 
birth 
Few months 
after birth 
Regeneration 
ability after 
injured 
Yes, throughout 
whole life 
(resection) 
Yes, throughout 
whole life 
(resection/ 
cryoinjury/ 
genetic ablation) 
Yes, within 1
st
 
week after birth 
(resection/ MI/ 
genetic 
ablation/ 
cryoinjury) 
1 case of 
newborn after 
MI 
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Table 1.2. Changes of various cardiomyocyte properties during maturation (Shintani et al., 2014; Yang et al., 2014b). 
  
Foetal/ neonatal cardiomyocyte Adult cardiomyocyte 
Morphology, 
structural 
properties 
Morphology Circular shape Rod shape 
Size Size increase for 30 to 40 fold during maturation 
Contractile apparatus 
(sarcomere) 
Longer and more organized sarcomeric structure towards maturation 
~1.95 μm ~2.2 μm 
Myofibrillar isoform 
Titan N2BA, 3200-3700 kDa Titan N2B, 3000 kDa 
Slow skeletal type troponin I1 
(TNNI1) 
Cardiac type troponin I3 
(TNNI3) 
αMHC/ MYH6 (human) βMHC/ MYH7 (human) 
βMHC/ MYH7 (mouse) αMHC/ MYH6 (mouse) 
Transverse tubules 
Lack in foetal, start to appear 
from P6-9 
Symbol of maturation 
Mitochondria Scatter distribution in cytoplasmic Distribute in cytoplasm in 
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reticular network crystal-like lattice pattern 
Small fraction of the myocyte 
volume. 
20-40% of myocyte volume 
No distribution of lamellar cristae 
in the inner membrane 
Regular distribution of mature 
lamellar cristae in the inner 
membrane 
Metabolic substrate Glycolysis (80%) Fatty acid β-oxidation (80%) 
Connexin 43 (gap junction 
protein) and N-cadherin 
(adherens junction protein) 
Circumferentially distribution 
Focus on intercalated disks (at 
the ends of the cells) 
Electrophysiology 
properties 
Resting membrane 
potential 
> -90 mV ~−90 mV 
Force 
~nN/ cell ~μN/ cell 
unknown (human) 44±11.7 mN/mm2 (human) 
0.4 to 0.8 mN/mm2 (rat) 56.4±4.4 mN/mm2 (rat) 
Conduction velocity unknown (human) 0.3 to 1.0 m/s (human) 
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0.33 m/s (canine) 0.50 m/s (canine) 
Membrane capacitance 17.5±7.6 pF ~150 pF 
Upstroke velocity ~50 V/s ~250 V/s 
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Table 1.3. Distinct epigenetic signatures at promoter and enhancer regions. 
Epigenetic signature Active Repressive 
Promoter H3K4me3 
5mC DNA 
H3K9me3 
H3K27me3 
Enhancer 
H3K27ac 
H3K4me1 
H3K27me3 
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Figure 1.1. Schematic of current therapeutic approaches and research interests for cardiac 
pathologies (Adapted and modified from (Garbern and Lee, 2013)).  
Current clinical therapeutic approaches for cardiac patients include medications, surgeries, medical 
assistant device and heart transplantation. Current research focuses for heart injury includes gene 
therapies, cell therapies, direct reprogramming of cardiomyocyte, delivery of engineered heart 
tissue as well as the activation of endogenous cardiomyocyte regeneration.  
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Figure 1.2. Schematic of current research models for cardiac regeneration in different 
species (Adapted and modified from (Uygur and Lee, 2016)).  
The figure illustrated different tactics to induce cardiac injury including apical resection, basal 
resection, cryoinjury, genetic ablation and MI in teleost, amphibian and mammals (Uygur and Lee, 
2016).   
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Figure 1.3. Signalling pathways involved in cardiac proliferation.  
The IGF and WNT pathways activate cardiomyocyte proliferation and survival through regulating 
GSK3β, while the Hippo pathway inhibits cardiomyocyte proliferation via phosphorylation of the 
effecter protein YAP (Xin et al., 2013b). 
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Figure 1.4. Epigenetic control of a tissue-specific gene.  
Inactive enhancers and promoters are marked with inhibitory histone marks and DNA methylation. 
Pioneering TFs are able to bind regions of heterochromatin and initiate remodelling of the 
epigenetic architecture surrounding tissue-specific gene loci. Evidence also suggests that eRNAs 
may be expressed before the acquisition of epigenetic changes and may complex with a component 
of the transcription initiation complex called mediator to establish nascent enhancer-promoter 
transcription complexes (Kaikkonen et al., 2013; Lai et al., 2013). In this way, pioneering TFs are 
capable of re-awakening dormant cell-type specific enhancers to initiate cell-type specific gene 
expression.  
Chapter 1 
 
 
45 
 
Figure 1.5. Epigenetic landscape during cardiac development and maturation.  
During maturation, functionally similar gene sets are correlated with similar epigenetic marks. 
Developmental genes and foetal contractile genes decrease in expression level and are associated 
with methylation and acquisition of the repressive histone mark (H3K27me3). In contrast, 
mitochondrial and metabolism-related genes, as well as adult contractile genes, increase in 
expression and acquire active histone marks (H3K27ac) and lose gene body methylation during 
maturation. Cell cycle genes decrease in expression level during maturation without consistent 
changes in DNA methylation or the repressive histone mark (H3K27me3) (Gilsbach et al., 2014; 
Sim et al., 2015). It should be noted that transcription of particular genes in both foetal and adult 
cardiomyocytes is highly correlated with H3K4me3, H3K4me1 and H3K27ac. 
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Figure 1.6. Postnatal cardiomyocyte epigenetic changes may prevent efficient cardiomyocyte cell cycle re-induction by pro-proliferative 
factors.  
Many pro-proliferative factors such as Notch, Wnt1, NGR, YAP, miR-15 inhibition, miR-590 and miR-199a (Porrello and Olson, 2014a), potently 
increase neonatal cardiomyocyte proliferation but do not induce adult cardiomyocyte proliferation to the same extent. Some of the gene targets of these 
pro-proliferative factors may be epigenetically blocked in adult cardiomyocytes. Hence, resetting of adult epigenetic signatures to a neonatal-like state 
may allow re-expression of these target genes and efficient adult cardiomyocyte proliferation (Gilsbach et al., 2014). 
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Figure 1.7. Summary of the 3 aims of this PhD Thesis in current research models. 
Cardiomyocytes lose their proliferative and regenerative capacity following injury during 
development but the molecular mechanisms remain unclear. The current PhD Thesis is designed to 
investigate the 3 following questions in order to understand the developmental changes that happen 
during cardiomyocyte development. Question 1. Is DNA methylation dynamically regulated during 
cardiomyocyte development and maturation (Chapter 3)? Question 2. Does DNA methylation 
transcriptionally regulate cell cycle genes during cardiomyocyte development and maturation 
(Chapter 4)? Question 3. Do changes in chromatin accessibility affect cardiomyocyte transcription 
during development (Chapter 5)? 
  
 
  
  
 
Chapter 2 
General Methods 
 
 
 
 
 
Science walks forward on two feet, 
Namely theory and experiment. 
But continuous progress is only made by the use of both. 
Robert A. Millikan. 
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Chapter 2. General Methods 
2.1. Experimental animals and tissue collection 
All protocols were approved by The University of Queensland Animal Ethics Committees 
(SBMS/342/13/NHMRC and SBMS/245/13/NHMRC).  
In Chapters 3 and 4, male C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME, USA) were 
used for global DNA methylation profiling and mRNA expression profiling during postnatal 
development (P1 to P84), as well as for RNA-seq and MBD-seq (P1 and P14). ICR/CD-1 mice 
(Charles River Laboratories, Wilmington, MA, USA) were used for neonatal 5aza-dC studies 
(described in Chapter 3). For DNA and RNA analysis, atrial tissues were removed from ventricles 
(septum intact) and ventricles were blotted and weighed before snap freezing in liquid nitrogen for 
storage at -80C prior to processing.  
In Chapter 5, ICR/CD-1 mice were used for the isolation of PCM1 (+) cardiomyocyte nuclei (P1, 
P14 and P56). Atrial tissues were removed from ventricles (septum intact) and ventricles were 
blotted before snap freezing in liquid nitrogen for storage at -80C prior to processing. 
2.2. DNA extraction and global analysis of DNA methylation 
DNA was isolated from C57BL/6 mouse cardiac ventricles using the DNeasy Blood & Tissue Kit 
(Qiagen, Venlo, Limburg, Netherlands) according to the manufacturer’s instructions. Briefly, 25 mg 
tissue was cut into ~1 mm
3
/piece, placed in a 1.5 mL microcentrifuge tube and combined with 190 
μL Buffer ATL. 20 μL proteinase K was added to the mixture and mixed thoroughly by vortexing. 
The solution was then incubated at 56°C overnight in a thermomixer and combined with 4 μL of 
100 mg/mL RNase A the next day. The mixture was mixed by vortexing, followed by 2 minutes 
incubation at room temperature. The mixture was then vortexed for 15 seconds, followed by adding 
400 μL Buffer AL-ethanol (Buffer AL and 100 % ethanol are premixed in 1 volume: 1 volume 
ratio), and mixed thoroughly by vortexing. The mixture was then transferred into the DNeasy Mini 
spin column placed in a 2 mL collection tube, followed by centrifugation at 6000 x g on Microfuge 
16 bench top centrifuge (Beckman Coulter, Brea, CA, USA) for 1 minute. Subsequently, the 
DNeasy Mini spin column was washed with 500 μL Buffer AW1, followed by centrifugation for 1 
min at 6000 x g. The DNeasy Mini spin column was then washed with 500 μL Buffer AW2, 
Chapter 2 
 
 
52 
followed by centrifugation for 3 minutes at maximum speed of Microfuge 16 bench top centrifuge 
to dry the DNeasy membrane. For elution, 100 μL of nuclease-free water was added to the DNeasy 
Mini spin column, incubated at room temperature for 1 minute and then centrifuged at 6000 x g for 
1 minute. 
For analysis of global DNA methylation, 5-methylcytosine (5-mC) levels were measured in DNA 
samples (100 ng per sample) using the MethylFlash Methylated DNA Quantification Kit 
(Colorimetric) (Epigentek, Farmingdale, NY, USA), strictly complying with the manufacturer’s 
instructions (detail referred to Epigentek handbook #P-1036). In this assay, DNA is bound to strip 
wells that are specifically treated to have a high DNA affinity. The fraction of methylated to 
unmethylated DNA is then quantified through an ELISA-like reaction by reading the absorbance in 
a microplate spectrophotometer at 450 nm.  
2.3. RNA extraction, cDNA synthesis and real-time quantitative PCR 
(qPCR) 
In Chapters 3 and 4, total RNA was extracted from mouse cardiac ventricles using TRIzol (Thermo 
Fisher Scientific (Ambion), Waltham, MA, USA) according to the manufacturer’s recommended 
protocol. Briefly, up to 20 mg heart tissue was lysed in 1 mL TRIzol solution, followed by 
homogenization on ice until no tissue chunks were visible. The mixture was then placed at room 
temperature for 5 minutes and then combined with 0.2 mL of chloroform. The mixture was 
subsequently vortexed for 15 seconds and rested at room temperature for 3 minutes, followed by 
centrifugation at 4C at maximum speed of Microfuge 16 bench top centrifuge for 15 minutes. The 
aqueous phase was moved carefully by using a 200 μL pipette tip to transfer the solution to a new 
1.5 mL microcentrifuge tube. The aqueous phase solution was then combined with 0.5 mL of 100% 
isopropanol, mixed thoroughly and rested at room temperature for 10 minutes, followed by 
centrifugation at 4C at maximum speed of Microfuge 16 bench top centrifuge for 10 minutes. The 
supernatant was removed gently without interruption of the RNA pellet. The RNA precipitate was 
then washed gently with 1 mL of 75% ethanol (prepared with sterilized milliQ water), followed by 
centrifugation at 4C at 7500 x g for 10 minutes. Following removal of the supernatant, the 1.5 mL 
microcentrifuge tube was air-dried for 10-15 minutes and RNA was eluted in 30 μL of nuclease-
free water (Thermo Fisher Scientific (Ambion)) and incubated at 65C for 10 minutes until the 
pellet was completely dissolved. RNA samples were then stored at -80C until further usage. 
Genomic DNA contamination was removed using the TURBO DNA-free kit (Thermo Fisher 
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Scientific (Ambion)) prior to synthesis of cDNA templates (described below). The whole isolation 
procedure was performed at 4C according to manufacturer’s instructions unless stated otherwise. 
In Chapter 5, RNA was extracted from isolated PCM1 (-/+) nuclei with TRIzol followed by Direct-
zol RNA mini-prep kit (Zymo Research, Irvine, CA, USA), according to the manufacturer’s 
recommended protocol, with DNase I treatment in the column to remove genomic DNA 
contamination. Briefly, isolated PCM1 (-/+) nuclei were lysed in 1 mL TRIzol, followed by 1 mL 
of 100% ethanol and mixed thoroughly. The mixture was then placed in a tube rotator and rotated 
for 5 minutes. The mixture was subsequently transferred carefully to a Zymo-Spin IIC Column and 
centrifuged at maximum speed for 30 seconds using Microfuge 18 bench top centrifuge (Beckman 
Coulter). The column was then washed with 400 μL RNA Wash Buffer and centrifuged for 30 
seconds at maximum speed of Microfuge 18 bench top centrifuge. A premixed DNase treatment 
solution (5 μL of 6 U/μL DNase I and 75 μL DNA Digestion Buffer) was then added to the column 
matrix to remove genomic DNA contamination. The column was incubated in the DNase treatment 
solution for 15 minutes at room temperature, followed by addition of 400 μL Direct-zol RNA 
PreWash Buffer and centrifuged for 30 seconds at maximum speed of Microfuge 18 bench top 
centrifuge. The column was washed again with 700 μL RNA Wash Buffer and centrifuged for 2 
minutes at maximum speed of Microfuge 18 bench top centrifuge to remove any residual liquid. 20 
μL of preheated nuclease-free water was added directly to the column matrix, incubated for 5 
minutes and centrifuged for 1 minute at maximum speed of Microfuge 18 bench top centrifuge. The 
whole isolation was performed under room temperature conditions according to manufacturer’s 
instructions. 
cDNA templates were synthesized using the SuperScript® III First-Strand Synthesis System 
(Thermo Fisher Scientific (Invitrogen)) using random hexamers. Briefly, 1 μg RNA was mixed with 
150 ng random hexamers and 1 μL of 10 mM dNTPs to make a total 13 μL mixture. The mixture 
was then incubated at 65C for 5 minutes followed by 4C for at least 1 minute. The mixture was 
subsequently mixed with a premixed reverse transcription (RT) solution (4 μL 5x First Strand 
Buffer, 1 μL 0.1mM DTT, 1 μL RNAse Out and 1 μL Superscript III, when no-RT control was 
generated, 1 μL Superscript III was replaced with 1 μL nuclease-free water). The mixture was then 
incubated under the following cycling conditions: 25C for 5 minutes, 50C for 60 minutes, and 
70C for 15 minutes. The cDNA templates were then stored in -20C until further usage. cDNA 
templates were diluted 5x with nuclease-free water before processing for qPCR.  
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qPCR was performed on the StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific 
(Applied Biosystems)) using SYBR® Green PCR Master Mix (Thermo Fisher Scientific 
(Invitrogen)), as previously described (Porrello et al., 2009). Standard PCR primers for qPCR are 
listed in Table 2.1, 2.2. 18S ribosomal RNA was used as a housekeeping control for all PCR 
reactions (Table 2.3). In Chapter 5, where RNA was extracted from the nucleus, primers were 
designed to span within single exon to ensure non-processed RNA was amplified with no-RT 
templates served as negative control, these primers are listed in Table 2.4. All used primers have 
efficiency at a range of ~80% -130%. 
2.4. Histological analysis 
Hearts were briefly rinsed in PBS (Thermo Fisher Scientific (Gibco)), fixed in 4% 
paraformaldehyde overnight, and then stored in PBS at 4˚C until paraffin embedding. Sections (5 
m thickness) were processed for H&E staining according to standard procedures, as previously 
described (Porrello et al., 2011a).  
2.5. Immunofluorescence staining for Dnmts, cell proliferation and 
hypertrophy 
Sections were de-paraffinized and washed with PBS prior to immunostaining as previously 
described (Porrello et al., 2011b). For Dnmt1, Dnmt3a and phosphorylated-histone H3 (pH3) 
immunostaining, sections underwent antigen retrieval by boiling in Tris-EDTA buffer (pH 9.0) at 
110°C for 20 minutes in the decloaking chamber (Biocare medical, Concord, CA, USA). Sections 
were then recovered in PBS for 20 minutes at room temperature, followed by permeabilisation in 
0.3% Triton for 5 minutes, washing in PBS (3 x 3 minutes) and then blocking in 10% goat serum 
(in PBS) at room temperature for 20 minutes. Primary antibodies were diluted in 2% goat serum 
and incubated overnight at 4°C. The following primary antibodies were used for 
immunofluorescence staining: Dnmt1 (D63A6) (1:100, rabbit monoclonal #5032S, Cell Signaling, 
Danvers, MA, USA), Dnmt3a (D23G1) (1:100, rabbit monoclonal #5398S, Cell Signaling), cardiac 
Troponin-T (1: 100, mouse monoclonal MS-295-P1, Thermo Scientific, Waltham, MA, USA), pH3 
(Ser10) (1:100, rabbit polyclonal 06-570, Merck Millipore, Darmstadt, Germany). Following 
primary antibody incubation, sections were washed in PBS (3 x 5 minutes) and then incubated with 
secondary antibodies conjugated with Alexa Fluor 488 or 555 (1: 400, Thermo Fisher Scientific 
(Molecular Probes)) and Hoechst 33342 (1:1000, H21492, Thermo Fisher Scientific (Invitrogen)) at 
room temperature for 1 hour in the dark. Sections were washed in PBS (3 x 3 minutes) before being 
Chapter 2 
 
 
55 
mounted with Fluoromount-G (Southern Biotech, Birmingham, AL, USA). For quantification of 
hypertrophy, heart sections were stained with wheat germ agglutinin (WGA, 50 g/mL, W11261, 
Thermo Fisher Scientific (Molecular Probes)) as previously described (Porrello et al., 2011b). 
Quantitative analyses of cardiomyocyte mitosis and cross sectional area were performed using 
ImageJ as previously described (Porrello et al., 2011b). 
2.6. Bisulphite sequencing  
Bisulphite sequencing was performed on genomic DNA from cardiac ventricles obtained at P1, P7 
and P28 (n=3 per time point). DNA samples underwent bisulphite conversion using the EZ DNA 
Methylation kit (Zymo Research). Bisulphite PCR primers are listed in Table 2.5. Bisulphite-
converted DNA samples were then used as a template for PCR reactions using Hi Fidelity Platinum 
Taq DNA polymerase (Thermo Fisher Scientific (Invitrogen)) with the following cycling conditions: 
95°C for 3 minutes, 40 cycles of 95°C for 30 seconds, 58°C for 30 seconds, 72°C for 45 seconds, 
followed by 72°C for 5 minutes. The PCR product was purified using the QIAquick Gel Extraction 
Kit (Qiagen) and cloned into the TOPO plasmid (Thermo Fisher Scientific (Invitrogen)) for 
downstream sequencing. Following transformation and blue-white Xgal selection in competent 
E.coli (New England Biolabs, Ipswich, MA, USA), 6 positive clones per heart sample were picked 
and processed for Sanger sequencing (Australian Genome Research Facility, Brisbane, QLD, 
Australia). Bisulphite sequencing primers are listed in Table 2.5. Bisulphite sequencing results 
were then analysed using BISMA software, as previously described (Rohde et al., 2010). 
2.7. Statistical analysis 
All non-bioinformatics statistical analyses were performed using GraphPad Prism 6.0. For 
comparisons between two groups, a two-tailed unpaired Student’s t-test was used. For multiple 
group comparisons, a one-way ANOVA followed by Bonferroni post-test was used. For 
comparison between multiple groups with multiple variables, a two-way ANOVA followed by 
Bonferroni post-test was used. All data are presented as mean ± s.e.m., except for the scatter plot of 
quantified cardiomyocyte cross-sectional surface area (Figure 3.3I), which is shown as a median. 
Detailed statistical analysis methods and sample sizes are indicated in the figure legends. For all 
statistical analyses: *P<0.05 and ** P <0.001. For bioinformatics analysis, including RNA-seq, 
MBD-seq and Gene Set Enrichment Analyses (GSEA), an false discovery rate (FDR) p- ≤ 0.05 
using the correction procedure of Benjamini and Hochberg was used (Benjamini and Hochberg, 
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1995). Gene GO analysis (pathway/ process/network) of MetaCore from Thomson Reuters was 
performed using only statistically significant gene sets. 
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Table 2.1. List of primer sequences for SYBR Green qPCR analysis.  
Targeted gene Primer sequence (Human) Primer sequence (Mouse) 
18s F' GCTGAGAAGACGGTCGAACT CCCTCCAATGGATCCTCGTT 
18s R' CGCAGGTTCACCTACGGAAA TCGAGGCCCTGTAATTGGAA 
DNMT1 R' - GCCATCTCTTTCCAAGTCTTT 
DNMT1 L' - TGTTCTGTCGTCTGCAACCT 
DNMT2 F' - AGAGGATGGAACCTCTGCGT 
DNMT2 R' - CCACATGTGCAGGGATATGA 
DNMT3A R' - GCTTTCTTCTCAGCCTCCCT 
DNMT3A L' - CCATGCCAAGACTCACCTTC 
DNMT3B F' - ATCCATAGTGCCTTGGGACC 
DNMT3B R' - CTGGCACCCTCTTCTTCATT 
DNMT3L R' - GCTTGCTCCTGCTTCTGACT 
DNMT3L L' - GGTGTGGAGCAACATTCCAG 
TET1 F' - GGGAGCTCATGGAGACTAGG 
TET1 R' - AGAGCTCTTCCCTTCCTTCC 
TET2 F' - CTTCTCTGCTCATTCCCACA 
TET2 R' - AGCTCCGACTTCTCGATTGT 
TET3 R' - CAGCGATTGTCTTCCTTGGT 
TET3 L' - GCCTGCATGGACTTCTGTG 
GADD45A F' - AAGACCGAAAGGATGGACAC 
GADD45A R' - ACCACGTTATCGGGGTCTAC 
GADD45B R' - TCTGCAGAGCGATATCATCC 
GADD45B L' - CGGCCAAACTGATGAATGT 
GADD45G R' - AAGTTCGTGCAGTGCTTTCC 
GADD45G L' - CGCACAATGACTCTGGAAGA 
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NEAT1 F' - TAGGTTCCGTGCTTCCTCTT 
NEAT1 R' - ACATCCTCCACAGGCTTACC 
IGF2BP3 R' - GGGCGGGATATTTCGTATCT 
IGF2BP3 L' - GCGCTTTCAGGTAAAATGGA 
CDK14 R' - CCAGGTGCTTGATCACTGAA 
CDK14 L' - TCGCTCTGAAGAAAGAGGACA 
CHTF18 R' ACGCAGGAAGTTGTCAAACA ACGGTGCTTAAGCTGGAGTC 
CHTF18 L' CTCACAGCGATTCTACCGTG GTGACAAGGGCTCTCTGACC 
CIT R' - TTGGAGGTGTCATCGTCAGA 
CIT L' - CACCCTTTCTTTGCCAGAAC 
CTDP1 R' - CTGTCATCACTGCCCTCTCC 
CTDP1 L' - ACAACCCAGTATGTCCGAGG 
GPSM2 R' - TTCAGCAGCACTTCAGCAAC 
GPSM2 L' - TCCTAGTCTACGGCCAGAGG 
IGF2 R' - TGAGAAGCACCAACATCGAC 
IGF2 L' - CTTCTCCTCCGATCCTCCTG 
IGF2BP2 R' - CCGAATCTGGATTCTTCTGC 
IGF2BP2 L' - GACCCTCTCGGGTAAAGTGG 
PAK4 R' - TACAGGCACCTGGTCTGAAG 
PAK4 L' - GTACGCGGGCACAGAGTT 
PRIM2 R' - GGTTGAGCAGAGGCTGAAGT 
PRIM2 L' - GAACGAGTTTAGAGCCACGC 
SH3PXD2B R' - AAAGAACTTGCTGTAGCGCC 
SH3PXD2B L' - CGTGCCCAACAAGCATTA 
UBE2C R' TTGTAAGGGTAGCCACTGGG CACCCACTTGAACAGGTTGT 
UBE2C L' TCAAATGGGTAGGGACCATC CGGCTACAGCAGGAACTGAT 
KLF9 R' - CGCGAGAACTTTTTAAGGCA 
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KLF9 L' - CAGTGGCTGTGGGAAAGTCT 
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Table 2.2. List of primer sequences for SYBR Green qPCR analysis (did not work).  
Targeted gene Primer sequence (Human) Primer sequence (Mouse) 
INSC R' - CGAGTGGCTCTCATCAGTCA 
INSC L' - GCACACTGGCCTCTATCTGC 
INSC R'-2 - GTCAAGATGTCAGCCAAGCA 
INSC L'-2 - TAGCCCTCTTCAAGGTCTGC 
KDM2B R' - TCCTGCTGTTGTTCGGTTG 
KDM2B L' - GACGACTATGAATCGGAGCC 
KDM2B R'-2 - AACTTGCCCTTAGGCCGAC 
KDM2B L'-2 - GCTGCTCCAGCCATGTCA 
POLD2 R' - GCTGCAGCTCACACAACTTC 
POLD2 L' - ATATTTATGCCACCCGCCTC 
POLD2 R'-2 - GGACATGGCCTTGAACAGAG 
POLD2 L'-2 - AGATGAGACCGTTCCTGGTG 
SMYD2 R' - CGTCCACATTTTGACAATCC  
SMYD2 L' - ACCTCCTCTTCTCCTGCCC 
SMYD2 R'-2 - AGTAGAACGCCTGCTTGCAC 
SMYD2 L'-2 - CGACCTCCTCTTCTCCTGC 
PTPRR R' - GCTACTCCTTGGCGGAAGAT 
PTPRR L' - AATTCCAGCAGCAAATGTGA 
PTPRR R'-2 - GAAGATCCGAAGCAGGGTTA 
PTPRR L'-2 - CCTGCATATGACCCGTCTCT 
CIT R' TCAGACTTGAGGGTGGGAAC - 
CIT L' GTTTGAAGGTCTTTGCTGCC - 
CIT R'-2 GAGAGGATGAAACCCACGAA - 
CIT L'-2 TTTGCTGCCATCCTTTCTTC - 
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IGF2BP3 R' CTGCAGTTTCCGAGTCAGTG  - 
IGF2BP3 L' ATCCCGCCTCATTTACAGTG  - 
IGF2BP3 R'-2 ACAGCTCTCCACCACTCCAT - 
IGF2BP3 L'-2 GTCCCAAAAAGGCAAAGGAT - 
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Table 2.3. Ct value of housekeeping gene 18s in different studies. 
Studies Conditions 
Mean Ct value of 
18s 
± S.E.M 
Mouse 
developmental 
profiling study 
P1 6.97 0.03 
P7 7.10 0.05 
P14 7.22 0.05 
P28 7.08 0.06 
P56 7.11 0.02 
Mouse 5aza-dC 
study 
Saline 7.23 0.12 
5aza-dC 7.24 0.12 
Human Heart-Dyno 
5aza-dC study 
Control  13.81 0.09 
10μM 5aza-dC 13.83 0.08 
Mouse PCM1 study 
P1-PCM1(-) 11.55 1.06 
P1-PCM1(+) 11.10 1.16 
P14-PCM1(-) 11.09 0.47 
P14-PCM1(+) 11.94 0.60 
P56-PCM1(-) 10.60 0.87 
P56-PCM1(+) 13.05 0.96 
Human PCM1 
study 
Foetal (13-19 wks)-PCM1(-) 15.03 2.25 
Foetal (13-19 wks)-PCM1(+) 15.43 1.31 
0-10 yrs-PCM1(-) 13.95 0.36 
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0-10 yrs-PCM1(+) 13.41 0.62 
10-30 yrs-PCM1(-) 16.23 0.89 
10-30 yrs-PCM1(+) 14.06 0.85 
30+ yrs-PCM1(-) 14.31 0.37 
30+ yrs-PCM1(+) 14.54 1.25 
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Table 2.4. List of primer sequences for SYBR Green real-time qPCR analysis targeting 
nuclei RNA.  
Cell 
type 
markers 
Targeted 
gene 
Primer sequence (Human) Primer sequence (Mouse) 
House 
keeping 
gene 
18s F' GCTGAGAAGACGGTCGAACT CCCTCCAATGGATCCTCGTT 
18s R' CGCAGGTTCACCTACGGAAA TCGAGGCCCTGTAATTGGAA 
Cardio
myocyte
s 
MYH6 F' TACCTCCGCAAGTCAGAGAA AACTCAGCTGACCTGCTCAA 
MYH6 R' CTCGGTTTCAGCAATGACC GCCCCGATGGAATAGTACAC 
MYH7 F' CCACTTCTCCCTGATCCACT GTGAAGGAGGACCAGGTGAT 
MYH7 R' TACAAGCCCACGACAGTCTC TAGCGCTCCTTGAGGTTGTA 
TNNC1 F' CCTTCGACATCTTCGTGCT CTGCATCAGCACCAAGGA 
TNNC1 R' TCCACCTCATCGATCATCTC TCAATCATCTCCTGCAGCTC 
TNNI3 F' CTTTGACCTTCGAGGCAAGT AGCAGGAGATGGAACGAGAG 
TNNI3 R' AGGTCCAGGGACTCCTTAGC GCCCATCCAACTCCAAAG 
Fibro 
blasts 
COL1A1 F' GTACTGGATTGACCCCAACC CAATGGTGAGACGTGGAAAC 
COL1A1 R' TACACGCAGGTCTCACCAGT GGTTGGGACAGTCCAGTTCT 
COL3A1 F' GGCAAAGATGGAACCAGTG GCCACCTTGGTCAGTCCTAT 
COL3A1 R' CTCAGATCCTCTTTCACCTCTG GCAGTCTAGTGGCTCCTCATC 
FBN1 F' GAAAGTGGCTGTCTCAATGG GCTCCTCGAGTCCTACACG 
FBN1 R' TCACACTGGGGTCCAGTAAA CTCTTCTCTTGGCCCGATT 
DDR2 F' GCCAGATTTGTCCGGTTC TCCTGAGATTCCAGTGCAAC 
DDR2 R' CAGACACAGCCGTAAAGCTC GGGTCCCCACAAGAGTGATA 
Immune 
cells 
ITGAM F' GGGTTCAACTTGGACACTGA GTGTCATGGCTTCAATCTGG 
ITGAM R' TCCCTGAAGCTGGACCAC CAAGCTGGACCACACTCTGT 
Endothe
lial cells 
VWF F' GCCTCCAAAGGGCTGTATC CTCTTTGGGGACGACTTCAT 
VWF R' CCGCAGGTCTTGTTGAAGTA AAGGAACGTTTCTGGCAGTC 
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Table 2.5. List of primer sequences for bisulphite sequencing.  
Targeted gene Primer Sequence 
Igf2bp3 F' TAGGTAAAATGGAATTATATGGGAAAT 
Igf2bp3 R' ACAACAATAACCCAAAAACAAAAAC 
Neat1 F' GGTTGTGAATGTTTTAGATGAATGTT 
Neat1 R' CAAACTACAAAAACAAAAAAAATAAAC 
Topo M13 Reverse CAGGAAACAGCTATGAC 
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It is not the strongest of the species that survive, 
nor the most intelligent, 
but the one most responsive to change. 
Charles Darwin. 
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Chapter 3. Dynamic changes in the cardiac methylome 
during postnatal development 
Relatively little is known about the mechanisms of how epigenetics guides postnatal organ 
maturation. The goal of this chapter was to determine whether DNA methylation plays an important 
role in guiding transcriptional changes during the first two weeks of mouse heart development, 
which is an important period for cardiomyocyte maturation, loss of proliferative capacity and loss 
of regenerative potential. RNA-seq and MBD-seq identified dynamic changes in the cardiac 
methylome during postnatal development (2545 DMRs from P1 to P14 in the mouse). The vast 
majority (~80%) of DMRs were hypermethylated between P1 and P14 and these hypermethylated 
regions were associated with transcriptional shut down of important developmental signalling 
pathways, including Hedgehog, BMP, TGF, FGF and Wnt/-catenin signalling. Postnatal 
inhibition of DNA methylation with 5aza-dC induced a marked increase (~3-fold) in cardiomyocyte 
proliferation and ~50% reduction in the percentage of binucleated cardiomyocytes compared to 
saline-treated controls. This chapter provides novel evidence for widespread alterations in DNA 
methylation during postnatal heart maturation and suggests that cardiomyocyte cell cycle arrest 
during the neonatal period is subject to regulation by DNA methylation.  
3.1. Introduction 
The mammalian heart undergoes several important physiological transitions during neonatal life, 
which allow the heart to adapt to the postnatal environment. In rodents, the first two weeks of 
postnatal heart development coincide with rapid cardiac growth, cardiomyocyte cell cycle 
withdrawal, a marked increase in the proportion of binucleated cardiomyocytes and cardiomyocyte 
hypertrophy. Additionally, there is a metabolic transition from glycolysis to fatty acid oxidation, 
increased extracellular matrix production and changes in the expression and organization of 
sarcomeric proteins (Porrello and Olson, 2014b). Importantly, it is also during this period, that the 
robust regenerative potential of the neonatal rodent heart diminishes (Porrello et al., 2011b; Porrello 
et al., 2013). These neonatal developmental transitions are associated with alterations in the 
expression of thousands of genes embedded within tightly controlled transcriptional networks. 
However, the transcriptional regulatory mechanisms that guide neonatal heart development remain 
poorly understood. 
Chapter 3 
 
 
70 
Epigenetic modifications have emerged as critical regulators of gene expression changes during 
heart development and disease. The control of gene expression is subject to diverse regulatory 
actions that involve DNA bound TFs including: ATP-dependent chromatin remodelling, covalent 
histone modifications such as acetylation and methylation, and DNA methylation. Genetic deletion 
of chromatin modifying proteins (including HMTs, acetylases, deacetylases and ATP-dependent 
remodelling factors) are implicated in cardiac developmental processes including defects in 
cardiomyocyte proliferation (Chang and Bruneau, 2012). Recent studies have further interrogated 
the relationship between chromatin modifications (histone acetylation and methylation) and gene 
transcription on a genome-wide scale, which has identified important relationships between 
chromatin transitions and transcription during cardiac lineage commitment (Wamstad et al., 2012). 
It has also become apparent that the cardiac cell cycle is under epigenetic control, as comparison of 
embryonic and adult rodent cardiomyocytes revealed an enrichment of H3K9me3 (associated with 
transcriptional repression) at the promoters of cell cycle genes during cardiac maturation (Sdek et 
al., 2011). A recent study has also identified numerous epigenetic modifications at Notch 
responsive promoters that appear to be important determinants of myocyte proliferative responses 
to Notch ligands (Felician et al., 2014a). Curiously, despite intensive interrogation of the roles of 
chromatin modifiers during cardiac development and disease, there have been few systematic 
studies on the impact of DNA methylation. 
DNA methylation occurs by covalent modification at carbon 5 of cytosine, predominantly in the 
context of a cytosine-guanine dinucleotide (CpG) (Suzuki and Bird, 2008). The mechanisms for 
establishing and maintaining DNA methylation are well established and involve three 
methyltransferases (Dnmts) in mammals - Dnmt1, 3a and 3b (Wu and Zhang, 2014). Germline 
deletion studies in mice have established essential roles for Dnmts during embryonic heart 
development (Li et al., 1992). More recent genome-wide DNA methylation profiling studies have 
identified widespread alterations in DNA methylation patterns during early embryonic heart 
development and have revealed potentially important associations with transcriptional changes in 
cardiogenic genes (Chamberlain et al., 2014). Moreover, dynamic changes in DNA methylation 
patterns correlate with gene expression changes in heart failure (Movassagh et al., 2011) and dilated 
cardiomyopathy (Haas et al., 2013) in humans and inhibition of DNA methylation may be 
cardioprotective in settings of norepinephrine-induced cardiac hypertrophy (Xiao et al., 2013) and 
ischemic heart disease (Watson et al., 2013). These findings suggest that DNA methylation is 
important for cardiac gene expression during embryonic heart development and in various adult 
disease settings. However, the impact of DNA methylation during cardiac maturation in the 
neonatal period has not been investigated.  
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In this chapter, it was hypothesised that DNA methylation plays a key role in the repression of 
transcriptional networks governing cardiomyocyte proliferation during the neonatal period. The 
current chapter presents the first systematic analysis of DNA methylation during postnatal heart 
development. Two waves of DNA methylation have been identified during the neonatal period and 
demonstrate that inhibition of DNA methylation during neonatal heart development prolongs the 
proliferative capacity of cardiomyocytes and is associated with a profound reduction in 
cardiomyocyte binucleation. Moreover, a genome-wide approach have been taken to analyse 
neonatal changes in DNA methylation and transcription, which shows differential methylation 
events across thousands of loci, some of which are associated with transcriptional changes in 
important developmental signalling pathways for muscle growth and differentiation. These results 
provide new insight and information on the regulation of cardiac gene expression subject to changes 
by DNA methylation in the neonatal period.  
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3.2. Methodology 
3.2.1. In vivo administration of 5aza-dC to neonatal mice 
The hypomethylating agent 5aza-dC (Sigma-Aldrich, St. Louis, MO, USA) was made fresh daily by 
dissolved in saline and administered to neonatal ICR/CD-1 mice through daily subcutaneous 
injections (1 mg/kg) from P2 to P12. Control mice received a daily subcutaneous injection of an 
equivalent volume of saline. All animals were euthanized at P7 or P12 by asphyxiation with CO2 
followed by cervical dislocation. Hearts were harvested for DNA/RNA extraction, histology and 
cell isolations as described in Chapter 2. 
3.2.2. Cardiomyocyte isolation and quantification of binucleation  
Hearts were harvested and fixed in 4% PFA for 1 hour at room temperature. Cardiomyocytes were 
isolated by enzymatic digestion of fixed cardiac tissues using a combination of collagenase D (2.4 
mg/mL, Roche, Basel, Switzerland) and collagenase B (1.8 mg/mL, Roche) with overnight shaking 
at 37°C until the tissue was fully digested. Cell suspensions were then pelleted at 300 x g for 3 
minutes at room temperature and then re-suspended in PBS. For nuclei staining, cell suspensions 
were stained with Hoechst 33342 (1:500, Thermo Fisher Scientific (Invitrogen)) for 10 minutes at 
room temperature. Cells were then pelleted at 300 x g for 3 minutes and washed in PBS before 
being re-suspended in Fluoromount-G (Southern Biotech) and mounted on slides. Bright field and 
fluorescence images were acquired for 100 cells per sample and overlayed for post-analysis in 
ImageJ (version 1.47v, National Institutes of Health, Bethesda, MD, USA). Quantification of 
cardiomyocyte nucleation, cell width and cell length were performed under blinded conditions. 
3.2.3. Transcriptional profiling with RNA-seq  
Cardiac ventricles were harvested at P1 and P14 (n=9 per group) from C57BL6/J mice as described 
above and were homogenised in PBS. Three individual hearts were pooled per replicate. This 
homogenate was divided between transcriptome and methylome assays. RNA was isolated by 
TRIzol extraction (Thermo Fisher Scientific (Ambion)) followed by QiaQuick MinElute (Qiagen) 
cleanup including on-column DNase digestion. RNA quality was verified with MultiNA 
bioanalyzer (Shimadzu, Kyoto, Kansai, Japan). Purified mRNA was prepared using Dynabeads® 
Oligo (dT) 25 (Thermo Fisher Scientific (Ambion)) enrichment. Libraries were generated using the 
NEBNext® mRNA Library Prep Reagent Set for Illumina (New England Biolabs). Libraries were 
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validated on MultiNA bioanalyzer and sequenced at a concentration of 10 pM (Illumina, San Diego, 
CA, USA). Base-calling was performed off-line with OLB v1.8. 
3.2.4. MBD-seq 
Genomic DNA for CpG methylation profiling was isolated using the DNeasy Blood & Tissue Kit 
(Qiagen). DNA was fragmented by BioRuptor sonication (Diagenode, Denville, NJ, USA). 
Fragmented DNA was analyzed with bioanalyzer, and 1 g of sonicated DNA underwent methyl-
CpG enrichment using the MethylMiner™ Methylated DNA Enrichment Kit (Thermo Fisher 
Scientific (Applied Biosystems)). Sequencing libraries were generated using the NEBNext® DNA 
Library Prep Reagent Set (New England Biolabs) for Illumina. Libraries were validated on 
MultiNA bioanalyzer and sequenced as above. MBD-seq measures average methyl-cytosine levels 
in the sequenced fragments (150-250 bp in length) (Stevens et al., 2013). 
3.2.5. Bioinformatics analyses 
Sequence reads underwent 3’ base quality trimming using the Fastx toolkit with a minimum Phred 
quality score (Q) of 30 and a minimum read length of 20 nt. RNA-seq reads were aligned to the 
mouse genome sequence (GRCm38.70/mm10) using Olego with default settings (Wu et al., 2013). 
Reads aligning to Ensembl-annotated exons with a strict mapping quality (Q≥20) were counted with 
BedTools (Quinlan and Hall, 2010) and used to construct a data matrix comprising genes with an 
average of 10 reads or more per sample across the experiment. Differential gene expression analysis 
was performed using edgeR (v3.2.4) (Robinson et al., 2010). Heatmaps were generated from 
normalized and scaled gene expression values in R (Reich et al., 2006).  
MBD-seq reads were aligned to the mouse genome (GRCm38.70/mm10) using Burrows Wheeler 
Aligner (BWA) with default settings (Li and Durbin, 2009). Reads from each developmental stage 
were pooled and a single large alignment file (bam format) prepared for P1 and P14. MACS (Zhang 
et al., 2008) was then used to directly compare P1 to P14 and identify regions of interest. MACS 
peak-calling was performed with a shift size of 75 bp and otherwise default parameters. DMRs 
were defined as coordinates initially identified using MACS peak calling determined to have a 
statistically significant signal difference (P1 vs. P14, FDR ≤ 0.05) and all DMRs exhibited greater 
than 30% fold change. Intersection between our DMRs and Ensembl genomic features was 
performed with BedTools. Likewise, intersection between DMRs and TF binding sites or DNaseI 
hypersensitivity sites defined by the Encyclopedia of DNA Elements (ENCODE) project 
(http://genome.ucsc.edu/ENCODE/downloadsMouse.html) was determined. Peak files from Mouse 
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ENCODE project (mm9) were converted to mm10 coordinates using liftOver tool 
(http://hgdownload.soe.ucsc.edu/admin/exe/) with the mm9 to mm10 chain file (http://hgdownload-
test.cse.ucsc.edu/goldenPath/mm9/liftOver/mm9ToMm10.over.chain.gz) using the default settings. 
Enrichment of TF binding motifs between in P14 and P1 peaks was computed using Homer 
(http://homer.salk.edu/homer/ngs/index.html). Gene expression, methylation and gene set 
enrichments with an FDR p-value ≤ 0.05 were considered significant. Gene GO analysis 
(pathway/process/network) was performed using MetaCore from Thomson Reuters 
(https://portal.genego.com/cgi/data_manager.cgi) on significant gene sets. All network relationship 
analyses were performed using the direct interaction analysis function. GSEA was performed on 
these data as previously described (Subramanian et al., 2005) using publicly available gene sets 
(www.broadinstitute.org/gsea/msigdb ).  
3.2.6. Data access 
RNA-seq and MBD-seq data from this project is available from GEO 
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE59971. 
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3.3. Results 
3.3.1. Dynamic regulation of DNA methylation machinery during postnatal 
cardiac maturation 
Total DNA methylation was measured in mouse hearts at P1, P7, P14, P28 and P84. Genomic DNA 
methylation levels remained steady from P1 to P14 but markedly decreased thereafter (Figure 
3.1A). Subsequently, the expression levels of Dnmts was measured by real-time qPCR in mouse 
hearts from P1 to P84 (Figure 3.1B). Consistent with an overall decrease in genomic DNA 
methylation levels after P14, qPCR profiling of Dnmt1, Dnmt3a and Dnmt3b confirmed decreased 
mRNA expression levels in postnatal maturation of cardiac tissue. This result was verified at the 
protein level by immunohistochemistry staining (Figure 3.1C). Dnmt1 and Dnmt3a were 
predominantly localized to the nucleus of cardiomyocytes with high expression levels at P1 and P7 
(Figure 3.1C). While Dnmt1 exhibited a dramatic decrease in expression levels after P7, such that 
it became hardly detectable in cardiomyocytes by P14 and P28, Dnmt3a maintained its expression 
level until P14 but was undetectable in P28 hearts (Figure 3.1C). Dnmt1 and Dnmt3a were also 
expressed in non-myocytes at early developmental time-points but were undetectable in all cell 
types by P28 (Figure 3.1C). The expression levels of the non-canonical Dnmts, Dnmt2 and Dnmt3l 
were also checked by qPCR analysis. While Dnmt2 expression levels did not dramatically change 
throughout life, Dnmt3l was significantly up-regulated after P14 (Figure 3.2A). 
Given the decrease in global DNA methylation levels after P14, the expression levels of TETs and 
Growth Arrest and DNA Damage 45 (Gadd45s) was profiled because they are implicated in active 
DNA demethylation (Wu and Zhang, 2014). Real-time qPCR analysis showed that Gadd45a and 
Gadd45g were up-regulated at P14 and Gadd45a expression continued to increase until P28 
(Figure 3.2B, C). However, the mRNA expression levels of Tet1-3 and Gadd45b all decreased 
during postnatal heart maturation (Figure 3.2B, C).  
3.3.2. DNA methylation is required for cardiomyocyte cell cycle arrest and 
binucleation in vivo  
To better understand the role of DNA methylation in regulating postnatal cardiac development, 
hypomethylating agent 5aza-dC was used to pharmacologically inhibit DNA methylation of 
neonatal mice from P2 (Figure 3.3A). 5aza-dC is a clinical medication for myelodysplastic 
syndromes and acute myeloid leukaemia. It effectively prevents DNA methylation by incorporating 
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into DNA as the analogue of cytidine, which cannot be methylated or through inhibition of Dnmts 
(Christman, 2002; Karahoca and Momparler, 2013). 5aza-dC treated mice grew normally for the 
first 5 days of exposure but stopped gaining weight thereafter and the experiment was terminated at 
P12 (Figure 3.3A). Systemic administration of 5aza-dC induced ~50% reduction of genomic DNA 
methylation levels in P12 hearts (Figure 3.3B). Inhibition of DNA methylation was associated with 
a significant increase in heart size, as indicated by a pronounced increase in the heart weight to 
body weight ratio (HW/BW) at P7 and P12 (Figure 3.3C, D).  
To understand whether the increased heart weight following inhibition of neonatal DNA 
methylation was caused by cell proliferation, heart sections were stained with antibodies 
recognising pH3 and cTnnT to quantify the incidence of cardiomyocyte mitosis. At P7, an increase 
in the number of pH3
+
 cells by ~50% in cardiomyocytes and ~25% in non-myocytes was observed 
in 5aza-dC treated hearts (Figure 3.3E, F) and was associated with a ~50% reduction in the 
percentage of binucleated cardiomyocytes (Figure 3.3G). A reduced percentage of binucleated 
cardiomyocytes in the 5aza-dC treated group was also noted at P12 (Figure 3.3G). While no effect 
of 5aza-dC on cell size was detected at P7, a modest increase in cell size was observed at P12 
(Figure 3.3H, I). Interestingly, cardiomyocyte hypertrophy at P12 was associated with an increase 
in cell length in both mono- and bi-nucleated cardiomyocyte populations (Figure 3.3J, K, L). 
Together, these findings suggest that inhibition of DNA methylation during neonatal life prevents 
cardiomyocyte cell cycle arrest and binucleation, increasing heart size postnatally. 
3.3.3. Neonatal cardiac maturation is associated with profound alterations in 
gene transcription 
To understand the transcriptional changes during neonatal heart maturation, RNA-seq was 
performed in P1 and P14 hearts. A total of 6476 genes were differentially expressed (FDR ≤ 0.05) 
between P1 and P14 cardiac ventricles (Figure 3.4A; Table 3.1). Among these differentially 
expressed genes, 3233 genes were expressed at significantly higher levels at P14, whereas 3243 
genes were expressed at higher levels at P1 (Figure 3.4A, B; Table 3.1). Gene GO pathway 
analysis revealed an increase in the expression of genes at P14 that were predominantly involved in 
metabolism (oxidative phosphorylation) and cytoskeletal remodelling which is consistent with the 
well known changes in metabolic substrate utilization and cytoskeletal rearrangement (Porrello and 
Olson, 2014b) that occur after birth in mammals (Figure 3.4C). On the other hand, the majority of 
genes that decreased in expression levels at P14 were associated with cell cycle checkpoints, DNA 
replication, the DNA damage response and cytoskeletal remodelling, consistent with the well-
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established phenomenon of cardiomyocyte cell cycle arrest and ultrastructural maturation following 
birth (Porrello and Olson, 2014b) (Figure 3.4C).  
3.3.4. Differential methylated regions characterize neonatal cardiac maturation 
Given the importance of DNA methylation for postnatal cardiomyocyte cell cycle arrest and 
binucleation, whether there are alterations in DNA methylation across the genome have been 
assessed during neonatal cardiac maturation. DNA samples from P1 and P14 cardiac ventricles 
were processed for whole-genome DNA methylation sequencing (MBD-seq), known as 
MethylMiner, which have been previously validated (Pirola et al., 2011). Analysis of the total 
number of reads processed indicated that the numbers of aligned reads used in peak calling were 
similar for P1 and P14 sample groups (Table 3.2). The MBD-seq analysis identified 2545 DMRs 
between P1 and P14 (Figure 3.5A; Table 3.1). Among these DMRs, 2005 regions (~80%) were 
hypermethylated and 540 regions (~20%) were hypomethylated at P14 relative to P1 (Figure 3.5A, 
B; Table 3.1). Notably, P14 DMRs had a higher CpG dinucleotide content (28.95±0.006 / kilobase 
pair (kbp) at P14 vs. 13.02±0.012 / kbp at P1) and higher G/C nucleotide content (553.0±0.021 / 
kbp at P14 vs. 396.8±0.116 / kbp at P1) than the P1 DMRs. Interestingly, DNA hypermethylation 
was noted across all mouse chromosomes at P14 (Figure 3.5C). Intersection of differentially 
methylated peaks with the mouse genome revealed that approximately 4.8% of the genome was 
differentially methylated between P1 and P14 (Figure 3.5D). The majority of DNA methylation 
peaks at P14 occurred across protein coding DNA sequences (CDS) and exons, with almost one-
third of coding regions displaying an increase in methylation levels from P1 to P14 (Figure 3.5D).  
3.3.5. Gene expression changes implicated in cardiac maturation are subject to 
DNA methylation 
Because neonatal cardiac development is subject to broad changes in DNA methylation we 
examined associations with gene expression by intersecting RNA-seq and MBD-seq data sets. In 
total, 564 DMRs overlapping promoters (+/- 3 kbp TSS) and gene bodies were associated with 
significant changes in mRNA expression levels between P1 and P14 (Figure 3.6A, Top; Table 3.3; 
Appendix 7.1). The majority of DMRs associated with gene expression changes at P14 overlapped 
protein coding sequences and exons (Table 3.3). In total, 143 hypermethylated regions were 
associated with transcriptional repression at P14, while a much larger number of hypermethylated 
regions (n=385) were associated with transcriptional activation during neonatal cardiac maturation 
(Figure 3.6A, Bottom; Table 3.3; Appendix 7.1). A smaller number of hypomethylated regions 
were similarly associated with either transcriptional repression or activation at P14 (Figure 3.6A, 
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Bottom; Table 3.3; Appendix 7.1). To explore relationships between DNA methylation and 
transcription in greater detail, statistical correlation analyses were performed between P14 
methylation peaks across different genomic features and mRNA expression changes. At P14, DNA 
methylation across exons was highly positively correlated with gene expression (Figure 3.7A). 
Similarly, DNA methylation across promoter regions at P14 was also typically associated with 
increased transcription at P14 (Figure 3.7B). In contrast, DNA methylation across exons and 
promoter regions at P1 negatively correlated with gene expression levels (Figure 3.7). These 
observations are consistent with genome-wide methylation profiling studies in other cell types, 
which suggest the impact of DNA methylation on gene transcription is highly context-dependent 
(Jjingo et al., 2012). 
To validate these novel associations between methylation and transcription during neonatal heart 
development, two of the most highly differentially methylated genes between P1 and P14 were 
analysed by qPCR and bisulphite sequencing. Igf 2 binding protein 3 (Igf2bp3) represented the top 
candidate for genes displaying increased methylation associated with decreased mRNA expression 
at P14, while the long non-coding RNA, nuclear paraspeckle assembly transcript 1 (Neat1), 
represented the top candidate for genes displaying decreased methylation and increased expression 
at P14 (Figure 3.6A, Bottom). Real-time qPCR analysis confirmed that Igf2bp3 expression levels 
decreased from P1 to P84, while the expression level of Neat1 significantly increased after birth 
(Figure 3.6B), consistent with the RNA-seq data. Bisulphite sequencing was also performed on 
these two gene loci (Figure 3.6D). Bisulphite sequencing results strongly validated our MBD-seq 
data and confirmed increased methylation across the Igf2bp3 locus and decreased methylation 
across the Neat1 locus from P1 to P28 (Figure 3.6D, Figure 3.8). To further confirm that the 
expression level of Igf2bp3 and Neat1 was regulated by DNA methylation, their mRNA expression 
level was also examined in heart samples from mice that were treated with 5aza-dC. Both Igf2bp3 
and Neat1 exhibited higher expression levels in 5aza-dC treated groups (Figure 3.6C), which was 
consistent with their methylation/expression patterns during neonatal cardiac development.  
3.3.6. DNA methylation regulates transcription of critical developmental 
signalling networks during neonatal life 
Next, Gene GO analysis was performed to explore the potential mechanisms underlying 
relationships between DNA methylation and gene transcription during neonatal heart development. 
Gene GO was used for process network analysis of various gene sets representing different 
relationships between DNA methylation and gene transcription (Figure 3.9A, 3.10A, 3.11A, 
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Appendix 7.1). Process network analysis for genes with increased DNA methylation and reduced 
expression at P14 identified a highly significant enrichment for genes associated with several 
important developmental signalling pathways including Hedgehog, TGF, FGF, vascular 
endothelial growth factor (VEGF), Notch and the Wnt/-catenin pathway (Figure 3.9A). In 
addition, genes with increased methylation and decreased expression during neonatal cardiac 
maturation were also highly enriched for genes associated with cell adhesion and extracellular 
matrix interactions (Figure 3.9A). Further analysis of this gene set revealed an interaction network 
centred on Smad3, a critical downstream TF for the TGF signalling pathway (Figure 3.9B). For 
genes displaying increased methylation and increased transcription at P14, Gene GO analysis also 
revealed a significant enrichment for genes associated with developmental signalling pathways such 
as Notch, but, in addition, this gene set was also highly enriched for genes associated with muscle 
contraction, inflammation and the immune response (Figure 3.10A). Analysis of this gene set 
identified multiple interaction nodes converging on Notch1, NF-B and the CBP (Figure 3.10B). 
While no significant interaction networks was identified for the small subset of genes displaying 
decreased methylation and decreased expression at P14, analysis of the gene set associated with 
decreased methylation and increased expression identified a significant interaction network 
involving multiple components of the epidermal growth factor receptor (EGFR) and 
phosphoinositide 3-kinase (PI3K)/Akt signalling pathway (Figure 3.11). These findings suggest 
that DNA methylation regulates the expression of multiple components of key developmental 
signalling pathways for cardiac development during neonatal life. 
3.3.7. Analysis of DNase hypersensitivity regions and TF binding sites 
associated with DNA methylation during neonatal cardiac maturation 
DNA methylation peaks at P14 were intersected with DNase hypersensitivity sites, which are 
indicative of open chromatin and active transcription, using GSEA with reference to the mouse 
ENCODE project. Intersection of DNA methylation peaks at P14 with ENCODE data identified 
DNase hypersensitivity regions associated with undifferentiated mouse ESCs (Figure 3.12A). 
GSEA was also used to intersect P14 methylation peaks with ChIP-seq data from the mouse 
ENCODE project for identification of TF binding sites. Intersection of DNA methylation peaks at 
P14 with ENCODE revealed a significant overlap with ChIP-seq data sets for multiple TFs 
associated with muscle differentiation in C2C12 cells (Figure 3.12B). Notably, P14 methylation 
peaks displayed significant intersection with myogenic TF binding sites (e.g. myogenin (Myog) and 
Myod), as well as transcriptional repressors (neuron-restrictive silencer factor (Nrsf) and CCTC 
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binding factor (Ctcf)) and transcriptional effectors of Wnt signalling (transcription factor 3 (Tcf3)) 
(Figure 3.12B).  
Additionally, a de novo search for enriched TF binding sites was performed to identify binding sites 
that overlapped with DNA methylation peaks at P1 and P14. Intersection of DNA methylation 
peaks at P14 with known TF binding motifs using Homer revealed a highly significant enrichment 
for several TF binding sites associated with myogenic differentiation including MADS-box, Tbx5, 
Smad2/3/4, and Foxh1 (Figure 3.12C). These findings point to a potential interaction between 
myogenic and Smad TFs with the DNA methylation machinery during neonatal heart maturation.   
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Table 3.1. Summary of the total number of differentially expressed genes and DMRs 
between P1 and P14 from RNA-seq and MBD-seq. 
  
Number of regions 
Higher at P1 
Number of regions 
Higher at P14 
Total 
RNA-seq (FDR ≤ 0.05) 3243 3233 6476 
MBD-seq (FDR ≤ 0.05) 540 2005 2545 
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Table 3.2. MBD-seq quality control summary. 
  Total reads QC passed reads Aligned reads 
P1-1 33903541 33675705 32911534 
P1-2 34214266 33751319 33036386 
P1-3 33554267 33361709 32690433 
P14-1 30736962 30597908 30167706 
P14-2 34335375 34131579 33532376 
P14-3 32694036 32526986 31806532 
P1 Total 101672074 100788733 98638353 
P14 Total 97766373 97256473 95506614 
 
 
Chapter 3 
 
 
83 
Table 3.3. Summary of the total number of genes and distribution of DNA methylation marks with differential methylation levels and 
mRNA expression changes between P1 and P14 (CpG shore: CGS). 
Correlation of mRNA 
expression levels and DNA 
methylation levels 
Number 
of genes 
% 
TSS 1 kbp  TSS 3 kbp  Exon CDS CGI CGS Intergenic Intron 
↑CpG ↓mRNA 143 25.9 37.1 69.9 65.0 16.1 25.2 4.9 90.9 
↓CpG ↑mRNA 36 19.4 41.7 22.2 16.7 0.0 16.7 2.8 88.9 
↑CpG ↑mRNA 355 36.1 55.5 90.1 87.0 34.9 45.6 8.2 94.1 
↓CpG ↓mRNA 30 16.7 30.0 43.3 30.0 0.0 13.3 10.0 86.7 
Total number of genes 564 
        
*Please note that many DMRs overlapped multiple regions of a gene (e.g. a DMR can span exons and introns of the same gene). Therefore, the 
percentage of the distribution of DNA methylation marks does not sum up to 100%. 
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Figure 3.1. DNA methylation profiling during postnatal cardiac development.  
A. Genomic DNA methylation levels in mouse cardiac ventricles from P1 to P84 (n=3 per time 
point; *P<0.05).  
B. qPCR gene expression profiling of Dnmt1, 3a and 3b in mouse cardiac ventricles from P1 to 
P84. Expression levels of each Dnmt are normalized to 18S and represented as a fold change 
relative to P1 ventricles (n=3 per time point; *P<0.05, **P<0.001).  
C. Immunohistochemistry staining for Dnmt1 and Dnmt3a in mouse hearts from P1 to P28. Red = 
cTnnT, green = Dnmt1 or Dnmt3a, blue = nuclei. Dnmt1/3a positive cardiomyocytes are also 
shown in the high magnification inset in the top right hand corner of each panel. Scale bar = 50 m 
in main figure and 5 m in high magnification inset.  
Chapter 3 
 
 
85 
 
Figure 3.2. Expression profiling of non-canonical Dnmts and enzymes involved in active 
DNA demethylation during postnatal cardiac development.  
A. qPCR gene expression profiling of Dnmt2 and Dnmt3l in cardiac ventricles from P1 to 12 
weeks-of-age. (n=3 per group).  
B. qPCR gene expression profiling of Tet family enzymes from P1 to 12 weeks-of-age (n=3 per 
group). 
C. qPCR gene expression profiling of Gadd45 family enzymes from P1 to 12 weeks-of-age (n=3 
per group). All gene expression values are normalized to 18S and presented as a fold change 
relative to P1. All data are presented as mean ±s.e.m. *P<0.05, ** P <0.001).   
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Figure 3.3. Pharmacological inhibition of DNA methylation during neonatal life promotes 
cardiac cell proliferation and blocks cardiomyocyte binucleation.  
A. Growth curve for CD-1/ICR mice treated with 5aza-dC from P2 to P12 (n=14-15 per group). 
*P<0.05, **P<0.001.  
B. H&E staining of saline and 5aza-dC-treated hearts at P12.  
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C. Genomic DNA methylation levels of saline and 5aza-dC treated mice at P12 (n=4 per group; 
*P<0.05).  
D. Heart weight to body weight ratios for saline and 5aza-dC-treated mice at P7 (n=11-17 per 
group) and P12 (n=7-14 per group). **P<0.001.  
E. Immunohistochemistry staining of saline and 5aza-dC-treated hearts at P7. Green = pH3, red = 
cardiac troponin T, blue = nuclei. pH3
+
 cardiomyocytes are also shown in the high magnification 
inset in the top right hand corner of each panel. Scale bar = 50 m in the main figure and 10 m in 
the high magnification inset.  
F. Quantification of pH3
+
cardiomyocytes (CM) and non-cardiomyocytes (non-CM) in saline and 
5aza-dC-treated hearts at P7. Data are presented as cells/field for n=4-6 independent samples per 
group (10 fields of cells assessed per heart). **P<0.001.  
G. Quantification of the percentage of binucleated cardiomyocytes at P7 (n= 4-6 per group; N=100 
cells per sample) and P12 (n= 3-5 per group; N=100 cells per sample). **P<0.001.  
H. WGA staining of saline and 5aza-dC-treated hearts at P12. Scale bar = 50 m.  
I. Scatter plot of quantified cardiomyocyte cross-sectional surface area in saline and 5aza-dC-
treated hearts at P7 (n=4-5 per group) and P12 (n= 3-5 per group) (10 fields of cells assessed per 
heart). Blue line represents median. **P<0.001.  
J. Hoechst staining of mononucleated and binucleated cardiomyocytes. Scale bar = 10 m.  
K, L. Quantification of cardiomyocyte length (K) and width (L) in saline and 5aza-dC-treated 
hearts at P12 (n= 3-5 per group; N=100 cells per heart). Data are presented as average cell length or 
width per group. All values are presented as mean ± s.e.m. *P<0.05, **P<0.001.  
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Figure 3.4. RNA-seq analysis of gene expression changes during neonatal heart 
development.  
A. Smear plot of RNA-seq data showing average signal intensity (x-axis) versus log2 fold change in 
gene expression (P14/P1). Differentially expressed genes (FDR ≤ 0.05, n=6476) are shown in red 
and non-significant changes are shown in black.  
B. Heatmap of differentially expressed genes from P1 to P14. Genes with higher expression levels 
are shown in yellow whereas genes with lower expression levels are shown in red.  
C. Gene GO pathway analysis (MetaCore) for differentially regulated genes in P1 versus P14 
hearts. Genes that have higher expression levels at P1 (Blue) or higher expression levels at P14 
(Red).  
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Figure 3.5. MBD-seq analysis of DNA methylation changes occurring during neonatal 
heart development.  
A. Smear plot of MBD-seq data showing average signal intensity (x-axis) versus log2 fold change 
in MBD enrichment (P14/P1). DMRs (FDR ≤ 0.05, n=2545) are shown in red and non-significant 
changes are shown in black.  
B. Heatmap of DMRs identified from MBD-seq. Regions with higher methylation levels are shown 
in yellow whereas regions with lower methylation levels are shown in red.  
C. Distribution of DMRs across each chromosome at P1 (black) and P14 (red) for mouse (mm10) 
genome normalised by chromosome length.  
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D. Distribution of DMRs shown by genomic features. Hypermethylated regions at P1 are shown in 
yellow, hypermethylated regions at P14 are shown in red and regions without significant 
differential methylation are shown in blue. 
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Figure 3.6. Integration of RNA-seq and MBD-seq identifies complex relationships between 
DNA methylation and transcription during neonatal heart development.  
A. (Top) Venn diagram of differentially regulated genes from RNA-seq and MBD-seq data sets. 
564 genes with differential methylation between P1 and P14 were also differentially expressed 
during this period. (Bottom) The scatter plot shows log2 fold changes in mRNA expression levels 
(y-axis) against log2 fold changes in MBD enrichment (x-axis).  
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B. qPCR gene expression profiling of Igf2bp3 and Neat1 in mouse cardiac ventricles from P1 to 
P84. Expression levels of Igf2bp3 and Neat1 are normalized to 18S and represented as a fold 
change relative to P1 ventricles (n=3 per group). Data are presented as mean ± s.e.m. *P<0.05, 
**P<0.001.  
C. qPCR gene expression profiling of Igf2bp3 and Neat1 in saline and 5aza-dC treated hearts at P7. 
Expression levels of Igf2bp3 and Neat1 are normalized to 18S and represented as a fold change 
relative to P1 ventricles (n=4-6 per group). Data are presented as mean ± s.e.m. *P<0.05, 
**P<0.001.  
D. Bisulphite sequencing of Igf2bp3 and Neat1 in cardiac ventricles at P1, P14 and P28 (n=3 per 
group). A schematic of the genomic region selected for bisulphite sequencing is shown above with 
the sequenced region denoted by red arrows. Black dot: methylated CpG site, white dot: 
unmethylated CpG site. Quantification of the percentage of CpG methylation of target genes at P1, 
P14 and P28 is also shown. Data are presented as mean ± s.e.m. *P<0.05, **P<0.001. 
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Figure 3.7. Statistical correlation analysis of DMRs with gene expression changes at P1 and 
P14.  
A. GSEA identifies a positive correlation between exon methylation and gene transcription at P14. 
In contrast, methylation across exon at P1 was negatively correlated with gene expression levels at 
P1.  
B. GSEA identifies a positive correlation between TSS methylation and gene transcription at P14. 
In contrast, methylation across TSS at P1 was negatively correlated with gene expression at P1. 
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Figure 3.8. Map of MBD-seq reads across the Igf2bp3 and Neat1 loci in P1 and P14 hearts.  
A. Map of MBD-seq reads across the Igf2bp3 locus between P1 and P14. DMR highlighted in red.  
B. Map of MBD-seq reads across the Neat1 locus between P1 and P14. DMR highlighted in red. 
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Figure 3.9. Gene ontology and biological network analysis for hypermethylated genes 
associated with transcriptional repression during neonatal cardiac maturation.  
A. Gene GO process network analysis for the 143 genes with increased methylation and decreased 
mRNA expression from P1 to P14.  
B. Interaction network created by Gene GO using genes with increased DNA methylation and 
decreased mRNA expression levels from P1 to P14.  
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Figure 3.10. Gene ontology and biological network analysis for hypermethylated genes 
associated with transcriptional activation during neonatal cardiac maturation. 
A. Gene GO process network analysis for the 355 genes with increased methylation and increased 
mRNA expression from P1 to P14.  
B. Interaction network created by Gene GO using genes with increased DNA methylation and 
increased mRNA expression levels from P1 to P14.  
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Figure 3.11. Gene ontology and biological network analysis for hypomethylated genes 
associated with transcriptional activation during neonatal cardiac maturation.  
A. Gene GO process network analysis for the 36 genes with decreased methylation and increased 
mRNA expression from P1 to P14.  
B. Interaction network created by Gene GO using genes with decreased DNA methylation and 
increased mRNA expression levels from P1 to P14.  
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Figure 3.12. Analysis of DMRs for enriched DNase hypersensitivity sites and enriched TF 
binding sites at P14.  
A. Relative fold enrichment of Mouse ENCODE DNase hypersensitivity between P14:P1 peak sets. 
Peak intersections with a positive value show enrichment in P14 peak regions (hypermethylation), 
while negative values depict enrichment in the P1 peak regions (hypomethylation).  
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B. Relative fold enrichment of Mouse ENCODE TF binding sites between P14:P1 peak sets. Peak 
intersections with a positive value show enrichment in P14 peak regions (hypermethylation), while 
negative values depict enrichment in the P1 peak regions (hypomethylation).  
C. De novo analysis of enriched TF binding sites between P14 and P1 using Homer. TF binding 
motifs for Foxh1, Smad3 and MADS-box are displayed on the right.  
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3.4. Discussion and conclusion 
This chapter demonstrates, for the first time, that DNA methylation events are associated with 
changes in cardiac gene expression during neonatal heart development. The findings indicate that 
DNA methylation levels are not static during postnatal heart development but rather undergo 
dynamic alterations during neonatal life. Specifically, two postnatal waves of DNA methylation 
were identified in the rodent heart involving increased site-specific methylation from P1 to P14, 
followed by a global decrease in genomic methylation levels after P14. Importantly, global 
inhibition of DNA methylation during the neonatal period promotes cardiac cell proliferation and 
inhibits cardiomyocyte binucleation, suggesting that DNA methylation is required for neonatal 
cardiac maturation. Bioinformatics analyses suggest that this process might be regulated through 
methylation of several canonical developmental and differentiation-associated signalling pathways 
including Hedgehog, TGFFGF, Notch and Wnt. Notably, DMRs were highly enriched for MyoG, 
Tbox and Smad 2/3/4 TF binding sites, suggesting that interplay between myogenic TFs and the 
epigenetic machinery might contribute to the regulation of gene expression networks during 
neonatal cardiac differentiation. The current chapter identifies a novel role for DNA methylation 
during neonatal heart development and is consistent with an epigenetic mechanism for cell cycle 
arrest in the postnatal heart. 
One of the most surprising observations of the current study was the identification of two postnatal 
waves of DNA methylation; one coinciding predominantly with increases in site-specific 
methylation from P1 to P14 and another involving global hypomethylation after P14. This 
phenomenon is highly reminiscent of previously reported patterns of DNA methylation associated 
with aging and cancer (Issa, 2014). Specifically, methylation drift occurs during aging and cancer 
development, with numerous studies identifying an increase in site-specific DNA methylation (e.g. 
at promoter regions), occurring coincident with global hypomethylation across intergenic regions 
and repeat sequences (Issa, 2014). This DNA methylation pattern is conserved between species and 
across multiple organs during aging. Notably, a prominent methylation shift is observed in more 
proliferative tissues, including colon, stomach and liver (Issa, 2014). Interestingly, multiple studies 
suggest that age-related changes in DNA methylation predominantly occur at genes associated with 
developmental signalling pathways and organogenesis (Issa, 2014), which is similar to the findings 
of the current study in neonatal hearts. While the functional significance and specific genomic 
regions affected by the global hypomethylation after P14 are currently unclear, this process may 
reflect an age-dependent loss of DNA integrity during postnatal cardiac maturation. A recent report 
provided evidence for a progressive increase in oxidative DNA damage during postnatal cardiac 
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maturation (Puente et al., 2014) and several studies have suggested that the presence of unrepaired 
lesions in DNA substantially alters the methylation capacity of Dnmts, leading to DNA 
hypomethylation (Cerda and Weitzman, 1997; James et al., 2003). Interestingly, Gadd45a, which is 
induced by DNA damage and has been implicated in active DNA demethylation (Niehrs and 
Schafer, 2012), increased at P14. However, transcription of other enzymes implicated in DNA 
demethylation such as Tet1-3 decreased during postnatal heart development. It is currently unclear 
whether these DNA demethylating enzymes play a major role in the hypomethylation of the cardiac 
genome after P14 and further studies will be required to determine whether this is a cardiac-specific 
phenomenon or whether it has broader implications for postnatal maturation of other tissues.. 
These findings suggest that DNA methylation events during the first two weeks of life in rodents 
are required for cardiomyocyte cell cycle arrest and binucleation in vivo. While the study design 
does not permit exclusion of a possible contribution of systemic effects of 5azato the observed 
cardiac phenotype, the in vivo findings are consistent with two recent in vitro studies in cultured 
neonatal rat cardiomyocytes , which suggested that 5azainduces cardiomyocyte proliferation and 
inhibits endothelin-induced cardiomyocyte binucleation (Felician et al., 2014b; Kou et al., 2010; 
Paradis et al., 2014). These striking effects of 5azaon cardiomyocyte binucleation are particularly 
interesting given that hypomethylating agents such as 5azaare commonly used as anti-cancer drugs 
and have anti-proliferative effects in other cell types. However, it is also known that DNA 
methylation can have either positive or negative effects on cell proliferation depending on the 
epigenetic modification of different sub-sets of genes (e.g. oncogenes or tumour suppressor genes). 
In the present chapter, complex relationships have been identified between DNA methylation 
during neonatal life and multiple components of key developmental signalling pathways. Neonatal 
cardiac maturation is associated with hypermethylation of multiple genes associated with critical 
cardiac developmental signalling pathways such as Hedgehog, FGF, TGF, Notch and Wnt 
signalling. Interestingly, many of these signalling pathways play key roles in the maintenance of 
cardiomyocyte proliferation during zebrafish heart regeneration (Choi et al., 2013) and activation of 
these pathways drives precocious proliferation of neonatal rodent cardiomyocytes (Porrello and 
Olson, 2014b). However, re-activation of developmental signalling in adult cardiomyocytes does 
not robustly re-induce cell cycle activity in adult binucleated cardiomyocytes (Felician et al., 2014a; 
Porrello and Olson, 2014b). These findings suggest that epigenetic regulation of key developmental 
signalling pathways during neonatal life contributes to cardiomyocyte terminal differentiation. 
It is noteworthy that DMRs at P14 were highly enriched for TF binding motifs for myogenic TFs 
(e.g. MADS-box, Tbx5) and Smad-related TFs (e.g. Smad2/3/4 and Foxh1). The over-
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representation of these TF binding sites is particularly interesting given the critical role of TGF 
and myogenic TFs during muscle differentiation. For example, Smad TFs interact with Mef2 to 
target critical components of the myogenic transcription machinery during C2C12 differentiation 
(Liu et al., 2004). While the precise mechanism by which the DNA methylation machinery is 
recruited to specific DNA sequences during neonatal heart development is currently unclear, this 
process may involve interactions between de novo methyltransferases (Dnmt3a/b) and myogenic 
TFs (Hervouet et al., 2009). Moreover, the role of TGF signalling warrants further investigation, 
as a recent study suggests that TGF-induced anti-proliferative responses involve the recruitment of 
DNA methylation/de-methylation enzymes to Smad2/3 target genes (Thillainadesan et al., 2012). A 
recent study also suggests that interactions between Foxh1/Smad2/3 transcriptional complexes and 
switch-enhancer elements for pluripotency genes underlie context-specific responses to TGF 
mesoendoderm specification (Beyer et al., 2013). Interestingly, we observed significant enrichment 
for pluripotency-related genes at DNase hypersensitivity regions, as well as enrichment for 
Smad2/3/4 and Foxh1 binding sites, suggesting that a similar mechanism may be engaged during 
cardiomyocyte terminal differentiation. Future studies will be required to dissect the potential 
involvement of TGF signalling, as well as interactions between the DNA methylation machinery 
and myogenic TFs, during cardiomyocyte terminal differentiation. 
Overall, the present chapter provides novel insights into the regulatory role of DNA methylation 
during neonatal cardiac maturation. Although further work is required to elucidate the mechanisms 
that induce specific methylation changes in the postnatal heart, the current chapter provides support 
for an epigenetic mechanism for cardiomyocyte terminal differentiation. Additional interrogation of 
the role of DNA methylation during neonatal heart development may provide an enhanced 
understanding of the mechanisms that drive cardiac cell cycle arrest and binucleation.  
3.5. Summary and future direction 
This chapter provides novel evidence for DNA methylation during postnatal heart maturation and 
suggests that cardiomyocyte cell cycle arrest during the neonatal period is subject to regulation by 
DNA methylation. However, the mechanism by which DNA methylation shuts down the cardiac 
cell cycle after birth remains unclear. In the following chapter, the role of DNA methylation in 
regulating cell proliferation genes as well as human cardiomyocyte proliferation are examined to 
further understand the mechanism of postnatal cardiomyocyte maturation in rodents and humans. 
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Chapter 4. DNA methylation is essential for cell cycle 
regulation in mouse and human cardiomyocytes 
4.1. Introduction 
In Chapter 3, DNA methylation was found to be an essential upstream regulator of cardiomyocyte 
proliferation during early postnatal heart development in the mouse. However, a direct relationship 
between DNA methylation and the expression of proliferative gene networks during neonatal 
myocyte development was not evident in previous studies (Chapter 3). As DNA methylation is 
known for its ability to induce long-lasting transcriptional repression, it was hypothesised that DNA 
methylation regulates early postnatal cardiomyocyte proliferation through direct repression of cell 
cycle promoters.  
DNA methylation status has been repeatedly linked with cancer cell proliferation through 
repression of tumour suppressor genes or activation of oncogenes, both of which play a critical role 
in regulating cell cycle activity (Baylin, 2005; Ehrlich, 2002; Luczak and Jagodzinski, 2006). With 
respect to heart development, Li et al reported that loss of DNA methylation leads to foetal lethality 
by E10.5 with cardiac developmental defects, suggesting an indispensible role of DNA methylation 
during embryonic heart development (Li et al., 1992). A more recent study by Felician and 
colleagues has demonstrated that hypermethylation in the promoter region of Notch signalling 
components and target genes occurs concomitant with the developmental shutdown of this critical 
signalling pathway during cardiomyocyte terminal differentiation (Felician et al., 2014a). Treatment 
of 5aza-dC caused hypomethylation at promoter loci of Notch signalling components (Notch1, 
Hes1, cell cycle promoters) and increased expression levels of associated genes. Moreover, 5aza-dC 
caused activation of cell proliferation in neonatal cardiomyocytes, suggesting DNA methylation 
modulates cardiomyocyte proliferation through transcriptional repression (Felician et al., 2014a). 
Furthermore, another recent study has reported that inhibition of neonatal rat cardiomyocyte 
proliferation following treatment with dexamethasone is due to promoter hypermethylation and 
transcriptional repression of cell cycle genes, including Ccnd2 (Gay et al., 2016). Gay et al. also 
demonstrated that 5aza-dC reactivated cell proliferation in dexamethasone-treated cardiomyocytes 
through restoration of Ccnd2 expression, providing further support for a direct role for DNA 
methylation in regulating transcription of cell cycle genes (Gay et al., 2016). Therefore, 
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identification of the direct targets of DNA methylation at specific cell cycle genes is critical to 
understand the mechanism of postnatal cardiomyocyte cell cycle arrest. 
In the present chapter, the relationship between DNA methylation and transcription of specific 
genes involved in cell proliferation were investigated in both mouse and human cardiomyocytes. 
Cross-referencing the RNA-seq and MBD-seq datasets from Chapter 3 identified a subset of cell 
proliferation genes that were differentially methylated during mouse heart development. Moreover, 
in vitro cell culture of human ESC differentiated cardiomyocytes demonstrated that DNA 
methylation was crucial for human cardiomyocyte proliferation. However, only 1 out of 4 of the 
validated DNA methylation target genes was conserved between mouse and human cardiomyocytes, 
implicating potential species differences in the cardiomyocyte cell cycle regulatory network. These 
results provide further evidence for a role of DNA methylation in regulating genes involved in cell 
proliferation during cardiomyocyte maturation and also suggest potential species differences 
between rodents and humans.   
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4.2. Methodology 
4.2.1. Identification of differentially regulated and methylated cell cycle related 
genes 
Utilizing the genes that were previously identified from RNA-seq and MBD-seq in Chapter 3 
(Appendix 7.1), 143 genes with hypermethylation associated with transcriptional repression, as 
well as 36 genes with hypomethylation associated with transcriptional activation were isolated from 
the list. Genes that were previously known to be involved in cell cycle and proliferation activities 
were then selected using the NCBI (http://www.ncbi.nlm.nih.gov/) and GeneCards 
(www.genecards.org) databases for further experimental validation.  
4.2.2. In vitro administration of 5aza-dC to 3D hESC differentiated 
cardiomyocytes  
Briefly, the embryonic stem cell line H9 (WiCell, Madison, WI, USA) was maintained in mTeSR 
(Stemcell Technologies, Vancouver, Canada) on Matrigel (Corning, Tewksbury, MA, USA) coated 
flasks and was passaged using TypLE (Thermo Fisher Scientific (Gibco)). ESCs were differentiated 
into cardiac cells using 2D cardiomyocyte differentiation protocol yielding ~75% cardiomyocytes 
and ~25% stromal cells. Differentiated cardiomyocytes were then seeded into a 96-well cardiac 
tissue engineering platform (Heart-Dyno) recently developed in the Cardiac Regeneration Lab 
which facilitates mechanical loading during culture to form hCOs (Figure 4.5A, B). Tissues formed 
over 2 days and were cultured for another 5 days (Figure 4.5A). For 5aza-dC treatment experiments, 
5aza-dC was added 7 days after differentiated cardiomyocytes were seeded in the Heart-Dyno. 
5aza-dC was prepared fresh daily in culture media and a final concentration of 10μM 5aza-dC was 
used to treat hCOs with no treatment (media alone) used as control.  
4.2.3. DNA and RNA extraction of 3D hESC derived cardiomyocytes  
For DNA or RNA extraction of hCOs, 3 hCOs were pooled together prior processing using standard 
methods (described in Chapter 2 – 2.2, 2.3). 
4.2.4. Immunostaining of hCOs for proliferation 
48 hours after hCOs were treated with 10μM 5aza-dC, tissues were washed wish PBS followed by 
fixation with 1% PFA at room temperature for 20 minutes. Tissues were then washed with PBS and 
Chapter 4 
 
 
108 
then blocked in blocking buffer (PBS, 5% FBS, 0.025% Triton X-100) for 5 minutes at room 
temperature. Primary antibodies were diluted in blocking buffer and incubated overnight at 4°C. 
The following primary antibodies were used for immunofluorescence staining: ACTN2 (EA-53, 
1:1000, mouse monoclonal A7811, Sigma-Aldrich) and pH3 (Ser10) (1:100, rabbit polyclonal 06-
570, Merck Millipore). Following primary antibody incubation, sections were washed in blocking 
buffer for 1 hour at 4°C and then incubated with secondary antibodies conjugated with Alexa Fluor 
488 or 555 (1: 400, Thermo Fisher Scientific (Molecular Probes)) and Hoechst (1:1000, H21492, 
Thermo Fisher Scientific (Molecular Probes)) overnight at 4°C. Tissues were washed in blocking 
buffer for 1 hour at 4°C followed by another wash in PBS before being mounted with Fluoromount-
G (Southern Biotech). Photos were taken under Olympus FV1000 Inverted Confocal Microscope 
(Olympus, Shinjuku, Tokyo, Japan). Quantitative analyses of cardiomyocyte mitosis were 
performed using ImageJ as previously described (Porrello et al., 2011b) 
4.2.5. Visualization of ENCODE ChIP-seq peaks (H3K4me1, H3K4me3 and 
H3K27ac) in UCSC genome browser 
The Igf2bp3 and Ube2c genomic loci were visualized using the UCSC genome browser 
(http://genome.ucsc.edu) with tracks for CGI and ENCODE ChIP-seq results for H3K4me1, 
H3K4me3 and H3K27ac turned on.  
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4.3. Results 
4.3.1. Identification of cell cycle and proliferation genes regulated by DNA 
methylation during mouse heart development 
To further understand the role of DNA methylation in regulating postnatal cardiomyocyte cell cycle 
arrest, a set of genes with previously reported functions in regulating cell cycle activity and cell 
proliferation were selected for further analysis (Figure 4.1; Table 4.1). As DNA methylation is 
known for its canonical role in transcriptional repression, this analysis focused on identifying cell 
proliferation genes that exhibited an inverse relationship between transcription and DNA 
methylation (Figure 4.1). Specifically, cell proliferation genes were selected from 2 correlations of 
DNA methylation and transcription, which were increased DNA methylation associated with 
decreased expression of cell cycle activators or decreased DNA methylation associated with 
increased expression of cell cycle inhibitors (Figure 4.1; Table 4.1). From P1 to P14, a total of 16 
cell cycle genes were identified that were hypermethylated and transcriptionally repressed. In 
contrast, only 2 cell cycle genes were hypomethylated and transcriptionally activated from P1 to 
P14 (Figure 4.1; Table 4.1).  
qPCR analysis was performed to examine the mRNA levels of selected proliferation genes between 
P1 to P84. Insc, Kdm2b, Pold2 and Smyd2 were not analysed because they could not be efficiently 
detected after testing 2 different qPCR primer sets (Table 2.2). For proliferation genes displaying 
hypermethylation associated with transcriptional repression, Igf2, Igf2bp2, Igf2bp3, and Pak4 were 
significantly down-regulated between P1 and P14, consistent with the RNA-seq datasets presented 
in Chapter 3 (Figure 4.2). The rest of the candidates exhibited no statistically significant changes in 
gene expression between P1 and P14 (Figure 4.2). The same analysis was also performed on the 
proliferation genes displaying hypomethylation associated with transcriptional activation between 
P1 and P14 (except for Ptprr, which failed to be efficiently detected after testing 2 different qPCR 
primer sets). None of these candidates were significantly regulated by qPCR (Figure 4.3A).  
To further validate the relationship between DNA methylation and transcription of the selected cell 
proliferation genes, qPCR analysis was performed to examine their expression levels in heart 
samples from mice that were treated with 5aza-dC. Consistent with the expression profiling during 
development (Figure 4.2), Igf2bp3 exhibited higher expression levels in 5aza-dC treated mice, 
confirming the relationship between its expression levels and DNA methylation (Figure 4.4). 
Interestingly, while Chtf18, Cit and Ube2c were not significantly regulated between P1 and P14, 
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their expression levels were significantly up-regulated in 5aza-dC treated mice, suggesting that 
DNA methylation is essential for their transcriptional regulation during early postnatal heart 
development in the mouse (Figure 4.4). On the other hand, the expression levels of cell 
proliferation genes that were hypomethylated and associated with transcriptional activation were 
also examined but these were not significantly regulated by 5aza-dC (Figure 4.3B). Together, these 
findings suggest a subset of genes involved in cell proliferation is subject to regulation by DNA 
methylation during postnatal heart development in the mouse.  
4.3.2. DNA methylation is linked to human cardiomyocyte proliferation 
As previously discussed in this thesis, mouse and human hearts have some significant differences in 
their physiological characteristics (Table 1.1). Therefore, it is important to understand whether 
DNA methylation plays a conserved role in regulating transcription of cell proliferation genes in 
human cardiomyocytes. Employing a 96-well miniaturized human cardiac organoid platform that 
was previously established in the lab (Figure 4.5A, B), 10 μM 5aza-dC was administered to 
cultured hCOs to inhibit global DNA methylation levels. The concentration of 10 μM was selected 
based on previous studies where it was shown to efficiently inhibit DNA methylation without 
causing pathological effects (Palii et al., 2008; Zhou et al., 2015). 
Administration of 5aza-dC induced >50% inhibition of genomic DNA methylation levels in the 
Heart-Dyno tissues, although this did not reach statistical significance (P=0.77) (Figure 4.5C). To 
test whether inhibition of DNA methylation induced cardiomyocyte proliferation, hCOs were 
stained with pH3 and the cardiac marker ACTN2 to quantify the incidence of cardiomyocyte 
mitosis. A 2-fold (from ~1% to ~2%) increase in the number of pH3
+
 cells by in cardiomyocytes 
was observed in 5aza-dC treated human cardiac organoids (Figure 4.5 D, E), suggesting that DNA 
methylation is linked to human cardiomyocyte proliferation.  
4.3.3. DNA methylation of cell proliferation target genes is not conserved 
between mice and humans 
In order to determine whether the regulation of cell cycle genes by DNA methylation is conserved 
between mice and humans, the expression levels of the 4 validated cell cycle and proliferation 
genes (CHTF18, CIT, IGF2BP3, and UBE2C) in section 4.3.1 (Figure 4.4) were examined in the 
5aza-dC treated hCOs. CIT and IGF2BP3 could not be detected in hCOs after testing with 2 
different qPCR primer sets (Table 2.2). qPCR analysis showed that only the expression levels of 
CHTF18 were increased following inhibition of DNA methylation in hCOs (Figure 4.6), 
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suggesting that DNA methylation is required for transcription of this gene in both mouse and 
human cardiomyocytes.  
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Table 4.1. Summary of cell cycle and proliferation related genes with differential methylation levels and mRNA expression changes 
between P1 and P14 (NA: not available, UC: unchanged). 
Cell cycle related genes in ↑CpG associated with ↓mRNA gene set (16/ 143) 
Genes Comments 
Cell cycle 
promoter 
or 
repressor 
Expression 
changes in 
development
al mouse 
heart (P1 to 
P84) 
Expression 
changes in 
5aza treated 
mouse heart 
Expression 
changes in 
5aza treated 
human 
Heart-
Dynos 
References 
CDK14 
Cyclin-dependent kinase 14.  
Regulates cell cycle and proliferation 
through interaction with CCND3. siRNA 
inhibition led to cell cycle arrest at G1 
phase. Regulates Wnt signalling through 
LRP6 during G2/M phase. 
Promoter ↓ UC NA 
(Davidson 
et al., 2009; 
Shu et al., 
2007) 
CHTF18 
Chromosome transmission fidelity factor 18. 
Associate with other component to form 
replication factor C (RFC) to load 
Promoter ↓ ↑ ↑ 
(Shiomi et 
al., 2007) 
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proliferating cell nuclei antigen (PCNA) 
onto DNA during S phase. 
CIT 
Citron rho-interacting serine/threonine 
kinase. 
Components of central spindle associate 
with KIF14 to regulate cytokinesis.  
Promoter ↓ ↑ NA 
(Gruneberg 
et al., 2006; 
Liu et al., 
2003) 
CTDP1 
Carboxy-terminal domain phosphatase 
subunit 1. 
Regulate transcription through 
phosphorylation of C-terminal domain of 
RNA polymerase II. Inhibition of CTDP1 
led to cell growth repression. 
Promoter ↓ UC NA 
(Nguyen et 
al., 2003; 
Zhong et 
al., 2016) 
GPSM2 
G-protein signalling modulator 2. 
Forms complex that guide mitotic spindle 
organization with LGL2 during mitosis. 
Promoter ↓ UC NA 
(Yasumi et 
al., 2005) 
IGF2 
Insulin-like growth factor 2. 
Member of insulin family of polypeptide 
growth factors. Governing development and 
Promoter ↓ UC NA 
(Chao and 
D'Amore, 
2008) 
Chapter 4 
 
 
114 
growth process. 
IGF2BP2 
Insulin-like growth factor 2 binding protein 
2. 
Member of IGF2 mRNA-binding protein. 
Binds to IGF2 and regulates IGF2 
translation. Regulate myoblast proliferation 
together with HMGA2. 
Promoter ↓ UC NA 
(Li et al., 
2012) 
IGF2BP3 
Insulin-like growth factor 2 binding protein 
2. 
Member of IGF2 mRNA-binding protein. 
Binds to IGF2 and regulates IGF2 
translation. Strong relationship with cancer 
development and malignancy. 
Promoter ↓ ↑ UC 
(Ennajdaou
i et al., 
2016; 
Lederer et 
al., 2014) 
INSC 
Inscuteable homolog. 
Regulates mitotic spindle orientation. 
Promoter NA NA NA 
(Hughes et 
al., 2004) 
KDM2B 
Lysine demethylase 2B. 
Regulates cell proliferation and senescence 
through p15. 
Promoter NA NA NA 
(He et al., 
2008) 
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PAK4 
p21 (RAC1) activated kinase 4. 
Regulates cell cycle through normal 
degradation of CDKN1A. Overexpression 
led to uncontrolled proliferation. 
Promoter ↓ UC NA 
(Nekrasova 
and 
Minden, 
2011, 
2012; Tian 
et al., 
2011) 
POLD2 
DNA polymerase delta 2, accessory subunit. 
Catalytic subunit of DNA polymerase delta. 
DNA polymerase delta interacts with PCNA 
to control DNA synthesis during DNA 
replication and repair.  
Promoter NA NA NA 
(Lu et al., 
2002; 
Perez et al., 
2000) 
PRIM2 
Primase (DNA) subunit 2. 
Subunit of DNA primase (key enzyme for 
DNA replication). 
Promoter ↓ UC NA 
(Zerbe and 
Kuchta, 
2002; 
Zhang et 
al., 2014) 
SH3PXD2B 
SH3 and PX domains 2B. 
Scaffold protein. siRNA inhibition led to 
Promoter ↓ UC NA 
(Hishida et 
al., 2008) 
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mitotic clonal expansion repression of 
adipocyte.  
SMYD2 
SET and MYND domain containing 2. 
Lysine methyltransferase. Regulate cell 
proliferation through methylation of p53 and 
RB. 
Promoter NA NA NA 
(Cho et al., 
2012; 
Huang et 
al., 2006) 
UBE2C 
Ubiquitin conjugating enzyme E2 C. 
Member of E2 ubiquitin conjugating 
enzyme family. Regulates cell proliferation 
through cyclin B.  
Promoter ↓ ↑ UC 
(van Ree et 
al., 2010) 
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Cell cycle related genes in ↓CpG associated with ↑mRNA gene set (2/ 36) 
Genes Comments 
Cell cycle 
activator 
or 
repressor  
Expression 
changes in 
development
al mouse 
heart (P1 to 
P14) 
Expression 
changes in 
5aza treated 
mouse heart 
Expression 
changes in 
5aza treated 
human 
Heart-
Dynos 
References 
KLF9 
Kruppel-like factor 9. 
Member of Kruppel-like transcriptional 
regulator family. Inhibition of KLF9 
promoted glioma cell proliferation.  
Repressor UC UC NA 
(Huang et 
al., 2015) 
PTPRR 
Protein tyrosine phosphatase receptor type R. 
Member of protein tyrosine phosphatase 
(PTP) family. PTP family is one of the key 
mechanisms of cell division and proliferation 
governing.  
Repressor NA NA NA 
(Chernoff, 
1999) 
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Figure 4.1. Identification of genes involved in cell proliferation from differentially 
methylated and transcribed genes during neonatal heart development.  
The scatter plot demonstrates differentially regulated and methylated genes from Chapter 3. The 
scatter plot shows log2 fold changes in mRNA expression levels (y-axis) against log2 fold changes 
in MBD enrichment (x-axis). Genes with increased (or decreased) methylation levels associated 
with decreased (or increased) transcription levels were selected for further cell cycle and 
proliferation analysis (framed by red rectangles). Genes that with previously reported functions in 
cell proliferation or cell cycle regulation were selected for further analysis (in red dots).  
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Figure 4.2. Profiling of cell cycle genes (hypermethylation associated with transcriptional 
repression) during heart development. 
qPCR gene expression profiling of cell cycle and proliferation candidate genes (hypermethylated 
and transcriptionally repressed) in mouse cardiac ventricles from P1 to P84. Expression levels are 
normalized to 18S and represented as a fold change relative to P1 ventricles (n=3 per group). Data 
are presented as mean ± s.e.m. *P<0.05, **P<0.001.   
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Figure 4.3. Profiling of the cell cycle gene, Klf9, (hypomethylation associated with 
transcriptional activation) during heart development and following 5aza-dC 
treatment in mice. 
A. qPCR gene expression profiling of Klf9 (hypomethylation associated with transcription 
activation group) in mouse cardiac ventricles from P1 to P84. Expression levels are normalized to 
18S and represented as a fold change relative to P1 ventricles (n=3 per group). Data are presented 
as mean ± s.e.m. **P<0.001. 
B. qPCR gene expression profiling of Klf9 in saline and 5aza-dC treated hearts at P7. Expression 
levels are normalized to 18S and represented as a fold change relative to P1 ventricles (n=4-6 per 
group). Data are presented as mean ± s.e.m.   
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Figure 4.4. Transcription of cell cycle genes (hypermethylation associated with 
transcriptional repression) are subjected to DNA methylation in 5aza-dC 
treated mouse hearts. 
qPCR gene expression profiling of cell cycle gene candidates (from hypermethylation associated 
with transcriptional repression group) in saline and 5aza-dC treated hearts at P7. Expression levels 
are normalized to 18S and represented as a fold change relative to P1 ventricles (n=4-6 per group). 
Data are presented as mean ± s.e.m. *P<0.05.   
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Figure 4.5. DNA methylation is linked to cardiomyocyte proliferation in 3D cultured hCOs. 
A. Timeline of human ESC culture, differentiation and 3D hCOs culture.  
B. Schematic of 96-well Heart Dyno platform. (*Figure A and B are kindly provided by Dr Richard 
Mills.)  
C. Genomic DNA methylation levels in hCOs treated with saline or 5aza-dC (n=3 pooled samples, 
each pooled sample contained 3 hCOs).  
D. Quantification of pH3
+
cardiomyocytes in control and 5aza-dC-treated hCOs. Data are presented 
as % of cardiomyocytes/hCOs for n=13-15 independent hCOs tissue per group (3 fields of cells 
assessed per hCO). *P<0.05.  
E. Immunohistochemistry staining of saline and 5aza-dC-treated hCOs. Green = ACTN2, red = 
pH3, blue = nuclei. pH3 positive cardiomyocytes with disassembled sarcomeres are also shown in 
the high magnification inset in the top left hand corner of each panel. Scale bar = 50 m in main 
figure and 5 m in high magnification inset.  
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Figure 4.6. Profiling of validated cell cycle genes in 5aza-dC treated hCOs. 
qPCR gene expression profiling of validated cell cycle candidates (from hypermethylation 
associated with transcriptional repression group) in control and 5aza-dC treated hCOs. Expression 
levels are normalized to 18S and represented as a fold change relative to control (n=9 pooled 
samples, each pooled sample contained 3 hCOs). Data are presented as mean ± s.e.m. *P<0.05.  
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Figure 4.7. Maps of ENCODE H3K4me1, H3K4me3 and H3K27ac ChIP-seq peaks across 
the Igf2bp3, Ube2c and Chtf18 loci at E14.5 and 8 weeks old hearts.  
A. Maps of ENCODE H3K4me1, H3K4me3 and H3K27ac ChIP-seq peaks across the Igf2bp3 locus 
in E14.5 and 8 week-old mouse hearts. Selected region highlighted by red box. 
B. Maps of ENCODE H3K4me1, H3K4me3 and H3K27ac ChIP-seq peaks across the Ube2c locus 
in E14.5 and 8 weeks-old mouse hearts. Selected region highlighted by red box. 
C. Maps of ENCODE H3K4me1, H3K4me3 and H3K27ac ChIP-seq peaks across the Chtf18 locus 
in E14.5 and 8 weeks-old mouse hearts. Selected region highlighted by red box.  
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4.4. Discussion and conclusion 
This chapter uncovers an essential role for DNA methylation in the regulation of cardiomyocyte 
proliferation in both rodent and human cardiac cells for the first time. These experimental findings 
indicate that DNA methylation is involved in regulating several cell cycle promoters during early 
postnatal cardiac development. Specifically, 4 cell proliferation genes (Chtf18, Cit, Igf2bp3, and 
Ube2c) were validated as being subject to regulation by DNA methylation during mouse heart 
development. Importantly, global inhibition of DNA methylation in human cardiac organoids also 
promoted cardiomyocyte proliferation, suggesting that the effect of global DNA methylation in 
restraining cardiomyocyte proliferation is conserved between rodents (Chapter 3) and humans. 
Notably, out of 4 validated DNA methylation targets involved in cell proliferation in the mouse, 
only CHTF18 was also validated as a putative DNA methylation target in human cardiac cells. This 
result indicates that the mechanism by which DNA methylation regulates cardiomyocyte 
proliferation may differ in mice and humans.  
One of the most interesting observations in this chapter is that inhibition of DNA methylation 
induces cardiomyocyte proliferation in human ESC-derived cardiomyocytes, which is similar to the 
result previously observed in the developing mouse heart (Chapter 3). This result suggests that 
DNA methylation plays an essential role in restraining cardiomyocyte proliferation in both rodents 
and humans. This is a potentially important finding as inhibition of DNA methylation using 
hypomethylating agents such as 5-aza is currently used as a clinical therapeutic approach for 
myelodysplastic syndromes and acute myeloid leukaemia (Christman, 2002). However, it is 
important to note that the effects of DNA methylation inhibitors on cardiomyocyte proliferation 
were observed in immature cardiomyocytes and DNA methylation likely plays diverse roles in 
regulating cell proliferation at different stages of development. Human ESC-derived 
cardiomyocytes have been previously characterized to be similar to foetal or embryonic 
cardiomyocytes (Veerman et al., 2015). While the current results provide supporting evidence for a 
role of DNA methylation in guiding cardiomyocyte cell cycle shutdown during development, it is 
unclear whether inhibiting DNA methylation at later stages of development (i.e. in adulthood) is 
sufficient for cardiomyocyte cell cycle re-entry. Interestingly, recent studies have demonstrated that 
5aza improves cardiac function and fibrosis following MI in the adult mouse heart via modulation 
of macrophages (Jeong et al., 2015; Kim et al., 2014). However, none of the studies have reported 
the effects of 5aza on cardiomyocyte proliferation in the adult heart following injury. Future 
characterization of the effects of modulating DNA methylation on cardiomyocyte proliferation in 
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the setting of adult heart disease could provide new therapeutic avenues towards cardiac 
regeneration.  
Although DNA methylation clearly constrains cardiomyocyte proliferation, very few cell cycle 
genes appear to be directly by DNA methylation at their gene promoters during cardiomyocyte 
maturation. The analyses undertaken in this chapter reveal that only 4 out of 179 differentially 
methylated cell cycle genes showed a direct relationship between DNA methylation levels and gene 
transcription. This result implies that while DNA methylation is essential for cardiomyocyte 
proliferation, the direct regulation of cell cycle genes is uncommon. Similarly, a recent whole 
genome methylation analysis of mouse heart development also found limited evidence for direct 
methylation of cell cycle genes during cardiomyocyte maturation (Gilsbach et al., 2014). It is 
possible that DNA methylation regulates cardiomyocyte proliferation through modulation of other 
signalling components including TFs instead of direct regulation of cell cycle genes. In fact, 
research in the cancer biology and cellular reprogramming fields has revealed that a few TFs can 
single-handedly alter cellular behaviour or even cell identity. For instance, a recent study has shown 
that transcription of FOXF2 is highly sensitive to regulation by DNA methylation in breast cancer 
cells, and is sufficient to drive the cascade of events triggering (or repressing) breast cancer (Tian et 
al., 2015). Moreover, another study found that cancer cells could be directly reprogrammed to less 
proliferative states by targeting Dnmt3a to differentially methylated SOX2 binding sites (Rivenbark 
et al., 2012). Notably, one of the DNA methylation target genes, Ube2c, regulates protein 
degradation by catalysing ubiquitin modifications of proteins (Hao et al., 2012). DNA methylation 
may regulate subsets of genes by mediating Ube2c without directly influencing their transcription. 
Overexpression of Ube2c leads to degradation of cyclin B, which has been shown to increase 
susceptibility to carcinogens (van Ree et al., 2010). Together, these results illustrate that DNA 
methylation can affect cell proliferation simply through regulation of a few TFs without direct 
regulation of a subset of cell cycle genes. Future studies are required to identify the TF networks 
that are targeted by DNA methylation during cardiomyocyte maturation, which might provide 
further understanding of how DNA methylation regulates cardiomyocyte proliferation. 
Although DNA methylation does not directly regulate the majority of cell proliferation genes at cell 
cycle promoters, 4 methylated cell cycle genes were identified in this chapter. Chtf18, Cit, and 
Ube2c have been previously reported as cell cycle regulators (Shiomi et al., 2007, Gruneberg et al., 
2006; Liu et al., 2003, van Ree et al., 2010). Specifically, Cit can regulate cell cycle through 
forming a complex with Klf14 at central spindle and midbody during G2/M stage transition 
(Gruneberg et al., 2006; Liu et al., 2003). In addition, Chtf18 has been previously shown to drive 
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cell cycle by forming a complex with the replication factor C to load proliferating cell nuclear 
antigen (PCNA) to DNA. DNA polymerase η will then be activated following the loading of PCNA 
to DNA to initiate DNA synthesis (Shiomi et al., 2007). Notably, Chtf18 is the only conserved 
DNA methylation target gene that was identified in this Chapter, supporting a previous study that 
has demonstrated its conservation for DNA replication between yeast, flies and mammals 
(Berkowitz et al., 2008). Furthermore, Igf2bp3 is an important member of a critical upstream 
signalling pathway that drives cell proliferation (Ennajdaoui et al., 2016; Lederer et al., 2014, 
Chernoff, 1999). In particular, Igf2bp3 (Palanichamy et al., 2016; Schaeffer et al., 2010) and Ube2c 
(Bajaj et al., 2016; Chou et al., 2014; Shen et al., 2013; Shuliang et al., 2013) have been widely 
studied in various cancers, confirming their ability to promote cell proliferation. Interestingly, their 
expression levels are substantially down-regulated during postnatal cardiac development. However, 
it is also apparent that reactivation of their expression levels following treatment of 5-aza in both 
mouse and human systems are very modest. This could be due to other epigenetic regulatory 
mechanisms, such as H3K4me1, H3K4me3 and H3K27ac. For example, utilizing the ENCODE 
ChIP-seq results through UCSC genome browser, it was found that these genes progressively lose 
these active histone marks during heart development from E14.5 to 8 weeks of age (Figure 4.7). It 
is important to note that transcription is collectively influences by various epigenetic marks rather 
than DNA methylation alone. Therefore, the developmental shutdown of these proliferation genes 
might due to the combined effects of DNA methylation, histone methylation as well as histone 
acetylation. Modification of one epigenetic mark might not provide enough stimulation for the 
reactivation of these genes. It will therefore be important in the future to look at the epigenome in 
its entirety to better understand underlying relationships between epigenetic modifications and 
transcription during cardiomyocyte maturation.  
While animals are widely used in research studies and have greatly contributed our understanding 
of various developmental and disease processes, many biological differences between rodents and 
humans have prevented translation of many experimental results into the clinic (Mak et al., 2014; 
Shanks et al., 2009). In fact, it was previously reported that the successful rate of experimental 
translation from mouse to human clinical trials in cancer research is less than 8% (Mak et al., 2014). 
Moreover, recent studies have revealed the distinct differences between mice and humans from 
proximal and distal regulatory elements to TF landscape (Cheng et al., 2014; Monaco et al., 2015; 
Pishesha et al., 2014; Shay et al., 2013). In particular, only ~30% of the top 500 human expressed 
genes have equivalent orthologous in the top 500 expressed genes in stage-matched mouse 
erythroid cells (Pishesha et al., 2014). Moreover, these studies have demonstrated that while 
promoter regions generally demonstrate high interspecies fidelity, promoter sequences with less 
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than 65% conservation show little correlation to gene expression levels across species (Cheng et al., 
2014; Pishesha et al., 2014), suggesting diverse TF regulation and promoter usage in different 
species. These variations in the control of gene transcription might contribute to important 
physiological differences between mice and humans. However, it is also important to be aware that 
the previous study of DNA methylation in the mouse was observed under the dynamic in vivo 
process of heart development. On the other hand, the engineered human heart tissue is a static in 
vitro culture system that might not completely recapitulate the cardiomyocyte maturation and 
development processes. Furthermore, it is noteworthy that previous RNA-seq and MBD-seq 
(Chapter 3) datasets were derived from whole ventricular tissue lysates, which comprise mixed cell 
populations. As such, differentially transcribed and methylated genes could be caused by artefacts 
related to changes in cellular composition during postnatal heart maturation. Future interrogation of 
the regulatory role of DNA methylation in purified mouse and human cardiomyocyte populations is 
essential in order to shed further light on the underlying epigenetic basis for postnatal 
cardiomyocyte maturation.  
4.5. Summary and future direction 
This chapter provides supporting evidence for direct regulation of a small subset of cell 
proliferation genes by DNA methylation during postnatal cardiomyocyte maturation. The current 
findings suggest that DNA methylation restrains both mouse and human cardiomyocyte 
proliferation. However, given the technical limitations imposed by analysis of DNA methylation 
events in whole tissue preparations in Chapters 3 and 4, the epigenetic mechanisms underlying 
postnatal cardiac cell cycle arrest, especially in human cardiomyocytes, remains elusive. In the 
following chapter, a series of refined and cell type specific analyses are conducted to further 
delineate relationships between the chromatin landscape and transcription during postnatal 
cardiomyocyte maturation in rodents and humans. 
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Chapter 5. Chromatin accessibility dynamics during 
human and mouse cardiac development 
5.1. Introduction 
In Chapter 4, it was shown that DNA methylation is essential for cardiomyocyte proliferation. 
However, DNA methylation did not increase at the majority of cell cycle gene promoters, 
suggesting that DNA methylation regulates cardiomyocyte proliferation via an alternative 
mechanism. However, the previous chapters also identified several technical limitations, such as 
lack of cellular resolution and a reliance on single epigenetic marks, which may have precluded 
identification of cardiomyocyte specific epigenetic mechanisms that guide postnatal maturation and 
cell cycle arrest. In this chapter, two state-of-the-art experimental approaches are adapted to directly 
interrogate dynamic changes in the chromatin landscape during postnatal rodent and human 
cardiomyocyte maturation. 
Classic approaches for isolation of different cell populations from the adult heart require perfusion 
of enzymatic solutions followed by fluorescence-activate cell sorting (FACS), which requires the 
integrity of the whole heart structure and the use of fresh tissue. This approach is not suitable for 
archival specimens (Bell et al., 2011), which is a major limitation for research using human material. 
Recent publications have reported an alternative method for isolation of cardiomyocytes from 
frozen heart tissue, which combines cellular fractionation and immunostaining with the 
cardiomyocyte-specific marker PCM1 to isolate myocyte specific nuclei (Alkass et al., 2015; 
Bergmann and Jovinge, 2012; Bergmann et al., 2015; Preissl et al., 2015a). This method has been 
used to isolate cardiomyocyte nuclei from human and mouse heart tissue and various studies have 
demonstrated the utility of this approach for downstream transcriptomic and epigenomic 
assessments, including RNA-seq and ChIP-seq (Alkass et al., 2015; Bergmann et al., 2015; 
Gilsbach et al., 2014; Preissl et al., 2015a). Therefore, this approach provides a relatively simple 
method for the isolation of cardiomyocyte specific nuclei for epigenetic studies in both rodents and 
humans.  
It is evident that various epigenetic modifications collectively regulate chromatin accessibility, 
which dictates the transcription of underlying genes (Gillette and Hill, 2015; Han et al., 2011; 
Quaife-Ryan et al., 2016). The chromatin landscape alternates between euchromatin (a relatively 
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open structure that is accessible for transcriptional activation) and heterochromatin (more 
compacted chromatin state that is associated with transcriptional repression). These alternative 
chromatin states are influenced by chemical modifications of histone proteins and DNA (see 
Chapter 1). Recent genome-wide approaches have begun to assess the epigenetic landscape using 
next-generation sequencing methods coupled with biochemical pull-down approaches for individual 
epigenetic marks. Some of the most common approaches include MBD-seq or methylated DNA 
immunoprecipitation (MeDIP-seq) (for DNA methylation) (Harris et al., 2010) and ChIP-seq (for 
individual histone modifications) (Furey, 2012). Despite their undisputed utility, these approaches 
only interrogate individual epigenetic modifications without investigating the integrated influence 
of multiple epigenetic marks on chromatin structure. In contrast, other approaches such as DNase I 
hypersensitive site sequencing (DNase-seq) (Boyle et al., 2008) and high-throughput sequencing for 
formaldehyde-assisted isolation of regulatory elements (FAIRE-seq) (Gaulton et al., 2010) have 
been developed to bypass individual epigenetic marks and investigate their integrated product – the 
chromatin accessibility landscape. While DNase-seq and FAIRE-seq have illuminated our 
understanding of chromatin structure and the influence of regulatory elements on transcriptional 
regulation (Gerstein et al., 2012), they often require large amounts of starting materials (>1 million 
cells), which is a challenge for research involving human tissue biopsy specimens. More recently, 
ATAC-seq was developed, which utilizes the properties of transposase to sequence accessible 
regions of open chromatin (Buenrostro et al., 2013)., ATAC-seq provides a new strategy to 
investigate the global chromatin landscape and TF occupancy at the same time. A major advantage 
of this approach is that it requires minimal starting material (500 to 50,000 cells), with more recent 
studies further refining this approach for single cells (Buenrostro et al., 2015b; Cusanovich et al., 
2015). This significant reduction in the input material requirements for sequencing of accessible 
chromatin increases the feasibility of this approach for numerous biological studies including those 
involving human tissue.  
In this chapter, PCM1 isolation of cardiomyocytes, ATAC-seq and RNA-seq are combined to 
define the relationship between the global chromatin landscape, TFs and transcriptional regulation 
during cardiomyocyte maturation in rodents (P1, P14 and P56) and humans (foetal (14-19 wks), 0-
10 yrs, 10-30 yrs and 30+ yrs). Integrating RNA-seq and ATAC-seq datasets revealed a positive 
correlation between chromatin accessibility and active transcription states in cardiomyocytes. 
Furthermore, motifs for several TFs that are essential for cell proliferation were associated with 
chromatin compaction and transcriptional repression of cell cycle genes during cardiomyocyte 
maturation. Together, these results provide novel insight into the relationship between chromatin 
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accessibility and transcription during cardiomyocyte maturation and suggest a potential epigenetic 
mechanism for postnatal cardiomyocyte cell cycle arrest. 
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5.2. Methodology 
5.2.1. Experimental human tissue collection 
All protocols were approved by The University of Queensland Institutional Human Research Ethics 
Committee (SBS/2014000329). 
In collaboration with Professor Cristobal G. dos Remedios and Dr Sean Lal from the University of 
Sydney, human heart tissues spanning a large developmental period, from foetal (13-19 wks) 
(provided by commercial supplier – Advanced Bioscience Resource, Alameda, CA, USA), 0-10 yrs, 
10-30 yrs, and 30+ yrs were obtained from The Sydney Human Heart Tissue Bank. All human heart 
specimens were donated from healthy, non-diseased donors and the tissues have been archived in 
liquid nitrogen since collection (Table 5.1). Left ventricular cardiac tissues from donors were 
selected for this study.  
5.2.2. PCM1 isolation of cardiomyocyte nuclei 
Cardiomyocyte specific nuclei were isolated according to a previous publication (Bergmann and 
Jovinge, 2012). Mouse hearts were pooled to obtain enough material for sequencing (P1: 12 hearts/ 
sample, P14 and P56: 6-7 hearts/ sample). For human samples, ~1g of ventricular tissue was used 
per sample, left ventricular tissue samples were then dissected and minced into approximately 
1mm3 cube and electrically homogenised in 15mL lysis buffer (0.32M sucrose, 10mM Tris-HCl 
(pH = 8), 5mM CaCl2, 5mM magnesium acetate, 2.0mM EDTA, 0.5mM EGTA, 1mM DTT and 1X 
Complete protease inhibitor (all chemical reagents were acquired from Sigma-Aldrich). Heart lysate 
was combined with another 15mL lysis buffer and subsequently homogenised for 10-15 strokes 
using dounce tissue grinder (Wheaton, Millville, NJ, USA). Cell lysate was then filtered through a 
70μM filter followed by a 40μM cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA) and 
centrifuged to pellet nuclei at 1000 x g (Allegra X-15R, Beckman Coulter) for 5 mins. Nuclei 
pellets were then resuspend in 2-4mL sucrose buffer (1M sucrose, 10mM Tris-HCl (pH = 8), 5mM 
magnesium acetate, 1mM DTT and 1X Complete protease inhibitor) and the suspension was 
cushioned on top of 2 times volume of the sucrose buffer, followed by centrifugation to pellet 
nuclei at 1000xg (Allegra X-15R, Beckman Coulter) for 5 mins. Nuclei pellets were then washed 1 
time in 1mL nuclei storage buffer (NSB, 0.44M sucrose, 10mM Tris-HCl (pH = 7.2), 70mM KCl, 
10mM MgCl2, 1.5mM spermine and 1x Complete protease inhibitor). Washed nuclei pellets were 
then resuspended in NSB and stained for cardiomyocyte nuclear specific marker, PCM1 antibody 
(1:200, HPA023374, Sigma-Aldrich) at 4ºC for 45 minutes. Omitting the primary antibody served 
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as a control for positive staining. Nuclei were washed twice in NSB and stained for secondary 
antibody conjugated with Alexa Fluor 633 (1:500, Thermo Fisher Scientific (Molecular Probes)) or 
Brilliant Violet 421 (1:400, #406410, Biolegend, San Diego, CA, USA) at 4ºC for 30 minutes. 
Nuclei were washed twice in NSB and resuspended in PBS before being processed for FACS. 
PCM1 (-/+) nuclei were separated by FACS. Collected PCM1 (-/+) nuclei were pelleted at 1500 x g 
(Allegra X-15R, Beckman Coulter) for 15 minutes (Figure 5.1). (Note: Various protocols for 
PCM1 isolation of nuclei were compared and are summarized in Appendix 7.2.) 
5.2.3. PCM1+ nuclei purity confirmation 
For confirmation of cardiomyocyte purity, sorted PCM (-/+) nuclei were resuspended in 1mL 
TRIzol (Thermo Fisher Scientific (Ambion)) and stored in -80C prior to processing. RNA was 
extracted according to RNA extraction protocol listed in Chapter 2 and profiled for several 
cardiomyocyte, fibroblast, endothelial and immune cell markers through real-time qPCR (Table 
2.4). 
5.2.4. Transcriptional expression profiling with RNA-seq 
RNA extraction was performed according to the protocol described in Chapter 2. RNA quality was 
examined with the MultiNA bioanalyzer (Shimadzu) before library preparation. Ribosomal RNA 
was depleted from total RNA using NEBNext rRNA Depletion Kit (Human/Mouse/Rat) (E6310, 
New England Biolabs) followed by library generation using NEBNext Ultra Directional RNA 
Library Prep Kit for Illumina (E7420, New England Biolabs) according to the manufacturer’s 
protocol. Size selection was performed according to NEBNext® Ultra II DNA Library Prep Kit for 
Illumina (E7645, New England Biolabs) size selection to select library fragment sizes of 200-400bp. 
Libraries were validated on MultiNA bioanalyzer and diluted to a concentration of 10 pM for 100 
cycle, 40 million reads, single end sequencing on HiSeq2500 with version 4 reagents (Illumina). 
Base-calling was performed with RTA (version 1.8.66.3) and converted to fastq file using bcl2fastq 
(version 2.17.1.14). (Note: all human samples were extracted and sorted for cardiomyocyte nuclei 
in order to do RNA-seq and ATAC-seq. However, only selected samples were used for RNA-seq 
due to limited sample material (see Table 5.1, 5.2, 5.3).)  
5.2.5. Chromatin accessibility profiling with ATAC-seq 
Following PCM1 nuclei isolation, ATAC-seq libraries were generated according to the methods 
described in a previous publication (Buenrostro et al., 2015a). Briefly, nuclei pellets underwent 
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transposition reaction using Nextera DNA library preparation kit (FC-121-1030, Illumina) followed 
by purification using MinElute PCR purification kit (#28004, Qiagen), PCR amplification and 
qPCR strictly according to the published protocol. An extra PCR cycle step for library amplification 
was determined by qPCR for individual samples (Table 5.3, 5.4). Size selection by agarose gel was 
performed after PCR to select for library fragment sizes of 200-400bp. Libraries were validated on 
MultiNA bioanalyzer and diluted to a concentration of 10 pM for 100 cycle, 60 million reads, single 
end sequencing (for mouse) or 80 million reads, paired end sequencing (for human) on HiSeq2500 
with version 4 reagents (Illumina). Base-calling was performed with RTA (version 1.8.66.3) and 
converted to fastq file using bcl2fastq (version 2.17.1.14). 
5.2.6. Bioinformatics analyses (summarized pipeline at Table 5.5) 
RNA-seq  Sequence reads underwent 3’ base quality trimming using the Fastx toolkit with a 
minimum Phred quality score (Q) of 30 and a minimum read length of 20 nt. RNA-seq reads were 
aligned to the reference genome sequence (mouse: GRCm38.p4/mm10, human: GRCh38.p7/hg38) 
using STAR with default settings (Dobin et al., 2013). Reads aligning to Ensembl-annotated whole 
genes on the correct strand with a strict mapping quality (Q≥20) were counted with featureCounts 
(Liao et al., 2014) and used to construct a data matrix comprising genes with an average of 10 reads 
or more per sample across the experiment. Differential gene expression analysis was performed 
using edgeR (v3.2.4) (Robinson et al., 2010). Heatmaps were generated from normalized and scaled 
gene expression values with R in RStudio (Reich et al., 2006; RStudio, 2012).  
ATAC-seq   Paired sequence reads underwent quality trimming using the Skewer (0.1.122r) with 
default setting (Jiang et al., 2014) and aligned to the mouse genome (GRCm38.p4/mm10) using 
Burrows Wheeler Aligner (BWA, version 0.7.10-r806-dirty) with default settings (Li and Durbin, 
2009). Duplicate reads were removed before further analysis. Reads aligning to Ensembl-annotated 
1kp up- and down-stream of a TSS with a strict mapping quality (Q≥20) were counted with 
featureCounts (Liao et al., 2014) and used to construct a data matrix comprising genes with an 
average of 10 reads or more per sample across the experiment. Differential gene expression analysis 
was performed using edgeR (v3.2.4) (Robinson et al., 2010). Heatmaps were generated from 
normalized and scaled gene expression values with R in RStudio (Reich et al., 2006; RStudio, 
2012). Reads from each developmental stage were pooled and a single large alignment file (bam 
format) prepared for P1, P14 and P56. MACS (Zhang et al., 2008) was then used to directly 
compare P1 to P56 , P1 to P14 and P14 to P56 and identify regions of interest. MACS peak-calling 
was performed with a shift size of 75 bp and otherwise default parameters. Differentially accessible 
regions were defined as coordinates initially identified using MACS peak calling determined to 
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have a statistically significant signal difference (P1 vs. P56, FDR ≤ 0.05). Intersection between 
differential accessible chromatin regions and Ensembl genomic features was performed with 
BedTools (Quinlan and Hall, 2010).  
GSEA of RNA-seq and ATAC-seq  Gene GO process analysis was performed using MetaCore 
from Thomson Reuters (https://portal.genego.com/cgi/data_manager.cgi) on significant gene sets 
that formed different clusters. GSEA was performed on these data as previously described 
(Subramanian et al., 2005) using publicly available gene sets (www.broadinstitute.org/gsea/msigdb ) 
to determine the enrichment of Reactome or TF binding sites. 
Intersection of RNA-seq and ATAC-seq  A two-way enrichment analysis was used to identify 
gene sets simultaneously altered in gene expression and chromatin accessibility. First, genes in 
RNA and ATAC profiles were ranked by the sign of the fold change divided by the nominal p-value. 
These data were merged, followed by MANOVA test to determine the two-dimensional enrichment 
of gene sets. All statistical analyses were performed in R (Unpublished software by Antony Kaspi). 
Statistical analysis  Gene expression, chromatin structure and gene set enrichments with a FDR 
p-value ≤ 0.05 were considered significant.   
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5.3. Results 
5.3.1. Isolated PCM1 nuclei are enriched for cardiomyocyte specific markers 
To interrogate myocyte specific transcriptome and chromatin accessibility dynamics during cardiac 
maturation, cardiomyocyte specific nuclei were isolated from frozen ventricular mouse hearts from 
P1, P14 and P56 (Figure 5.1). Following the isolation of PCM1 (-/+) nuclei, nuclear RNA was 
processed for real-time qPCR for analysis of cell type specific markers (Figure 5.2, 5.3, 5.4). PCR 
profiling data of myocyte markers (Myh6, Myh7), slow skeletal and cardiac type troponin C1 
(Tnnc1) and Tnni3, showed significant enrichment of cardiomyocyte specific markers in PCM1
+
 
nuclei populations in P1, P14 and P56 samples (Figure 5.2). Next, the non-myocyte markers for 
fibroblasts (collagen type 1 or 3 alpha 1 chain (Col1a1, Col3a1), fibrillin 1 (Fbn1) and discoidin 
domain receptor tyrosine kinase 2 (Ddr2)) (Figure 5.3), endothelial cells (von Willebrand factor 
(Vwf)) and immune cells (integrin subunit alpha M (Itgam)) (Figure 5.4) were examined in the 
PCM1 (-/+) populations. PCM1
-
 populations were significantly enriched for non-myocyte specific 
markers at all 3 developmental stages. These findings confirm the purity of the isolated PCM1
+
 
populations that were subsequently used for sequencing.  
5.3.2. RNA-seq of PCM1+ nuclei identifies dynamic changes in the 
cardiomyocyte transcriptome during postnatal development 
RNA-seq was performed on the isolated myocyte specific PCM1
+
 fraction from P1, P14 and P56 to 
examine transcriptional changes during postnatal cardiomyocyte development. More than 92% of 
generated reads were uniquely mapped to the mouse genome with >83% of reads assigned to a 
specific gene, confirming the high quality of data generated in this RNA-seq experiment (Table 
5.6). Furthermore, multidimensional scaling (MDS) analyses were performed on all RNA-seq 
datasets to assess the degree of similarity of individual samples within the datasets. MDS plot 
showed clear separation of clusters for the P1, P14 and P56 samples and tight clustering of 
replicates within the sample groups (P1, P14 and P56) (Figure 5.5A), confirming the specificity 
and reproducibility of the sequencing datasets.  
Gene sets that were differentially transcribed (FDR p-value <0.05) between P1 vs. P14, P1 vs. P56 
or P14 vs. P56 were then selected to generate differential heatmap profiles (Figure 5.5B). The 
heatmap shows the formation of 5 distinct transcriptional clusters. Gene sets from different clusters 
were examined for their roles in different biological processes through ontology analysis. Gene sets 
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that were highly expressed in P1 cardiomyocytes and gradually shut down during development 
(cluster 5) were enriched for genes that were involved in cell cycle activities and cellular structure 
arrangement. Gene sets that were primarily repressed between P1 and P14 (cluster 3) were enriched 
for genes that participated in cell cycle S phase and DNA damage regulation. Conversely, gene sets 
that were significantly enriched in P14 and/or P56 cardiomyocytes (relative to P1) were associated 
with muscle contraction, skeletal muscle development, cell adhesion, inflammation and the immune 
response (cluster1).  
5.3.3. Analysis of transcriptional changes during defined windows of postnatal 
cardiomyocyte maturation 
To further understand specific transcriptional changes during different windows of postnatal 
development, the RNA-seq data were analysed according to the following comparisons: P1 vs. P14, 
P14 vs. P56 and P1 vs. P56. Between P1 vs. P14, there were 8193 differentially expressed genes 
with 4350 up-regulated and 3843 down-regulated at P14 (Figure 5.6A; Table 5.7). GSEA analysis 
revealed that genes that were highly expressed at P1 were largely involved in cell cycle activities, 
supporting the previous results from the heatmap cluster analysis (Figure 5.5B). Furthermore, these 
gene sets were enriched for E2f4 and Foxm1 regulated targets, which are cell cycle-related TFs 
(Figure 5.6B, C; 5.8B, C). 
A total of 7113 genes were differentially expressed between P14 and P56 with 3790 up-regulated 
and 3323 down-regulated at P56 (Figure 5.7A; Table 5.7). To understand the biological processes 
that were regulated at P14, genes enriched at P14 from the two comparisons (P1 vs. P14 and P14 vs. 
P56) were analysed. Together, genes that were highly enriched at P14 were associated with vascular 
reactivity, cell adhesion, extracellular matrix processes, muscle contraction and relaxation, immune 
response as well as metabolic activities, consistent with the maturation processes observed during 
postnatal heart maturation (Figure 5.6B, 5.7B). TFs that were known for regulating the 
aforementioned biological processes, such as Brg1 (Han et al., 2016; Zhang et al., 2011), Stat1 
(Gatto et al., 2014; Sisler et al., 2015); (Kim et al., 2015), Suz12 (Pasini et al., 2007) as well as 
MTA3 (Fujita et al., 2004; Fujita et al., 2003) were also enriched in these gene sets (Figure 5.6C, 
5.7C). Collectively, this suggested the establishment of terminal cardiomyocyte differentiation and 
immune responses by P14.  
Overall there were 10369 genes that were differentially expressed between P1 and P56, with 5281 
up-regulated at P1 and 5088 up-regulated at P56 (Figure 5.8A; Table 5.7). There was a marked 
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enrichment of genes that participated in cell cycle activities and that were regulated by the cell 
cycle TFs E2f4 and Foxm1 in P1 cardiomyocytes (Figure 5.8B, C). Interestingly, genes that were 
highly expressed at P56 (relative to P1) were largely associated with metabolic activities, especially 
tricarboxylic acid (TCA) cycle (Figure 5.7B, 5.8B). In addition, P56 up-regulated genes were 
regulated by TFs Stat1 and Pgc1a, a key inducer of mitochondria metabolism, consistent with the 
observation in the ontology analysis (Figure 5.7C, 5.8C).  
Together, the analysis between P1 vs. P14, P14 vs. P56 and P1 vs. P56 indicated distinct biological 
processes were taking place in cardiomyocytes during two defined postnatal developmental 
windows. 
5.3.4. Dynamic changes in the chromatin accessibility landscape during 
cardiomyocyte development 
In order to understand the changes in chromatin landscape during cardiomyocyte maturation, 
ATAC-seq was performed on the sorted PCM1
+
 nuclei samples. As previous papers have reported 
that TSSs are enriched in accessible chromatin regions, I focused on analysing the sequencing data 
within 1 kbp±TSS and genes assigned to these regions. Quality control results from BWA (Q10: 
confident in correcting mapped sequences >99%, Q20: confident in correcting mapped 
sequences >99.99%) indicated that at least 54% of the sequenced reads were correctly mapped and 
~3-4.5% were mapped to TSS (Table 5.8). Next, MDS analysis was performed to understand the 
similarity between different samples and showed that unique clusters were formed by the 3 
replicates in P1 and P56 group but not P14 group (Figure 5.9A). Gene sets with differential 
chromatin structure (FDR p-value ≤0.05) between P1 vs. P14, P1 vs. P56 or P14 vs. P56 were used 
to generate differential heatmap profiles (Figure 5.9B). The heatmap demonstrated the formation of 
3 clusters. Interestingly, gene sets that had highly accessible TSSs at P1 with reduced accessibility 
by P56 (cluster 3) were enriched for genes associated with cell adhesion, olfactory transduction and 
inflammation (Figure 5.9B). On the other hand, gene sets that had more compacted TSS at P1 and 
gradually gained accessibility by P56 were enriched for genes associated with cell adhesion, muscle 
development, cytoskeleton rearrangement and muscle contraction (cluster 1 and 2). Together, these 
results suggest that the chromatin landscape of cardiomyocytes underwent significant transitions 
from P1 to P56.  
Due to the variability of the P14 ATAC-seq datasets, which might be due to sample quality or 
reflect vibrant biological changes during this critical developmental transition, further analysis was 
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focused on P1 vs. P56. First, P1 vs. P56 ATAC-seq data was used to generate peak sets that mapped 
across the mouse chromosome regions to understand the distribution of open chromatin regions 
during development (Figure 5.9C). The data suggested that chromosomes 1,3,6,7 and 12 were 
relatively open at P1 while chromosomes 9, 11, 17 and 19 were relatively open at P56. Moreover, 
while the distribution of open chromatin signatures at GC regions was fairly similar (Figure 5.9D), 
P56 CpG sites were more accessible at P1 (Figure 5.9E). In addition, various genome features were 
mapped using P1 vs. P56 sequencing reads and indicated the enrichment of open chromatin at P56 
on CGIs, TSSs, introns, exons, enhancers, and TFBS, except intergenic regions (Figure 5.9F), 
suggesting the P56 cardiomyocyte genome encoded for more accessible chromatin regions.  
Differential analysis on P1 vs. P56 ATAC-seq datasets revealed that 882 genes had significant 
changes in chromatin structure within 1 kbp±TSS (Figure 5.10A; Table 5.9). GSEA analysis 
suggested that most of these regions were associated with genes involved in metabolism, especially 
fatty acid oxidation pathway and TCA cycle (Figure 5.10B). Moreover, analysis of enriched TFBS 
suggested an enrichment of Erra (essential for mitochondria biogenesis (Schreiber et al., 2004)) and 
BCL3 (critical component for adaptive immune response (Herrington and Nibbs, 2016)) (Figure 
5.10C). 
In summary, these data suggested a progressively open chromatin landscape at gene promoters was 
established during cardiomyocyte maturation between P1 and P56, which primarily occurred at the 
promoters of genes involved in cardiomyocyte metabolism and the immune response. 
5.3.5. Chromatin accessibility is reduced at E2f4 and Foxm1 sites during 
postnatal cardiomyocyte maturation 
RNA-seq and ATAC-seq (1 kbp±TSS) datasets were next intersected to understand the relationship 
between chromatin accessibility and transcriptional regulation. Importantly, the integration of both 
sequencing data sets demonstrated a strong positive correlation of active transcription with open 
chromatin at TSSs (Figure 5.11A). Analysis of the TFBS suggested that genes that were highly 
expressed and associated with open chromatin at P1 were significantly enriched for several critical 
TFs for cell proliferation, such as E2f4, E2f1 and Foxm1 binding sites (Figure 5.11B). Conversely, 
Pol2, Bcl3 and Erra binding sites were enriched in gene sets that were up-regulated with open 
chromatin at P56 (Figure 5.11C). In sum, these data revealed a positive relationship between 
transcription and open chromatin structure and identified several critical TFs that might participate 
in the cardiomyocyte maturation process.  
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5.3.6. Isolation of human cardiomyocyte nuclei for RNA-seq and ATAC-seq  
To fully understand the key developmental processes that govern mammalian cardiomyocyte 
maturation, a similar strategy was applied to archival human ventricular samples at various stages 
of development. RNA-seq and ATAC-seq of human cardiomyocyte nuclei would provide an 
understanding of cardiomyocyte specific transcriptional programs and chromatin landscape 
dynamics during human cardiac maturation for the first time (Table 5.1). Briefly, 4 sample groups 
were included for human RNA-seq and ATAC-seq, including foetal (13-19 wks), 0-10 yrs, 10-30 
yrs and 30+ yrs.  
Similar to mouse studies, PCM1
+
 nuclei were isolated from frozen human ventricular heart tissue 
samples from different age groups. Cardiomyocyte specificity of the PCM1
+ 
nuclei was tested by 
real-time qPCR for cell type specific markers (cardiomyocytes: MYH6, MYH7, TNNC1, TNNI3; 
fibroblast: COL1A1, COL3A1, FBN1, DDR2; endothelial cells: VWF and immune cells: ITGAM) 
(Figure 5.12). The results confirmed that human PCM1
+
 nuclei were highly enriched for 
cardiomyocyte specific markers. Next, isolated PCM1
+
 samples were processed for RNA-seq and 
ATAC-seq. Initial preliminary analysis of RNA-seq data showed that at least 89% of sequencing 
reads were uniquely mapped to the human genome and at least 75% were assigned to a gene, 
suggesting high quality sequencing data were generated (Table 5.2). In addition, MDS analysis of 
the sequenced samples revealed distinct clusters were formed by foetal, 0-10 yrs and 30+ yrs groups 
(Figure 5.13). Bioinformatics analysis of human RNA-seq and ATAC-seq data sets are underway. 
Unfortunately, due to time constraints, these data will not be included in this PhD Thesis. 
Nevertheless, this Thesis outlines the methodological pipelines for RNA-seq and ATAC-seq of 
mammalian cardiomyocyte nuclei, which will be used in the future to characterise the chromatin 
accessibility landscape of human cardiomyocytes for the first time. 
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Table 5.1. Selected human heart specimens for RNA-seq and ATAC-seq. 
Bin Age Code Sex 
Heart 
Tissue 
ATAC-
seq 
RNA-seq 
Foetal 
13 wks 9773 F LV x x 
14 wks 9770 F LV √ √ 
16 wks 9768 F LV √ √ 
19 wks 9763 F LV √ √ 
0-10 yrs 
3 wks 6012 M LV √ √ 
10 wks 4087 F LV/ IVS √ √ 
2 yrs 705 M LV √ √ 
4 yrs 4152 M LV √ √ 
10-30 yrs 
14 yrs 4043 M LV √ √ 
16 yrs 7072 M LV √ √ 
17 yrs 3134 M LV √ x 
17 yrs 7060 M LV √ x 
19 yrs 7012 M LV √ x 
23 yrs 4013 M LV √ x 
25 yrs 6038 M LV √ x 
29 yrs 5086 M LV √ x 
30+ yrs 
37 yrs 7040 M LV √ x 
40 yrs 6008 M LV √ √ 
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44 yrs 3122 M LV √ √ 
48 yrs 6052 M LV √ x 
55 yrs 4062 M LV √ x 
62 yrs 7028 M LV √ √ 
 
* Note:  
1. Foetal 13 wks sample only used for real-time qPCR due to no enough quantity for RNA-seq or 
ATAC-seq. 
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Table 5.2. Quality control of human PCM1+ nuclei RNA-seq reads by STAR and featureCounts (f: foetal, w: weeks, y: years). 
 
Total reads 
% 
Uniquely 
mapped reads 
% 
Multi-
mapped 
% 
Un-mapped 
Assigned reads 
% 
Assigned reads 
f14w 72,644,087 95.27% 3.19% 1.22% 59,636,409 82.09% 
f16w 52,242,769 95.77% 2.88% 1.11% 42,734,181 81.80% 
f19w 70,098,883 95.14% 3.16% 1.37% 56,937,531 81.22% 
3w 51,134,960 90.56% 6.92% 1.95% 38,386,008 75.07% 
10w 55,190,224 95.14% 3.05% 1.32% 44,175,023 80.04% 
2y 58,143,412 95.12% 3.29% 1.28% 45,813,276 78.79% 
4y 47,382,739 93.34% 4.52% 1.81% 36,925,972 77.93% 
14y 59,159,454 89.55% 8.66% 1.44% 44,714,807 75.58% 
16y 56,402,691 94.23% 4.21% 1.28% 44,517,834 78.93% 
40y 66,859,238 95.77% 2.73% 1.19% 52,788,846 78.96% 
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44y 47,682,840 93.59% 4.25% 1.58% 36,944,090 77.48% 
62y 56,246,363 95.10% 3.30% 1.28% 42,489,260 75.54% 
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Table 5.3. Additional PCR amplification cycle during human PCM1+ nuclei ATAC-seq 
libraries construction (f: foetal, w: weeks, y: years). 
Sample Rn (top) Rn (low) 
Rn (Sum)= 
Rn (top)-    
Rn (low) 
Extra PCR 
cycle 
f14w 0.8 0.06 0.74 11 
f16w 0.75 0.085 0.665 11 
f19w 0.8 0.09 0.71 11 
3w 0.73 0.065 0.665 11 
10w 0.85 0.09 0.76 10 
2y 0.625 0.09 0.535 14 
4y 0.8 0.06 0.74 10 
14y 0.775 0.12 0.655 11 
16y 0.71 0.05 0.66 12 
17y-3134 0.76 0.07 0.69 12 
17y-7060 0.775 0.075 0.7 11 
19y 0.74 0.14 0.6 11 
23y 0.675 0.08 0.595 13 
25y 0.59 0.06 0.53 14 
29y 0.755 0.095 0.66 12 
37y 0.765 0.075 0.69 11 
40y 0.795 0.12 0.675 12 
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44y 0.725 0.045 0.68 10 
48y 0.75 0.08 0.67 12 
55y 0.64 0.065 0.575 14 
62y 0.785 0.09 0.695 11 
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Table 5.4. Additional PCR amplification cycle during mouse PCM1+ nuclei ATAC-seq 
libraries construction. 
Sample Rn (top) Rn (low) 
Rn (Sum)= 
Rn (top)-    
Rn (low) 
Extra PCR 
cycle 
P1-1 2.2 0.3 1.90 5 
P1-2 2.4 0.4 2.00 7 
P1-3 2.3 0.25 2.05 7 
P14-1 2.3 0.3 2.00 8 
P14-2 2.25 0.3 1.95 9 
P14-3 2.25 0.25 2.00 9 
P56-1 2.25 0.25 2.00 8 
P56-2 2.25 0.5 1.75 7 
P56-3 2.3 0.65 1.65 8 
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Table 5.5. Bioinformatics analysis pipeline. 
 
Function Software  Input file type 
Reference 
file type 
Output file 
type 
1 
Qualicty control, 
trimming of poor 
quality 
sequencing reads 
Fastx 
toolkit 
(RNA) 
.fastq.gz - .fastq.gz 
Skewer 
(DNA) 
↓ 
2 Mapping 
STAR 
(RNA) 
.fastq.gz 
.fa 
(generated by 
STAR 
indexing) 
.bam 
BWA 
(DNA) 
.fa 
(generated by 
BWA 
indexing) 
.gtf 
↓ 
3 
Peak calling 
(DNA only) 
MACS .bam - .saf / .bed 
↓ 
4 
Count reads and 
generate matrix 
feature 
Counts 
to quantify at 
genes or specific 
genome 
feature: .bam 
(from BWA or 
.gtf / custom 
genome 
feature .saf 
.mx 
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STAR) 
to quantifiy 
global peak 
distribution: .ba
m (from BWA) 
.saf 
(generated 
from MACS 
by merging 
all peaksets) 
.mx 
↓ 
5 
Sample 
similarity test 
Rstudio .mx - 
MDS plot 
(.pdf / .jpg) 
↓ 
6 
Differential gene 
expression 
Rstudio- 
edgeR 
.mx - 
DGE 
spreadsheet 
(.xls) 
↓ 
7 Ontology GSEA 
.rnk (generated 
from logFC and 
adjusted p-value 
of edgeR) 
.gmt .xls / .pdf 
↓ 
8 
TF motifs 
analysis (DNA 
peaks only) 
Homer 
.bed (generated 
from .mx) 
unchange 
peak sets 
(.bed) and .fa 
.html  
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Table 5.6. Quality control of mouse PCM1+ nuclei RNA-seq reads by STAR and featureCounts. 
Sample Total reads 
%Uniquely 
mapped 
%Multimapped %Unmapped 
%Assigned 
reads 
Assigned 
reads 
P1-1 68,512,799 94.32% 2.00% 3.68% 85.48% 58,567,486 
P1-2 57,754,801 94.05% 1.99% 3.96% 85.21% 49,214,558 
P1-3 58,487,025 93.53% 2.13% 4.34% 84.78% 49,587,028 
P14-1 43,495,718 92.52% 2.40% 5.08% 84.24% 36,641,831 
P14-2 44,842,478 92.06% 2.28% 5.66% 83.71% 37,539,561 
P14-3 46,359,284 92.11% 2.22% 5.67% 83.90% 38,894,187 
P56-1 54,482,507 93.68% 2.46% 3.86% 84.22% 45,886,211 
P56-2 57,325,021 93.79% 2.20% 4.01% 84.53% 48,455,170 
P56-3 58,734,172 93.80% 2.15% 4.05% 84.37% 49,554,405 
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Table 5.7. Differential expression of mouse PCM1+ nuclei RNA-seq between P1 vs. P14, 
P14 vs. P56 and P1 vs. P56. 
 
DGE Up Dn 
P1 vs. P14 8193 4350 3843 
P1 vs. P56 10369 5088 5281 
P14 vs. P56 7113 3323 3790 
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Table 5.8.  Quality control of mouse PCM1+ nuclei ATAC-seq reads by BWA and featureCounts. 
Sample Total reads 
Mapped 
Q10 
Mapped 
Q20 
%MapQ 
Total Q20 
reads 
TSS 
assigned 
TSS 
assigned % 
Gene 
Assigned 
P1-1 72,517,156 53,640,927 53,640,927 73.97% 
176,640,656 
2674544 3.69% 3519093 
P1-2 77,059,406 48,347,793 48,347,793 62.74% 2576882 3.34% 3592856 
P1-3 111,552,674 74,651,936 74,651,936 66.92% 4106252 3.68% 5829840 
P14-1 109,087,985 70,455,399 70,455,399 64.59% 
181,838,251 
3896994 3.57% 5437797 
P14-2 95,137,466 64,086,045 64,086,045 67.36% 3723605 3.91% 5296468 
P14-3 86,128,542 47,296,807 47,296,807 54.91% 2595565 3.01% 3621401 
P56-1 75,413,580 55,506,944 55,506,944 73.60% 
138,382,130 
3365470 4.46% 4780900 
P56-2 71,660,454 49,474,315 49,474,315 69.04% 3091933 4.31% 4651638 
P56-3 46,835,518 33,400,871 33,400,871 71.32% 2079152 4.44% 3019502 
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Table 5.9. Differential chromatin landscape of mouse PCM1+ nuclei ATAC-seq between 
P1 vs. P14, P14 vs. P56 and P1 vs. P56. 
 
DGE Up Dn 
P1 vs. P14 55 40 15 
P1 vs. P56 882 476 406 
P14 vs. P56 62 53 9 
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Figure 5.1. Schematic of the isolation of cardiomyocyte specific nuclei. 
Left ventricular heart tissue was isolated from individual hearts and archived in liquid nitrogen. 
Archived heart samples were dissected and minced into approximately 1mm
3
 cubes, followed by 
two stages of homogenization and centrifugation. Nuclei pellets were then stained with PCM1 
antibody and PCM1 (-/+) nuclei were separated through FACS. All nuclei that went through FACS 
process were plotted according to forward scatter (FSC) versus side scatter (SSC). Singlet nuclei 
were further selected through FSC versus FSC width setting. Singlet nuclei were then plotted 
according to SSC and secondary antibody signal (Alexa Fluor 633 or Brilliant Violet 421). 
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Figure 5.2. PCM1+ nuclei enriches for cardiomyocyte specific markers during heart 
development. 
qPCR gene expression profiling of Myh6, Myh7, Tnnc1 and Tnni3 in PCM1 (-/+) cardiomyocyte 
populations from P1 to P14 and P56. (n=3 per group). All gene expression values are normalized to 
18S and presented as a fold change relative to PCM1
-
. All data are presented as mean ±s.e.m. 
*P<0.05, ** P <0.001).  
Chapter 5 
 
 
158 
 
Figure 5.3. PCM1- nuclei enriches for fibroblast specific markers during heart 
development. 
qPCR gene expression profiling of Col1a1, Col3a1, Fbn1 and Ddr2 in PCM1 (-/+) cardiomyocyte 
populations from P1 to P14 and P56. (n=3 per group). All gene expression values are normalized to 
18S and presented as a fold change relative to PCM1
+
. All data are presented as mean ±s.e.m. 
*P<0.05, ** P <0.001).  
Chapter 5 
 
 
159 
 
Figure 5.4. PCM1- nuclei enriches for endothelial and immune cell specific markers during 
heart development. 
qPCR gene expression profiling of Itgam and Vwf in PCM1 (-/+) cardiomyocyte populations from 
P1 to P14 and P56. (n=3 per group). All gene expression values are normalized to 18S and 
presented as a fold change relative to PCM1
-
. All data are presented as mean ±s.e.m. *P<0.05, ** P 
<0.001).  
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Figure 5.5. RNA-seq analysis of cardiomyocyte specific gene expression during heart 
development.  
A. MDS plot of RNA-seq data showing distinct clusters formed by 3 replicates of individual time 
point from P1 to P56.  
B. Heatmap of differentially expressed genes from P1 to P14 and P56. Genes with higher 
expression levels are shown in red whereas genes with lower expression levels are shown in blue. 5 
clusters were formed by the datasets. Gene GO process analysis (MetaCore) revealed the involved 
functional processes. 
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Figure 5.6. RNA-seq analysis of cardiomyocyte specific gene expression revealed cell cycle 
shut down activity during P1 and P14. 
A. Smear plot of RNA-seq data showing average signal intensity (x-axis) versus log2 fold change in 
gene expression (P14/P1). Differentially expressed genes (FDR ≤ 0.05, n=8193) are shown in red 
and non-significant changes are shown in black.  
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B. GSEA reactome analysis of differentially expressed genes from P1 to P14. Reactome that are 
enriched at P1 (Blue) or enriched at P14 (Red). 
C. GSEA TFBS analysis of differentially expressed genes from P1 to P14. TFBS that are enriched 
at P1 (Blue) or enriched at P14 (Red). 
.  
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Figure 5.7. RNA-seq analysis of cardiomyocyte specific gene expression revealed the 
activation of TCA cycle during P14 and P56. 
A. Smear plot of RNA-seq data showing average signal intensity (x-axis) versus log2 fold change in 
gene expression (P56/P14). Differentially expressed genes (FDR ≤ 0.05, n=7113) are shown in red 
and non-significant changes are shown in black.  
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B. GSEA reactome analysis of differentially expressed genes from P14 to P56. Reactome that are 
enriched at P14 (Blue) or enriched at P56 (Red). 
C. GSEA TFBS analysis of differentially expressed genes from P14 to P56. TFBS that are enriched 
at P14 (Blue) or enriched at P56 (Red). 
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Figure 5.8. RNA-seq analysis of cardiomyocyte specific gene expression revealed cell cycle 
shut down and activation of TCA cycle during P1 and P56. 
A. Smear plot of RNA-seq data showing average signal intensity (x-axis) versus log2 fold change in 
gene expression (P56/P1). Differentially expressed genes (FDR ≤ 0.05, n=10369) are shown in red 
and non-significant changes are shown in black.  
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B. GSEA reactome analysis of differentially expressed genes from P56 to P1. Reactome that are 
enriched at P1 (Blue) or enriched at P56 (Red). 
C. GSEA TFBS analysis of differentially expressed genes from P56 to P1. TFBS that are enriched 
at P1 (Blue) or enriched at P56 (Red). 
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Figure 5.9. ATAC-seq analysis of cardiomyocyte specific chromatin structure during heart 
development. 
A. MDS plot of ATAC-seq data showing distinct clusters formed by 3 replicates of P1 and P56.  
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B. Heatmap of differentially expressed genes from P1 to P14 and P56. Genes with higher 
expression levels are shown in red whereas genes with lower expression levels are shown in blue. 3 
clusters were formed by the datasets. Gene GO process analysis (MetaCore) revealed the involved 
functional processes. 
C. Distribution of differentially accessible regions across each chromosome at P1 (blue) and P56 
(red) for mouse (mm10) genome normalised by chromosome length. 
D. Distribution of differentially accessible regions across GC component at P1 (red) and P56 (blue) 
in mouse (mm10) genome. 
E. Distribution of differentially accessible regions across CpG sites at P1 (red) and P56 (blue) in 
mouse (mm10) genome. 
F. Distribution of differentially accessible regions shown by genomic features. Open chromatin 
regions at P1 are shown in blue, accessible chromatin regions at P56 are shown in red. 
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Figure 5.10. ATAC-seq analysis of cardiomyocyte specific chromatin structure showed 
enrichment of pathway for matured metabolism pathway between P1 and P56. 
A. Smear plot of ATAC-seq data showing average signal intensity (x-axis) versus log2 fold change 
in chromatin accessibility (P56/P1). Differentially accessible genes (FDR ≤ 0.05, n=882) are shown 
in red and non-significant changes are shown in black.  
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B. GSEA reactome analysis of differentially accessible genes from P56 to P1. Reactome that are 
enriched at P1 (Blue) or enriched at P56 (Red). 
C. GSEA TFBS analysis of differentially accessible genes from P56 to P1. TFBS that are enriched 
at P1 (Blue) or enriched at P56 (Red). 
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Figure 5.11. Integration of RNA-seq and ATAC-seq demonstrated a positive correlation of 
gene expression with chromatin structure between P1 and P56, with the 
enrichment of TF, E2F4 at P1.  
A. (Top) Venn diagram of all differentially regulated genes (no p-value threshold) from RNA-seq 
and ATAC-seq 1 kbp±TSS data sets. A total of 14230 genes were detected in both data sets. 
(Bottom) Heatmap contour of integration of RNA-seq and ATAC-seq data showed positive 
correlation between active transcription and open chromatin structure. The degree of positive 
correlation is shown from red (highest) to blue (lowest). 
B. GSEA TFBS analysis of differentially regulated genes from RNA-seq and ATAC-seq between 
P1 to P56. TFBS that are enriched at P1 open chromatin and actively transcripted genes are shown 
in blue. 
C. GSEA TFBS analysis of differentially regulated genes from RNA-seq and ATAC-seq between 
P1 to P56. TFBS that are enriched at P56 open chromatin and actively transcripted genes are shown 
in red. 
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Figure 5.12. PCM1+ nuclei enriches for cell type specific markers during human heart 
development. 
qPCR gene expression profiling of MYH6, MYH7, TNNC1, TNNI3; COL1A1, COL3A1, FBN1, 
DDR2; ITGAM and VWF in human PCM1 (-/+)cardiomyocyte populations from foetal, 0-10 yrs, 
10-30 yrs and 30+ yrs group (n=4-8 per group). All gene expression values are normalized to 18S 
and presented as a fold change relative to PCM1 (-/+). All data are presented as mean ±s.e.m.  
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Figure 5.13. RNA-seq analysis of cardiomyocyte specific gene expression during human 
heart development.  
MDS plot of RNA-seq data showing distinct clusters formed by replicates of individual time point 
from foetal, 0-10 yrs, 10-30 yrs and 30+ yrs.  
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Figure 5.14. Genomic feature analysis of ATAC-seq peak sets between P1 vs. P14 and P14 vs. 
P56. 
A. Distribution of differentially accessible regions shown by genomic features. Open chromatin 
regions at P1 are shown in blue, accessible chromatin regions at P14 are shown in red. CGI is 
marked in green box. 
B. Distribution of differentially accessible regions shown by genomic features. Open chromatin 
regions at P14 are shown in blue, accessible chromatin regions at P56 are shown in red. CGI is 
marked in green box. 
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Figure 5.15. Schematic of proposed model for chromatin landscape, DNA methylation and 
transcription regulation during postnatal cardiomyocyte maturation.  
In the proposed model, cell cycle related genes undergo chromatin compaction between P1 to P14 
and completely closed by P56, with potential increase methylation at CpG island of E2f4 regulated 
genes. Meanwhile, maturation required genes undergo hypomethylation and become more 
accessible between P14 to P56.  
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5.4. Discussion and conclusion 
The current chapter has shown for the first time that the chromatin landscape of cardiomyocytes is 
positively correlated with transcriptome changes during postnatal maturation. Current findings 
suggest that the cardiomyocyte transcriptome exhibits distinct biological changes during postnatal 
development from P1 to P14 and P14 to P56. Specifically, 2 distinct waves of transcriptional 
regulation have been identified involving the repression of cell cycle activities from P1 to P14 and 
the transition towards an adult metabolic system from P14 to P56. Importantly, bioinformatics 
analyses identified critical TF binding motifs that are enriched at these 3 distinct developmental 
time points, corresponding to the biological processes that are regulated during these critical stages 
of postnatal cardiac development. Furthermore, the chromatin landscape demonstrated a 
progressively open chromatin structure between P1 and P56, which was associated with the 
acquisition of an open chromatin state at the promoter regions of metabolic genes in adult 
cardiomyocytes. Moreover, a strong positive correlation between open chromatin structure in 
promoter regions and transcriptional activity was identified. Notably, the binding motifs of several 
core cell cycle TFs, such as E2f4, E2f1 and Foxm1, underwent chromatin compaction during 
cardiomyocyte maturation from P1 to P56, suggesting the postnatal repression of cardiomyocyte 
cell cycle genes could be related to chromatin remodelling at cell cycle promoters in 
cardiomyocytes. The current chapter identifies novel relationships between the chromatin 
accessibility landscape and transcription during postnatal cardiomyocyte maturation and is 
consistent with an epigenetic mechanism for postnatal cardiomyocyte cell cycle arrest.  
An important finding of the current chapter is the identification of a positive correlation between 
chromatin accessibility at gene promoters and active transcription of downstream genes in 
cardiomyocytes using ATAC-seq couples with RNA-seq. Moreover, this analysis enabled the 
identification of TFs governing cardiomyocyte transcriptional programs between P1 vs. P56. While 
the concept of chromatin accessibility enabling transcriptional activation is well accepted (Song et 
al., 2011; Thurman et al., 2012), this is the first time that cardiomyocyte transcriptome dynamics 
has been linked to the accessible chromatin landscape on a genome-wide scale during 
cardiomyocyte maturation. Importantly, the developmental acquisition of a condensed chromatin 
state at cell cycle related genes was associated with transcriptional repression of the cardiomyocyte 
proliferation program. Furthermore, transcriptional activity of cell cycle genes in P1 
cardiomyocytes was associated with accessible chromatin containing motifs for several cell 
proliferation TFs, such as E2f4, E2f1 and Foxm1. These findings support the hypothesis that 
postnatal cardiomyocyte cell cycle arrest is epigenetically regulated. Several lines of evidence 
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indicate that E2f1, E2f4 and Foxm1 comprise core TFs required for cardiomyocyte proliferation. A 
previous study has reported that E2f4 is localized in nuclei during cardiomyocyte mitosis and is 
essential for neonatal rat cardiomyocyte proliferation in vitro.(van Amerongen et al., 2010). 
Inhibition of E2f4 leads to premature repression of cardiomyocyte mitotic events (van Amerongen 
et al., 2010). However, overexpression of E2f4 led to restricted expression of E2f4 in the cytoplasm 
instead of the nucleus and failed to induce proliferation in neonatal rat cardiomyocyte in vitro. 
Similarly, E2f1 was reported to regulate cardiomyocyte proliferation (Ebelt et al., 2006). In addition, 
in vivo knock-out of Foxm1 caused embryonic lethality in mice due to ventricular wall thinning 
(Bolte et al., 2011; Bolte et al., 2012). Collectively, these TFs are highly associated with 
cardiomyocyte proliferation and it would be important to investigate their capacity to induce adult 
cardiomyocyte proliferation in vivo to fully understand their role in regulation of postnatal myocyte 
cell cycle shut down. Furthermore, as previously discussed in Chapter 1, many studies have shown 
that factors which can lead to potent activation of neonatal cardiomyocyte proliferation have failed 
to serve the same purpose in adult cardiomyocytes. The more compacted chromatin landscape 
around cell cycle genes in adult cardiomyocytes could provide an explanation for this phenomenon. 
Without pioneer TFs to open the chromatin structure at cell proliferation genes, mitogenic stimuli 
may not be able to reach their full potential in promoting cell cycle activation in the adult heart 
(Denny et al., 2016). Therefore, it will be important in the future to determine whether these TFs 
can initiate the open chromatin structure and compete with nucleosomes as pioneer TFs in adult 
cardiomyocytes. These studies will be important in determining therapeutic strategies for inducing 
cardiomyocyte proliferation in the injured adult heart.  
Another interesting result from this chapter is the regulation of distinct biological processes during 
defined windows of postnatal cardiac development. Cell cycle activity is repressed in mouse 
cardiomyocytes from P1 to P14, initiation of cell-cell contacts, immune system development and 
activation of adult metabolic pathways occurs from P1 to P14 and the full activation of the mature 
cardiomyocyte metabolic system is established between P14 and P56. These results not only 
support the previously well-known early postnatal cell cycle shut down of cardiomyocytes between 
P1 and P14 (Alkass et al., 2015; Soonpaa et al., 1996), but also provide novel understanding 
regarding the timing of different cellular transitions towards the acquisition of the final terminally 
differentiated, mature cardiomyocyte phenotype. In addition, the identification of TFs that drive 
these postnatal maturation processes at individual time points further supports the proposal of core 
TFs driving the cardiomyocyte maturation process (Consortium, 2012; Gerstein et al., 2012; Song 
et al., 2011). Future validation of these TFs in vivo and in human cardiomyocytes will provide a 
more complete understanding of their role during postnatal cardiac development.  
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Globally, the chromatin accessibility landscape appears to open between P1 and P56 across almost 
every genomic feature except intergenic regions. However, reflecting the transcriptional changes 
observed between P1, P14 and P56, chromatin accessibility also dynamically changes from P1 to 
P14 and P56, especially at the CGI regions (Figure 5.14). Interestingly, it was found that chromatin 
regions around CGI are compacted between P1 and P14 and then open between P14 and P56. This 
is particularly interesting, as previously in Chapter 3 (Figure 3.1A, B) it was shown that the cardiac 
methylome is hypermethylated between P1 and P14 and globally hypomethylated after P14. As 
CGI is enriched for CpG and DNA methylation prefers CpG sites, the current result provides 
supporting evidence for our previously proposed model whereby two waves of DNA methylation 
shape the cardiomyocyte epigenome during postnatal heart development. A working model is 
proposed whereby the transcription of cardiomyocyte cell cycle genes is gradually shut down due to 
chromatin compaction between P1 to P14. In contrast, a progressively open chromatin landscape is 
acquired between P14 and P56, which is associated with hypomethylation of cardiomyocyte 
structural (Gilsbach et al., 2014), immune-related and metabolic genes, without affecting the 
previously compacted cell proliferation genes. Together, these epigenetic modifications collaborate 
to re-structure the chromatin landscape and direct postnatal cardiomyocyte maturation (Figure 
5.15). 
5.5. Summary and future direction 
The experimental platform developed in this study has demonstrated developmental stage- and cell 
type-specific changes in the chromatin landscape and transcriptome during heart development. The 
positive correlation of chromatin landscape and transcription indicates a potential regulatory 
mechanism between the two. However, whether chromatin landscape is the cause of transcription 
regulation and postnatal cell cycle shutdown or simply a consequence of transcription status 
remains unclear. Future studies are required to interrogate this relationship during postnatal 
cardiomyocyte maturation.  
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An experiment is a question which science poses to Nature 
And a measurement is the recording of Nature’s answer. 
Max Planck. 
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Chapter 6. General Discussion 
6.1. Overview 
The mammalian heart has traditionally been recognised as an organ of limited regenerative capacity. 
This notion has recently been challenged by the observation that neonatal mice retain a transient 
capacity for heart regeneration for a short period after birth (Porrello et al., 2011b). Cardiac 
regeneration in neonatal mice, as well as adult zebrafish, is driven by cardiomyocyte proliferation 
(Haubner et al., 2012; Jopling et al., 2010; Kikuchi et al., 2010; Porrello et al., 2011b; Porrello et al., 
2013). Concordantly, many studies have demonstrated that mitogenic stimuli that promote 
cardiomyocyte proliferation in neonates fail to deliver the same outcome in adulthood (refer to 
Section 1.1.3). Therefore, there is intensive interest in defining the mechanisms that shut down 
cardiomyocyte proliferative capacity and drive cardiac maturation in the postnatal period. The role 
of epigenetics in postnatal cardiac maturation has gained considerable attention as one possible 
mechanism for cardiomyocyte terminal differentiation (refer to Section 1.5.1, 1.5.2), but this 
hypothesis has not been formally tested. Moreover, the roles of DNA methylation and chromatin 
dynamics in postnatal cardiomyocyte maturation remain largely unstudied and poorly understood.  
In this Thesis, 3 major questions have been asked and addressed (Figure 1.7): 
1. What is the role of DNA methylation in transcriptional regulation during cardiac maturation? 
2. Does DNA methylation regulate cardiomyocyte proliferation during mammalian heart 
development? 
3. What is the relationship between the chromatin accessibility landscape and transcription 
during mammalian cardiomyocyte maturation? 
The major findings of this Thesis are (Figure 6.1): 
1. The murine heart experiences two postnatal waves of DNA methylation and transcriptional 
remodelling during cardiac maturation (Chapter 3 and 5). 
 Between P1 and P14, the cardiac transcriptome transitions from a pro-proliferative 
state towards the acquisition of a mature structural, immune and metabolic state 
(Figure 3.4, 5.5). Site-specific hypermethylation occurs across thousands of 
genomic loci during this developmental window (Figure 3.1, 3.5). 
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 Between P14 to P56, the cardiomyocyte transcriptome shifts towards an oxidative 
metabolic system (Figure 5.5), which is associated with global hypomethylation of 
the cardiomyocyte genome (Figure 3.1). 
2. DNA methylation is essential for rodent and human cardiomyocyte proliferation (Chapter 3: 
Figure 3.3, Chapter 4: Figure 4.5).  
3. Identification of novel relationships between DNA methylation, chromatin accessibility and 
TFs (Chapter3 and 5): 
 Several canonical developmental and differentiation-associated signalling pathways 
including Hedgehog, TGFβ, FGF, Notch and Wnt are hypermethylated and 
transcriptionally repressed between P1 and P14. These hypermethylated regions are 
highly enriched for Smad TF motifs (Figure 3.9). 
 E2f4, E2f1 and Foxm1 dependent gene promoters become compacted during 
cardiomyocyte maturation, which is associated with transcriptional repression of cell 
cycle genes. In contrast, Erra dependent gene promoters become more accessible and 
transcriptionally activated postnatally (Figure 5.6B, 5.7B, 5.8B, 5.11B, C). 
4. The cardiomyocyte chromatin landscape is dynamically altered during development and is 
positively associated with transcription (Chapter 5: Figure 5.10A, 5.11). 
 
This PhD Thesis provides new insight into the role of DNA methylation and chromatin dynamics 
during cardiac development. This Thesis identifies novel relationships between DNA methylation, 
chromatin accessibility and transcription during cardiac development, suggesting a significant role 
for epigenetic modifications in the loss of cardiomyocyte proliferative potential during postnatal 
maturation. In addition, this Thesis uncovers previously unappreciated relationships between 
chromatin accessibility and core cell cycle TFs, which might contribute towards postnatal terminal 
differentiation of cardiomyocytes. Collectively, this Thesis supports the hypothesis that 
cardiomyocyte terminal differentiation and maturation are under epigenetic control. The following 
sections will discuss the importance of these findings and their broad implications for our 
understanding of cardiac developmental and regenerative biology.  
6.2. Postnatal remodelling of the cardiomyocyte epigenome – 
physiological adaptation with pathophysiological consequences?  
The research outcomes from this PhD Thesis demonstrate that the cardiac DNA methylome 
undergoes dynamic alterations during postnatal development. Specifically, two waves of postnatal 
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DNA methylation were identified, where focal hypermethylation occurs from P1 to P14 and global 
hypomethylation predominates from P14 to P56. Thousands of DMRs were identified during the 
critical P1 to P14 developmental window when cardiac regenerative capacity is lost in mice. 
Hypermethylation was associated with transcriptional repression of several components of 
signalling pathways associated with early cardiac development and proliferation and these 
hypermethylated regions were enriched for TF binding motifs related to TGF/Smad signalling, 
including Smad3, Foxh1 and Tbx5 (Sim et al., 2015). These results are supported by another study 
that has investigated the cardiac DNA methylome between ESCs, neonatal and adult 
cardiomyocytes (Gilsbach et al., 2014) (refer to section 1.5.1, 1.5.4). Combining the two datasets, it 
is becoming clearer that developmental signalling pathways are hypermethylated and repressed, 
while some maturation related signalling pathways (related to structural remodelling, metabolism 
and contraction) are progressively hypomethylated and expressed during cardiac maturation.  
Importantly, the phenomenon of focal hypermethylation at CGIs followed by global 
hypomethylation has been widely observed in both senescent and cancer cells when compared to 
“young” cells or non-cancerous cells, respectively (Berman et al., 2011; Cruickshanks et al., 2013; 
Hansen et al., 2011). In cancerous cells, this shift in DNA methylation is thought to act acts as a 
defence system enabling cell cycle shutdown in senescent cells. However, it also leads to DNA 
epigenome instability, which makes the cell vulnerable to carcinogenic stimuli and which cancerous 
cells eventually employ to overcome the cell cycle shutdown barrier (Cruickshanks et al., 2013; 
Gomez et al., 2016). Unlike cardiomyocytes, most cells that develop cancer retain proliferation 
capacity throughout life, which means that more proliferation events increase the exposure rate to 
carcinogens and therefore increase the likelihood for mutational events that can overcome intrinsic 
cell cycle regulatory mechanisms. Could this same DNA methylome drift happen during postnatal 
cardiac development and contribute to cardiomyocyte cell cycle arrest? Or could this phenomenon 
represent a physiological adaptation that induces cell cycle shutdown by acquiring a “senescent-like” 
cardiac methylome to maintain lifelong function of terminally differentiated cardiomyocytes? 
While cancer cells metastasise through the blood system, which passes through the heart, 
myocardial tumours are extraordinarily rare (~0.3-0.7% vs. high incident type cancer such as breast 
cancer at 12%) (DeSantis et al., 2014; Leja et al., 2011). From an evolutionary perspective, such a 
mechanism could promote organismal survival over the maintenance of specific organ regenerative 
capacity. 
While the current Thesis points towards an essential role for DNA methylation during postnatal 
cardiac maturation, there is still considerable debate regarding the requirement of Dnmts for normal 
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heart development. Several studies and results from this PhD Thesis have shown that Dnmt1, 
Dnmt3a and Dnmt3b are indispensible for heart development and maturation (Fang et al., 2016; 
Gilsbach et al., 2014; Li et al., 1992; Okano et al., 1999; Sim et al., 2015). Also, Gilsbash et al have 
shown that Dnmt3a/3b is essential for cardiac gene expression in the adult heart (Gilsbach et al., 
2014). However, a subsequent study from the same lab has suggested that Dnmt3a/3b are 
dispensable for the maintenance of postnatal cardiomyocyte function (Nuhrenberg et al., 2015) 
(refer to section1.5.4). Notably, while Dnmt1 has traditionally been known as a DNA methylation 
maintenance enzyme, recent studies have exhibited its de novo methylation ability (see (Jeltsch and 
Jurkowska, 2014) for detailed discussion), providing a potential compensatory effect for Dnmt3a/3b 
knockout in the study by Nuhrenberg et al. Furthermore, the results from this PhD Thesis indicate 
that DNA methylation is controlled during specific developmental windows, which may have been 
missed in the aforementioned studies. Due to the stage-specific activation and inhibition of the 
DNA methylation machinery, future studies should employ genetic tools that enable temporal 
deletion of DNA methyltransferases in cardiomyocytes at defined stages of postnatal development 
that coincide with the major methylome transitions reported here.  
It is also important to note that while the results from this PhD Thesis have reported 
hypermethylation at gene bodies at P14, Gilsbach et al reported a demethylation at gene bodies 
from foetal to adult stages (Gilsbach et al., 2014; Sim et al., 2015). This might potentially be due to 
the limitation of the selected sequencing approach, as MBD-seq is an enrichment-based genome-
wide sequencing approach that lacks the base-pair resolution of whole genome bisulphite 
sequencing, which was used by Gilsbach et al (Gilsbach et al., 2014; Sim et al., 2015). Also, a large 
cohort of hypermethylated genes was paradoxically up-regulated during development in Chapter 3. 
Importantly, the study from Chapter 3 was performed on whole heart tissue and this observation 
could be due to the presence of mixed cell populations in whole tissues. Nonetheless, this 
phenomenon has previously been observed in other genome-wide methylation studies (Ball et al., 
2009; Lister et al., 2009) and could reflect more complex relationships between region-specific 
DNA methylation patterns and gene transcription, or could be a general artefact of genome-wide 
studies using heterogeneous cell populations from whole tissues. 
Together, it is clear that DNA methylation has a role in postnatal regulation of cardiac development 
and maturation. Future studies are required to carefully investigate the developmental stage- and 
ventricular cardiomyocyte-specific functions of DNA methylation, which will provide a clearer 
picture of the requirement of DNA methylation for cardiomyocyte maturation. In addition, it is 
well-accepted that DNA methylation and other histone marks act in concordance to modify the 
Chapter 6 
 
 
185 
epigenome and transcription (Romanoski et al., 2015). It will therefore be important to take a 
broader view of the epigenome beyond single epigenetic marks in order to gain a more complete 
mechanistic understanding of the transcriptional control of cardiac development. 
6.3. Harnessing the DNA methylome for cardiac regeneration 
An interesting outcome of this PhD thesis was the observation that pharmacological inhibition of 
DNA methylation via the hypomethylating agent 5aza-dC induces proliferation of immature rodent 
and human cardiomyocytes (Chapter 3 and 4). Interestingly, 5aza-dC also reduced cardiomyocyte 
binucleation in vivo, which is consistent with another in vitro study showing reduced rates of 
binucleation in 5aza treated cardiomyocytes following agonist stimulation with endothelin (Paradis 
et al., 2014). Notably, the most successful clinical targets of 5aza or 5aza-dC - advanced 
myelodysplastic syndrome, chronic myeloid leukaemia and acute myeloid leukaemia - are all 
associated with mutations in TET2 and isocitrate dehydrogenase 1 or 2 (both associated with DNA 
hypomethylation) (Figueroa et al., 2010). This might explain why 5aza-dC is effective in this 
clinical setting. In fact, as 5aza and 5aza-dC are already FDA-approved for clinical use, their effects 
in promoting immature cardiomyocyte proliferation could indicate a potential usage for heart 
disease patients to stimulate cardiac regeneration. Interestingly, recent studies have administered 
5aza post-MI in adult rodent hearts and demonstrated improved functional outcomes, which were 
associated with changes in macrophage activity including increased anti-inflammatory macrophage 
(M2) number and decreased pro-inflammatory macrophage (M1) number (Jeong et al., 2015; Kim 
et al., 2014). However, cardiomyocyte proliferation rates were not examined in these studies. It is 
possible that 5aza is targeting upstream TFs that control the cardiac cell cycle (via hypomethylation) 
and immune system (via hypermethylation) to de-differentiate adult cardiomyocytes to a neonatal 
state post-MI. Future studies are required to understand the role of 5aza in promoting 
cardiomyocyte proliferation in the adult heart, which would help inform downstream clinical 
therapeutic possibilities. 
Beside the well-described de-methylating effects of 5-aza, the pharmacological mechanisms of 5aza 
and 5aza-dC remain unknown. Recent studies have linked both of these compounds to the 
regulation of cellular metabolism, including effects on mitochondrial copy number and oxidative 
phosphorylation in various cell lines, suggesting a possible link to metabolic regulation (San Martin 
et al., 2011; Sok AJ, 2014; Wen et al., 2013). Notably, a recent study has proposed that the 
postnatal transition to a high oxygen environment provides a key trigger for oxidative metabolism, 
DNA damage and cardiomyocyte cell cycle arrest (Puente et al., 2014). It is possible that the effects 
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of 5aza-dC on cardiomyocyte proliferation (and transcription) could be due to unexplored actions 
on cardiomyocyte metabolism. Further studies are required to assess the mechanistic basis for these 
effects and whether 5aza is sufficient to promote (or facilitate) cell cycle re-entry in adult 
cardiomyocytes. 
Maturation of human PSC-derived cardiomyocytes is another major barrier in the field (Veerman et 
al., 2015). The finding that DNA methylation facilitates cardiomyocyte cell cycle arrest and 
maturation also has important ramifications for the cell therapy field and for disease modelling 
applications. While transplanted immature cardiomyocytes can proliferate, mature and engraft 
within the injured heart over time in small animals (Funakoshi et al., 2016; Riegler et al., 2015), 
previous studies have shown that the injection of these immature cardiomyocytes into the infarcted 
primate heart leads to transient cardiac arrhythmias (Chong et al., 2014). Targeting the DNA 
methylome could provide one strategy for controlling cardiomyocyte proliferative potential and 
maturation prior to implantation. Future studies should focus on understanding the maturation 
effects of DNA methylation or 5aza-dC in hPSC-derived cardiomyocyte or organoid models. In 
summary, DNA methylation (or 5aza-dC) could be harnessed for multiple applications in 
regenerative medicine: (1) transient treatment for cardiomyocyte cell cycle re-entry in the adult 
heart or (2) promotion of cardiomyocyte proliferation or maturation in hPSC-derived 
cardiomyocytes.  
6.4. Chromatin accessibility and TF activity – towards a mechanistic 
understanding of cardiomyocyte maturation 
Over the decade, the ENCODE, FANTOM and EPIGENOME ROADMAP projects have revealed 
complex relationships between the epigenome and transcription. It has been shown that enhancers 
are one of the most critical components of a genomic module. Enhancers often exhibit exquisite cell 
type or tissue-specific expression patterns, which translate into cell type-specific functions and 
influence genotype-phenotype associations (Ashburner et al., 2000; Koche et al., 2011; Rada-
Iglesias et al., 2011; Roadmap Epigenomics et al., 2015). Accordingly, each cell type encompasses 
from 20,000 to 40,000 enhancers to drive its transcriptional profile. However, similar groups of 
enhancers are enriched for common motifs of various TFs (Roadmap Epigenomics et al., 2015), 
suggesting enhancers are common regulatory elements targeted by specific TFs to drive specific 
cellular functions and thereby modulate organismal development. This is further supported by 
previous studies in the reprogramming field where differential expression of TFs and dynamic 
regulation of target genes synchronizes and drives PSC differentiation into different germ layers 
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(Thomson et al., 2011; Tsankov et al., 2015). Previous studies have also illustrated that the same TF 
can regulate different target genes at different developmental stages by binding to unique enhancers 
or promoters to orchestrate differentiation events (Thomson et al., 2011; Tsankov et al., 2015). 
Others have provided supporting linkages for the gaps between TFs and enhancer or promoter 
regulation of target genes through chromatin remodelling via epigenetic modifications, suggesting 
that epigenomic modifications can precede transcriptional regulation (Koche et al., 2011; Roadmap 
Epigenomics et al., 2015; Romanoski et al., 2015). This Thesis identifies novel relationships 
between several cardiomyocyte developmental stage-specific TFs and transcription. It is possible 
that these specific TFs govern the chromatin landscape and transcription of target genes during the 
maturation process of cardiomyocytes. Future studies should elucidate whether these TFs directly 
modulate chromatin accessibility at cell cycle genes or whether chromatin modifications preclude 
binding of TFs to critical cell cycle regulatory regions. 
It is important to note that the cell cycle-associated TF, E2f4, which was identified in this PhD 
Thesis as significantly associated with open chromatin regions in neonatal cardiomyocytes, has 
been previously reported to associate with various epigenetic modifiers. E2F4 has been shown to 
form multimolecular complexes with pRb2, p130, HDAC1, SUV39H1 and p300 (or DNMT1) to 
regulate the transcription of estrogen receptor α through DNA methylation, histone deacetylation or 
histone methylation in breast cancer (Macaluso et al., 2003). A subsequent study has also validated 
that E2F4 recruited SIN3-HDAC complexes for transcriptional repression, while the HCF1-E2F1 
complex recruited MLL and SET1 H3K4 histone methyltransferase complexes for transcriptional 
activation during the cell cycle (Tyagi et al., 2007). Additionally, E2F4 can coordinate with 
KDM5A (histone demethylase) for strong repression of cell cycle genes during differentiation of 
ESCs. Notably, not only can E2f4 recruit epigenetic modifiers, it can also associate with chromatin 
remodellers to modify chromatin structure. A recent study has shown that E2f4 restricted liver 
regeneration by remodelling the chromatin landscape of cell cycle associated genes by forming 
E2f4-SWI/SNF-Arid1a complexes (Sun et al., 2016). Collectively, these results have indicated the 
potential of E2f4 to act as an upstream TF or even a pioneer TF to regulate chromatin structure and 
therefore the transcription of its target genes. Future studies are needed to validate whether E2f4 
could act as one of the most upstream TF for modulation of the chromatin landscape and 
transcription of cell cycle genes during postnatal cardiomyocyte maturation. 
So what environmental signals could dictate the activity of cell cycle TFs and chromatin 
accessibility changes during postnatal cardiac maturation? As previously mentioned, a recent study 
has linked the postnatal switch to an oxygen-rich environment and the subsequent transition 
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towards oxygen-dependant fatty acid metabolism as a central trigger for postnatal cardiomyocyte 
cell cycle shutdown (Puente et al., 2014). This switch from glycolysis to fatty acid metabolism 
could potentially have a direct impact on the downstream one-carbon metabolism pathway, which is 
a branching pathway of glucose metabolism and has been shown to be critical for tumour 
development (Gao and Locasale, 2016; Locasale, 2013; Maddocks et al., 2016). One-carbon 
metabolism is essential for cell proliferation as it utilises the glucose input and distributes the 
carbon units through downstream folate cycle, methionine cycle and trans-sulphuration pathway to 
govern various cellular process including biosynthesis, redox regulation and production of methyl 
groups for DNA methylation (Locasale, 2013). One-carbon metabolism is also indispensable for 
pluripotency of stem cells and the up-regulation of this pathway has been previously linked with 
hypermethylation and tumourigenesis (Locasale, 2013; Shyh-Chang et al., 2013; Wang et al., 2009). 
Notably, the methyl groups derived from the methionine cycle are required for DNA and histone 
methylation, which could potentially explain the loss of global DNA methylation that was observed 
between P1 and P14 in the mouse heart (Chapter 3). Furthermore, it is important to note that the 
oxygen-rich environment, oxidative metabolism and other environmental insults such as heat, UV 
radiation, H2O2 and cytokines can also lead to the generation of reactive oxygen species (ROS) 
(Finkel and Holbrook, 2000; Ziech et al., 2011). An imbalance between antioxidant components 
and ROS production in the cell can lead to an excess of ROS and oxidative stress. Importantly, 
previous studies have reported that ROS can activate several canonical signalling pathways, such as 
NF-κB, p53, PI3K/AKT, MAPK/ERK, Hippo and Wnt/β-catenin signalling pathways during aging, 
cancers, differentiation and disease, which in turn could activate downstream TFs controlling the 
cell cycle (Finkel and Holbrook, 2000; Holmstrom and Finkel, 2014; Korswagen, 2006; Mao et al., 
2015). Furthermore, ROS has also been shown to mediate the transcription of several TFs, such as 
AP1, NF-κB, and PGC1α (co-activator of TF PPARγ) in Alzheimer’s disease (Shi and Gibson, 
2007). Notably, ROS has direct influences on epigenetic modifications. Several studies have shown 
that free radicals can induce DNA lesions, which if unrepaired can cause genomic instability, which 
in turn causes DNA hypomethylation as the modified DNA bases fail to act as substrates for Dnmts 
(Franco et al., 2008; Ziech et al., 2011). In addition, previous studies have also shown that increased 
ROS regulates the activity of Sirt1 (deacetylase), which can also drive downstream epigenetic 
modifications (Shi and Gibson, 2007; Ziech et al., 2011). Recent studies have proposed that free 
radicals could also serve as nucleophiles or electrophiles to interfere with the methyl and acetyl 
transfer process of DNA methylation as well as histone methylation and acetylation (Afanas'ev, 
2014, 2015). Together, oxidative stress could potentially act as an initiator of signalling pathways 
for transcriptional regulation or by triggering the expression of upstream TFs. Alternatively, ROS 
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could also regulate the epigenetic landscape and thereby alter chromatin accessibility for 
transcription regulation.  
Collectively, several models are proposed for the postnatal modification of the cardiomyocyte 
epigenetic and chromatin landscape (Figure 6.2). Future studies are needed to experimentally test 
these proposed models for an enhanced understanding of postnatal cardiomyocyte maturation.  
6.5. Summary and future directions 
The heart acquires specialized functions during postnatal development that allow it to cope with the 
increased demands of life outside the womb. The specialized transcriptional program that gives 
adult cardiomyocytes their unique identity is epigenetically imprinted during neonatal life. Lessons 
from developmental studies suggest that the very same epigenetic signatures that give adult 
cardiomyocytes their identity might also present a roadblock to regeneration. It is likely that re-
introduction of regenerative capacity in the adult heart will require a combinatorial strategy 
targeting both the critical regenerative signalling pathways and the epigenetic brakes to 
regeneration. Locus-specific targeting of the epigenome will be critical in order to re-activate 
specific transcriptional networks but very few tools currently exist for site-directed engineering of 
the epigenome. Re-awakening developmental mechanisms for endogenous regeneration of the adult 
heart requires a deeper understanding of cell-type specific epigenetic signatures during cardiac 
development and the continued development of technologies for cellular reprogramming and 
epigenomic engineering. However, even under cell type and locus-specific targeting strategy, 
whether a fully developed and functioning adult heart can allow localized dedifferentiation, 
reprogramming and re-differentiation events which often link to structural remodelling, loss of 
contractile function and arrhythmia remains a question. Maybe the mammalian heart is not 
evolutionarily equipped for regeneration in adulthood and cell cycle shutdown represents an 
important physiological adaptation to oxygen-rich terrestrial life (Celine J Vivien, 2016). 
Regardless, a more comprehensive understanding of the relationships between the epigenome and 
transcription during cardiac development and postnatal maturation is necessary and could shape the 
future of regenerative medicine. 
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Figure 6.1. Summary of the 3 major findings of this PhD Thesis in current research models. 
The 3 major findings of this PhD Thesis are: 1. Two postnatal waves of DNA methylation are 
associated with postnatal heart maturation in mice (Chapter 3). 2. DNA methylation restrains 
proliferative capacity in rodent and human cardiomyocytes (Chapter 3 & 4). 3. Cardiomyocyte 
maturation is associated with loss of chromatin accessibility around cell cycle genes required for 
proliferation (Chapter 5).  
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Figure 6.2. Schematic of site specific chromatin remodelling during postnatal 
cardiomyocyte cell cycle shutdown. 
Cardiomyocytes encounter various external challenges (such as oxygen-rich environment, 
mechanical stress and cytokines stimulation) following birth, generating ROS and oxidative stress, 
which leads to activation of several signalling pathways. Activated signalling pathway could lead to 
the expression of TFs, chromatin remodellers (CRs) or epigenetic modifiers (ERs, such as HATs, 
HDACs, HMTs and Dnmts). In model 1, the expressed TFs can actively recruit CRs to perform 
chromatin remodelling and lead to the changes in transcription of downstream target genes. In 
model 2, the activated signalling pathways activates CRs or ERs and therefore changes the 
chromatin accessibility, allowing TFs to bind (or cannot bind) to open chromatin (or compacted 
chromatin) for transcription activation (or fail to activate) of downstream target genes.  
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A dream written down with a date becomes a goal. 
A goal broken down into steps becomes a plan. 
A plan backed by action makes your dreams come true. 
Greg Reid. 
  
 
Chapter 7 
 
 
195 
Chapter 7. Appendices 
7.1. Summary of genes with differential methylation levels and mRNA expression changes between P1 
and P14 (from Chapter 3). 
Gene Name 
MBD-Seq RNA-Seq 
Pattern logFC p-value DMRs co-ordinates Pattern logFC p-value 
4831426I19Rik ↑ 1.55 2.20E-02 104962279 - 104963658 ↓ -1.26 1.39E-02 
4930427A07Rik ↑ 1.88 2.01E-02 113160898 - 113162262 ↓ -2.38 2.52E-08 
4933413G19Rik ↑ 1.62 3.35E-02 128379233 - 128380307 ↓ -2.63 4.02E-04 
9830001H06Rik ↑ 1.93 4.82E-02 157059909 - 157060752 ↓ -0.99 2.31E-03 
Acan ↑ 1.49 3.34E-02 79093143 - 79094561 ↓ -1.48 2.06E-03 
Adcy5 ↑ 2.26 2.26E-02 35156499 - 35157497 ↓ -0.70 1.48E-02 
AI661453 ↑ 1.34 4.56E-02 47467093 - 47469664 ↓ -2.46 4.17E-09 
Ankrd6 ↑ 1.46 4.32E-02 32863841 - 32865107 ↓ -1.34 3.71E-03 
App ↑ 2.19 4.64E-02 85104550 - 85105050 ↓ -1.11 2.88E-05 
Arhgap39 ↑ 1.55 1.92E-02 76807751 - 76809479 ↓ -1.12 4.66E-03 
Arsg ↑ 2.21 4.65E-02 109502987 - 109503533 ↓ -0.88 4.77E-02 
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Atl1 ↑ 1.19 4.81E-02 69907646 - 69909652 ↓ -1.46 6.25E-05 
Bai2 ↑ 2.43 6.04E-03 129991875 - 129993335 ↓ -2.22 5.84E-06 
BC022687 ↑ 1.85 2.50E-02 112807400 - 112808107 ↓ -1.37 6.52E-04 
Bcl2l11 ↑ 1.82 2.03E-02 128124261 - 128125467 ↓ -1.02 1.02E-03 
Bmp7 ↑ 1.53 3.60E-02 172923549 - 172924414 ↓ -4.14 3.27E-28 
C530008M17Rik ↑ 1.92 2.34E-02 76857912 - 76859345 ↓ -2.97 1.11E-15 
Cacna2d2 ↑ 1.27 4.78E-02 107414024 - 107415347 ↓ -2.56 5.52E-10 
Ccdc85c ↑ 1.73 2.81E-02 108205536 - 108206709 ↓ -1.42 2.89E-02 
Cd276 ↑ 1.33 4.79E-02 58536269 - 58537710 ↓ -1.64 6.78E-08 
Cdh4 ↑ 2.21 4.96E-02 179770421 - 179771118 ↓ -3.81 6.77E-07 
Cdk14 ↑ 2.13 4.79E-02 5381612 - 5382585 ↓ -0.85 6.03E-03 
Cdkn1c ↑ 2.18 2.33E-03 143458486 - 143461261 ↓ -0.70 9.47E-03 
Celsr1 ↑ 1.34 3.73E-02 86029863 - 86032946 ↓ -0.80 2.26E-02 
Chst11 ↑ 2.12 2.99E-02 83050381 - 83051161 ↓ -1.17 1.55E-04 
Chtf18 ↑ 1.32 3.45E-02 25721671 - 25724363 ↓ -1.18 2.57E-02 
Cit ↑ 1.53 3.60E-02 115906891 - 115909185 ↓ -0.99 7.48E-03 
Cnn2 ↑ 2.21 2.27E-02 79994102 - 79994873 ↓ -1.04 6.60E-04 
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Col12a1 ↑ 1.60 3.67E-02 79599511 - 79600348 ↓ -2.63 8.73E-16 
Col18a1 ↑ 1.40 4.13E-02 77054486 - 77056107 ↓ -1.54 5.08E-05 
Cpne5 ↑ 1.72 2.66E-02 29160931 - 29161811 ↓ -1.40 2.76E-04 
Ctdp1 ↑ 2.40 6.28E-03 80433814 - 80434769 ↓ -1.05 9.15E-04 
Cttn ↑ 2.21 4.70E-02 144438518 - 144439229 ↓ -0.89 1.70E-04 
D430042O09Rik ↑ 2.22 3.61E-02 125803070 - 125803816 ↓ -0.85 2.55E-03 
D630045J12Rik ↑ 1.36 3.10E-02 38176726 - 38177991 ↓ -0.92 3.63E-02 
Dbn1 ↑ 1.29 4.61E-02 55475909 - 55478323 ↓ -0.92 3.01E-03 
Dcaf15 ↑ 1.41 4.15E-02 84094363 - 84098192 ↓ -0.84 2.37E-02 
Dhcr24 ↑ 2.05 2.81E-02 106581748 - 106582543 ↓ -2.87 2.83E-19 
Dstn ↑ 1.83 2.50E-02 143933955 - 143934771 ↓ -1.82 8.11E-10 
Etv6 ↑ 1.87 3.49E-02 134211046 - 134211870 ↓ -1.24 1.78E-06 
Fam171a2 ↑ 2.34 2.32E-03 102437116 - 102439296 ↓ -1.34 8.42E-03 
Fam53c ↑ 1.54 4.32E-02 34768017 - 34769176 ↓ -0.78 4.57E-03 
Fam73a ↑ 2.57 8.17E-03 152312817 - 152313541 ↓ -1.13 9.55E-04 
Fbxl7 ↑ 2.21 4.92E-02 26622960 - 26623831 ↓ -1.59 4.89E-02 
Fgfr2 ↑ 2.18 2.61E-02 132711566 - 132712610 ↓ -1.83 3.88E-05 
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Fstl3 ↑ 1.35 4.78E-02 79780908 - 79782124 ↓ -0.91 1.58E-02 
Ftcd ↑ 1.86 3.68E-02 76576136 - 76576982 ↓ -3.97 8.44E-18 
Fzd1 ↑ 2.58 1.28E-02 4755620 - 4756485 ↓ -1.56 1.07E-07 
Gli3 ↑ 1.32 4.95E-02 15724296 - 15725929 ↓ -1.34 3.07E-04 
Gm12892 ↑ 1.44 3.16E-02 122007888 - 122009735 ↓ -1.03 8.49E-03 
Gm14024 ↑ 2.36 3.73E-02 129259248 - 129259930 ↓ -2.50 2.90E-09 
Gm16323 ↑ 1.83 4.75E-02 30409794 - 30410776 ↓ -1.36 2.03E-02 
Gm16599 ↑ 2.30 1.05E-02 136274367 - 136275609 ↓ -2.90 9.71E-04 
Gm20431 ↑ 1.91 6.15E-03 167653945 - 167655010 ↓ -0.93 3.27E-02 
Gna13 ↑ 2.49 3.99E-02 109392522 - 109393132 ↓ -0.70 7.46E-03 
Gnaz ↑ 1.77 4.78E-02 74977448 - 74978176 ↓ -1.52 1.33E-02 
Gpr124 ↑ 1.49 4.38E-02 27120205 - 27122377 ↓ -1.19 1.23E-05 
Gpsm2 ↑ 1.40 4.38E-02 108686535 - 108687390 ↓ -1.37 6.00E-06 
Grik5 ↑ 2.12 1.28E-02 25013237 - 25014148 ↓ -0.96 1.43E-02 
Igf2 ↑ 1.79 3.08E-02 142667454 - 142668464 ↓ -2.60 8.24E-14 
Igf2as ↑ 1.79 3.08E-02 142667454 - 142668464 ↓ -3.79 3.45E-19 
Igf2bp2 ↑ 1.23 4.00E-02 22063185 - 22064361 ↓ -2.27 7.50E-16 
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Igf2bp3 ↑ 3.15 6.28E-03 49212755 - 49213556 ↓ -3.32 1.59E-27 
Igf2r ↑ 1.63 3.62E-02 12701614 - 12702649 ↓ -1.96 4.33E-11 
Insc ↑ 1.59 4.24E-02 114790713 - 114791592 ↓ -4.35 1.39E-16 
Iqgap3 ↑ 1.87 3.08E-02 88115564 - 88116242 ↓ -3.89 1.56E-19 
Itgad ↑ 1.86 4.40E-02 128205463 - 128206325 ↓ -1.89 6.55E-04 
Jub ↑ 1.95 1.28E-02 54569928 - 54570907 ↓ -1.37 5.37E-07 
Kalrn ↑ 2.55 4.32E-02 34081506 - 34082057 ↓ -1.39 4.78E-07 
Kcnq1 ↑ 1.40 2.50E-02 143375067 - 143377464 ↓ -0.97 2.20E-04 
Kdm2b ↑ 1.61 3.92E-02 122888157 - 122889107 ↓ -0.81 3.65E-02 
Klf14 ↑ 2.49 3.43E-02 30957472 - 30958197 ↓ -2.26 7.83E-04 
Lrrc4b ↑ 1.56 3.82E-02 44460601 - 44462954 ↓ -1.93 9.96E-03 
Lrrfip1 ↑ 1.80 3.74E-02 91008215 - 91009342 ↓ -0.59 2.84E-02 
Mex3b ↑ 1.97 1.51E-02 82869062 - 82870549 ↓ -2.21 5.76E-04 
Micalcl ↑ 1.97 4.67E-02 112406957 - 112407917 ↓ -0.98 3.26E-02 
Micall1 ↑ 1.85 2.72E-02 79120460 - 79121265 ↓ -0.57 2.44E-02 
Mtap1a ↑ 1.20 4.24E-02 121299258 - 121302682 ↓ -0.87 1.56E-03 
Mtrr ↑ 2.36 3.55E-02 68568579 - 68569068 ↓ -0.74 1.68E-02 
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Myh7 ↑ 1.94 3.58E-02 54978527 - 54979854 ↓ -4.26 3.05E-21 
Nat8l ↑ 1.62 3.99E-02 33997861 - 33998850 ↓ -0.97 4.65E-02 
Nedd4l ↑ 1.80 2.33E-03 65083377 - 65085824 ↓ -1.39 1.28E-08 
Nptxr ↑ 2.35 2.81E-02 79787807 - 79788443 ↓ -0.96 5.13E-03 
Osbpl5 ↑ 1.56 4.67E-02 143721250 - 143721869 ↓ -0.99 9.61E-04 
Pak4 ↑ 1.29 4.81E-02 28559296 - 28561303 ↓ -1.27 2.51E-04 
Parva ↑ 2.06 3.67E-02 112444663 - 112445335 ↓ -1.15 4.37E-06 
Pcdhga3 ↑ 1.34 2.61E-02 37765911 - 37768755 ↓ -1.23 4.53E-07 
Peg12 ↑ 2.49 1.67E-02 62463262 - 62464576 ↓ -2.07 3.98E-05 
Pemt ↑ 2.42 2.00E-02 59977251 - 59977757 ↓ -1.09 1.52E-02 
Phactr2 ↑ 1.56 3.90E-02 13314214 - 13315120 ↓ -0.76 5.01E-03 
Phc1 ↑ 1.76 4.82E-02 122322869 - 122323627 ↓ -1.26 7.79E-07 
Pip5k1b ↑ 2.26 2.81E-02 24527350 - 24527984 ↓ -0.96 1.75E-04 
Plekha7 ↑ 1.82 3.35E-02 116170303 - 116171098 ↓ -2.90 1.58E-12 
Pold2 ↑ 1.20 3.81E-02 5871934 - 5875424 ↓ -0.70 3.82E-02 
Prim2 ↑ 1.90 2.29E-02 33635843 - 33637012 ↓ -1.48 3.00E-05 
Prkag2 ↑ 1.80 2.27E-02 24947124 - 24947798 ↓ -2.17 9.54E-16 
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Prss57 ↑ 1.35 4.78E-02 79780908 - 79782124 ↓ -0.92 1.41E-02 
Ptgfrn ↑ 1.78 4.65E-02 101064201 - 101064813 ↓ -0.92 2.87E-04 
Ptprf ↑ 1.40 3.62E-02 118244152 - 118246567 ↓ -0.82 3.20E-03 
Rap1gds1 ↑ 1.81 4.82E-02 139017427 - 139018011 ↓ -0.95 2.55E-04 
Rasl11b ↑ 2.01 4.75E-02 74197812 - 74198891 ↓ -0.76 3.10E-03 
Rbm19 ↑ 1.25 4.80E-02 120179111 - 120180670 ↓ -0.76 3.56E-02 
Rgl1 ↑ 1.62 4.78E-02 152636946 - 152637663 ↓ -0.89 2.04E-04 
Rnf157 ↑ 1.16 4.13E-02 116341764 - 116345014 ↓ -1.01 2.36E-03 
Ror2 ↑ 1.74 2.34E-02 53118499 - 53119674 ↓ -2.95 6.40E-12 
Rph3al ↑ 1.55 4.51E-02 75859379 - 75860200 ↓ -1.57 2.33E-05 
Scd2 ↑ 1.45 4.78E-02 44303931 - 44304694 ↓ -2.87 1.96E-24 
Sdc1 ↑ 1.30 4.75E-02 8790077 - 8793016 ↓ -0.79 1.47E-02 
Sdk1 ↑ 2.01 3.10E-02 142172229 - 142172963 ↓ -2.71 2.04E-10 
Sergef ↑ 1.74 3.67E-02 46568573 - 46569888 ↓ -0.92 9.63E-03 
Sh3pxd2b ↑ 2.25 2.80E-02 32361566 - 32362296 ↓ -0.59 2.60E-02 
Sipa1l2 ↑ 2.17 2.42E-02 125447181 - 125448083 ↓ -0.54 4.98E-02 
Slc16a3 ↑ 1.35 4.81E-02 120954965 - 120957405 ↓ -2.84 1.05E-10 
Chapter 7 
 
 
202 
Slc8a2 ↑ 2.29 1.94E-02 16144571 - 16145709 ↓ -1.44 2.53E-03 
Slco2a1 ↑ 1.60 3.67E-02 103067275 - 103068253 ↓ -1.72 4.80E-09 
Smad3 ↑ 1.96 2.60E-02 63754693 - 63755837 ↓ -1.11 1.42E-05 
Smoc1 ↑ 1.76 2.71E-02 81138784 - 81139783 ↓ -1.19 1.84E-04 
Smyd2 ↑ 1.97 2.61E-02 189883230 - 189884052 ↓ -0.68 2.60E-02 
Spon2 ↑ 1.83 4.72E-02 33215219 - 33216043 ↓ -1.84 1.64E-08 
Spry2 ↑ 2.17 5.96E-03 105892647 - 105893752 ↓ -0.70 1.23E-02 
Spsb4 ↑ 1.70 3.35E-02 96995232 - 96996490 ↓ -0.86 3.51E-03 
Srebf2 ↑ 1.44 3.96E-02 82169726 - 82171851 ↓ -1.61 1.17E-08 
Stx11 ↑ 1.51 3.97E-02 12940482 - 12942121 ↓ -1.20 2.74E-02 
Stxbp1 ↑ 1.60 4.18E-02 32808779 - 32809565 ↓ -0.91 4.09E-04 
Sv2a ↑ 1.77 9.45E-03 96184806 - 96185680 ↓ -1.16 7.18E-05 
Synpo2l ↑ 2.56 2.42E-02 20662081 - 20662762 ↓ -1.40 1.92E-07 
Tdrd7 ↑ 2.23 3.52E-02 46032327 - 46033068 ↓ -0.66 1.42E-02 
Tenm4 ↑ 1.37 4.95E-02 96729116 - 96730078 ↓ -2.33 9.77E-10 
Tmem138 ↑ 1.66 4.60E-02 10571020 - 10571650 ↓ -0.88 2.01E-02 
Tnc ↑ 1.79 3.73E-02 64016596 - 64018467 ↓ -1.79 1.48E-10 
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Tnrc18 ↑ 1.44 3.24E-02 142774890 - 142776953 ↓ -1.50 9.55E-04 
Tox2 ↑ 1.22 4.35E-02 163317579 - 163320971 ↓ -1.31 4.99E-03 
Ttyh3 ↑ 1.45 3.35E-02 140634936 - 140636362 ↓ -1.04 1.64E-03 
Tubb6 ↑ 1.64 2.79E-02 67401040 - 67402500 ↓ -0.75 4.40E-03 
Ube2c ↑ 1.65 4.41E-02 164767375 - 164768370 ↓ -4.02 1.11E-27 
Vps8 ↑ 1.29 4.70E-02 21626553 - 21628510 ↓ -0.54 4.26E-02 
Wdr19 ↑ 1.54 3.44E-02 65245769 - 65246856 ↓ -1.31 1.10E-03 
Wwox ↑ 1.76 2.65E-02 114455852 - 114456850 ↓ -1.22 1.42E-04 
Ypel2 ↑ 2.03 4.79E-02 86945995 - 86946736 ↓ -1.00 1.27E-03 
Zbed3 ↑ 1.30 4.78E-02 95335582 - 95336997 ↓ -1.74 2.63E-10 
Zfp395 ↑ 1.20 4.32E-02 65384528 - 65386692 ↓ -0.72 1.04E-02 
Zfp608 ↑ 1.35 4.78E-02 54891516 - 54892275 ↓ -0.83 3.80E-02 
Zfp618 ↑ 1.44 1.63E-02 63132022 - 63134627 ↓ -2.35 5.41E-07 
1110002E22Rik ↑ 1.38 2.14E-02 138064713 - 138070690 ↑ 0.55 3.47E-02 
2200002D01Rik ↑ 1.35 4.71E-02 29246392 - 29247578 ↑ 1.12 7.67E-03 
2310050B05Rik ↑ 1.54 3.81E-02 81199006 - 81201489 ↑ 0.91 2.32E-03 
2310067B10Rik ↑ 2.08 4.39E-02 115785838 - 115786703 ↑ 1.07 2.87E-03 
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2510049J12Rik ↑ 1.93 3.77E-02 115586257 - 115587125 ↑ 1.96 6.51E-04 
2610027K06Rik ↑ 1.89 2.61E-02 85801164 - 85802106 ↑ 1.27 9.30E-03 
2900092E17Rik ↑ 1.49 3.15E-02 127001072 - 127002125 ↑ 0.82 1.66E-02 
4632433K11Rik ↑ 1.56 3.55E-02 5028736 - 5032390 ↑ 0.83 2.87E-02 
4931428F04Rik ↑ 1.92 4.73E-02 105290242 - 105291059 ↑ 1.20 1.77E-05 
6030419C18Rik ↑ 1.88 4.56E-02 58489808 - 58490602 ↑ 0.96 1.63E-02 
A530058N18Rik ↑ 1.90 4.69E-02 114051529 - 114052331 ↑ 0.86 3.49E-03 
Aatk ↑ 1.62 1.74E-02 120008927 - 120013270 ↑ 1.29 1.26E-02 
Abca7 ↑ 1.87 6.04E-03 80013034 - 80016328 ↑ 0.73 3.56E-02 
Abcc10 ↑ 1.33 3.82E-02 46305150 - 46307867 ↑ 1.06 9.55E-03 
Abcc8 ↑ 1.71 3.48E-02 46124532 - 46125834 ↑ 0.72 2.25E-02 
Abhd2 ↑ 1.51 3.43E-02 79359632 - 79360858 ↑ 0.75 6.64E-03 
Abi3 ↑ 2.11 3.37E-03 95830140 - 95831709 ↑ 1.70 1.35E-09 
Ablim2 ↑ 2.18 2.97E-02 35879955 - 35880829 ↑ 1.71 1.40E-07 
Ablim3 ↑ 1.35 4.12E-02 61800435 - 61801820 ↑ 1.11 1.31E-05 
Acacb ↑ 1.59 4.83E-02 114248291 - 114249266 ↑ 1.79 1.01E-09 
Ace ↑ 2.01 5.96E-03 105987558 - 105989356 ↑ 1.45 1.96E-06 
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Acvr2b ↑ 1.25 4.07E-02 119425891 - 119428951 ↑ 2.27 2.39E-04 
Acvrl1 ↑ 1.33 4.78E-02 101136864 - 101137912 ↑ 1.10 1.11E-04 
Adamts7 ↑ 2.19 2.61E-02 90182460 - 90183351 ↑ 0.85 1.14E-02 
Adamtsl5 ↑ 2.37 1.86E-03 80340925 - 80342953 ↑ 1.47 7.71E-09 
Ahdc1 ↑ 1.34 3.66E-02 133060480 - 133066597 ↑ 1.22 1.79E-02 
Aldh4a1 ↑ 1.61 1.05E-02 139639535 - 139640837 ↑ 0.56 3.98E-02 
Ank1 ↑ 1.31 4.79E-02 23032909 - 23034768 ↑ 2.08 1.67E-15 
Ankrd33b ↑ 1.42 2.71E-02 31296810 - 31299372 ↑ 0.80 7.45E-03 
Ankrd54 ↑ 1.40 4.81E-02 79054920 - 79055806 ↑ 0.74 4.17E-02 
Ankrd9 ↑ 2.13 1.63E-02 110976219 - 110977849 ↑ 3.52 4.54E-29 
Anks1 ↑ 1.16 4.69E-02 28051315 - 28054218 ↑ 1.61 3.36E-08 
Ano8 ↑ 1.78 2.30E-02 71483938 - 71485388 ↑ 0.66 4.65E-02 
Appl2 ↑ 2.46 2.14E-02 83615675 - 83616433 ↑ 0.96 4.06E-04 
Arhgap27 ↑ 1.88 1.63E-02 103332543 - 103334658 ↑ 1.45 2.78E-06 
Arhgef1 ↑ 1.33 3.97E-02 24921135 - 24924291 ↑ 0.99 1.79E-03 
Arhgef10l ↑ 1.80 4.31E-02 140514668 - 140515586 ↑ 0.96 1.35E-02 
Arhgef17 ↑ 1.48 2.20E-02 100880932 - 100883944 ↑ 0.80 2.07E-03 
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Arhgef37 ↑ 2.66 1.67E-02 61506953 - 61507616 ↑ 1.46 3.95E-02 
Armc2 ↑ 1.55 4.92E-02 41924239 - 41924954 ↑ 1.28 2.99E-04 
Asb10 ↑ 1.74 4.67E-02 24533104 - 24534196 ↑ 2.69 5.25E-23 
Asb2 ↑ 2.16 4.06E-02 103324714 - 103325734 ↑ 1.28 6.26E-04 
Atp2a3 ↑ 1.76 3.07E-02 72975083 - 72975875 ↑ 2.16 1.62E-12 
Atp2b1 ↑ 2.05 3.96E-02 98967161 - 98967864 ↑ 1.32 1.41E-04 
Atp9a ↑ 1.37 4.79E-02 168690151 - 168691337 ↑ 0.78 5.74E-03 
Atxn1 ↑ 1.49 3.36E-02 45566330 - 45568721 ↑ 0.67 4.09E-02 
Axin2 ↑ 1.78 1.05E-02 108941460 - 108943506 ↑ 1.76 2.84E-04 
BC020535 ↑ 2.58 4.04E-02 153070695 - 153071137 ↑ 1.68 2.31E-09 
Bcas3 ↑ 1.78 1.95E-02 85780813 - 85781640 ↑ 1.08 7.31E-05 
Bcl3 ↑ 1.45 4.81E-02 19808545 - 19810090 ↑ 2.51 3.96E-09 
Bcl6b ↑ 1.62 4.98E-02 70225757 - 70227092 ↑ 0.85 4.86E-04 
Cabp1 ↑ 1.86 1.25E-02 115175032 - 115175781 ↑ 2.12 1.50E-06 
Cacnb2 ↑ 1.54 4.47E-02 14738896 - 14740088 ↑ 0.81 2.63E-03 
Cadm4 ↑ 1.60 4.88E-02 24502318 - 24503078 ↑ 1.03 1.49E-03 
Cbfa2t3 ↑ 1.28 3.80E-02 122636751 - 122639445 ↑ 2.32 3.72E-13 
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Cbx6 ↑ 1.34 3.40E-02 79826778 - 79829612 ↑ 0.97 5.27E-05 
Cbx8 ↑ 2.11 2.53E-02 119037479 - 119038285 ↑ 0.95 1.03E-02 
Ccdc94 ↑ 1.79 4.83E-02 55966198 - 55967029 ↑ 0.96 1.68E-02 
Cd79b ↑ 1.91 2.01E-02 106313981 - 106314805 ↑ 1.35 2.41E-03 
Cdh13 ↑ 2.44 2.20E-02 119109393 - 119110003 ↑ 1.12 1.72E-05 
Cdh23 ↑ 2.03 9.96E-03 60564192 - 60565446 ↑ 3.34 5.09E-11 
Cdk20 ↑ 1.84 4.71E-02 64438465 - 64439150 ↑ 1.20 1.88E-03 
Chd7 ↑ 1.25 4.79E-02 8865394 - 8866951 ↑ 0.63 4.05E-02 
Chpf ↑ 1.40 4.78E-02 75474632 - 75476856 ↑ 1.74 1.71E-05 
Chrna10 ↑ 1.96 2.01E-02 102112729 - 102113969 ↑ 4.13 5.62E-08 
Chst12 ↑ 1.42 3.74E-02 140523278 - 140525345 ↑ 1.54 1.76E-03 
Cilp2 ↑ 2.40 3.12E-02 69880872 - 69882280 ↑ 3.52 2.25E-08 
Clec3b ↑ 2.45 2.14E-02 123156454 - 123157414 ↑ 2.56 3.38E-14 
Clpb ↑ 2.05 2.86E-02 101763240 - 101763996 ↑ 1.00 8.15E-05 
Cmss1 ↑ 2.21 2.34E-02 57390893 - 57392014 ↑ 0.62 2.72E-02 
Col11a2 ↑ 1.89 3.35E-02 34045687 - 34046595 ↑ 1.79 6.40E-04 
Cox6a2 ↑ 1.86 4.40E-02 128205463 - 128206325 ↑ 2.50 2.81E-08 
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Crat ↑ 1.83 4.75E-02 30409794 - 30410776 ↑ 0.69 4.46E-02 
Crebbp ↑ 1.43 3.64E-02 4083974 - 4086395 ↑ 1.31 1.19E-03 
Crlf2 ↑ 1.35 4.38E-02 109554287 - 109556834 ↑ 1.59 6.71E-03 
Cryab ↑ 2.08 2.61E-02 50751198 - 50752439 ↑ 0.81 4.98E-02 
Cryba4 ↑ 1.82 2.66E-02 112246226 - 112247125 ↑ 3.77 1.02E-13 
Cuedc1 ↑ 2.11 3.87E-02 88192165 - 88192832 ↑ 1.31 7.32E-07 
Cul9 ↑ 1.65 2.61E-02 46539966 - 46540932 ↑ 1.06 6.07E-03 
Cux2 ↑ 2.27 8.48E-03 121868851 - 121869943 ↑ 1.19 2.12E-04 
Cxxc5 ↑ 1.28 4.03E-02 35857859 - 35859800 ↑ 0.83 8.03E-03 
Cyth1 ↑ 1.43 4.86E-02 118165163 - 118166291 ↑ 0.72 3.75E-03 
D630044L22RIK ↑ 1.60 2.72E-02 25958845 - 25961076 ↑ 1.29 1.65E-02 
Dapk2 ↑ 1.65 4.43E-02 66220181 - 66221262 ↑ 1.96 4.19E-06 
Dbh ↑ 1.62 3.77E-02 27162124 - 27163060 ↑ 3.21 2.12E-24 
Dgkz ↑ 1.78 4.38E-02 91944567 - 91946043 ↑ 0.89 6.04E-03 
Dlg4 ↑ 1.27 4.69E-02 70040961 - 70044102 ↑ 1.44 8.35E-04 
Dlgap4 ↑ 1.08 3.33E-02 156761594 - 156764750 ↑ 0.84 3.34E-03 
Dll4 ↑ 2.49 2.34E-02 119323656 - 119324479 ↑ 1.46 9.18E-08 
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Dmpk ↑ 2.00 1.28E-02 19091437 - 19093106 ↑ 2.23 1.52E-15 
Dnaaf1 ↑ 1.17 4.85E-02 119595994 - 119599745 ↑ 2.15 4.53E-08 
Dnaaf3 ↑ 1.49 2.82E-02 4526667 - 4527949 ↑ 3.15 7.38E-19 
Dnase2a ↑ 2.71 1.13E-03 84911854 - 84912943 ↑ 1.11 8.24E-04 
Dnm1 ↑ 1.60 4.35E-02 32308588 - 32309377 ↑ 1.13 5.19E-03 
Dock6 ↑ 1.37 4.59E-02 21838437 - 21840223 ↑ 1.09 6.36E-05 
Dock8 ↑ 1.26 4.93E-02 25172102 - 25173129 ↑ 1.00 1.01E-03 
Dok5 ↑ 1.80 3.62E-02 170870228 - 170871157 ↑ 1.63 1.28E-02 
Dos ↑ 1.60 4.12E-02 80129310 - 80133513 ↑ 1.85 8.63E-10 
Dot1l ↑ 1.72 2.92E-02 80790415 - 80793069 ↑ 0.92 1.50E-03 
Dpysl4 ↑ 1.36 4.62E-02 139097630 - 139098985 ↑ 3.24 1.27E-16 
Dtx1 ↑ 2.15 3.15E-02 120682047 - 120682905 ↑ 1.75 1.39E-02 
Dysf ↑ 2.33 3.61E-02 84105780 - 84106539 ↑ 1.77 8.09E-13 
Efcab4a ↑ 1.78 3.88E-02 141464116 - 141465390 ↑ 1.46 2.63E-06 
Enthd2 ↑ 1.40 2.81E-02 120092636 - 120095123 ↑ 1.21 4.59E-05 
Fam109a ↑ 1.57 2.82E-02 121851379 - 121853604 ↑ 1.17 9.38E-05 
Fam193b ↑ 1.41 4.12E-02 55552576 - 55553427 ↑ 2.05 4.15E-11 
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Fam19a5 ↑ 1.71 3.18E-02 87757245 - 87758346 ↑ 2.59 4.70E-06 
Fastk ↑ 1.63 4.15E-02 24445489 - 24446363 ↑ 1.16 4.96E-04 
Fbrsl1 ↑ 1.14 4.67E-02 110430308 - 110433488 ↑ 1.06 8.12E-04 
Fbxl6 ↑ 1.22 4.02E-02 76539453 - 76541380 ↑ 1.16 7.45E-03 
Fbxo31 ↑ 1.45 3.36E-02 121555894 - 121557173 ↑ 2.37 1.25E-13 
Fbxo46 ↑ 1.42 4.45E-02 19135155 - 19137519 ↑ 1.59 6.93E-04 
Fgd2 ↑ 1.67 3.84E-02 29362452 - 29363770 ↑ 3.02 8.99E-12 
Fhl2 ↑ 2.05 4.52E-02 43131386 - 43132086 ↑ 0.82 3.00E-02 
Flcn ↑ 1.83 3.74E-02 59812366 - 59813073 ↑ 0.72 5.94E-03 
Fmnl1 ↑ 1.78 9.45E-03 103191725 - 103193440 ↑ 2.24 6.95E-15 
Foxo6 ↑ 2.48 5.96E-03 120266920 - 120268099 ↑ 1.51 5.89E-03 
Gabbr1 ↑ 2.17 3.88E-02 37050784 - 37051486 ↑ 1.47 9.19E-05 
Galntl2 ↑ 1.64 4.61E-02 32054837 - 32055650 ↑ 2.89 1.32E-20 
Gata2 ↑ 3.15 5.51E-04 88190013 - 88191408 ↑ 0.82 2.80E-02 
Gm11264 ↑ 2.36 2.50E-02 82065919 - 82066666 ↑ 1.86 4.88E-04 
Gm11474 ↑ 1.63 3.05E-02 167538394 - 167539498 ↑ 0.70 4.80E-03 
Gm11598 ↑ 2.11 3.96E-02 100243028 - 100243806 ↑ 1.58 2.41E-02 
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Gm11651 ↑ 2.01 5.96E-03 105987558 - 105989356 ↑ 1.21 1.52E-02 
Gm12992 ↑ 1.55 3.56E-02 131922232 - 131923460 ↑ 0.56 4.65E-02 
Gm14232 ↑ 1.48 3.99E-02 131170987 - 131173103 ↑ 1.90 8.58E-07 
Gm14290 ↑ 1.31 4.55E-02 167103828 - 167106903 ↑ 3.00 1.62E-17 
Gm14492 ↑ 1.93 3.93E-02 142507428 - 142508190 ↑ 2.94 1.12E-22 
Gm15821 ↑ 1.74 3.77E-02 34214944 - 34215755 ↑ 1.17 1.77E-02 
Gm5303 ↑ 1.47 4.69E-02 28361642 - 28362905 ↑ 1.30 1.33E-02 
Gngt2 ↑ 2.34 1.63E-02 95833356 - 95834506 ↑ 0.65 1.63E-02 
Gp1bb ↑ 1.80 4.07E-02 18624301 - 18625756 ↑ 0.72 3.62E-02 
Gtdc2 ↑ 1.35 4.70E-02 121981790 - 121983969 ↑ 1.80 4.20E-06 
Gtpbp3 ↑ 1.78 2.30E-02 71483938 - 71485388 ↑ 0.80 2.40E-02 
Hagh ↑ 1.62 3.68E-02 24856347 - 24857128 ↑ 0.64 3.62E-02 
Hcn2 ↑ 1.52 3.41E-02 79734717 - 79742099 ↑ 3.58 1.34E-29 
Hipk2 ↑ 1.61 4.82E-02 38715821 - 38716402 ↑ 1.08 1.41E-02 
Hk3 ↑ 1.42 2.53E-02 55002079 - 55007503 ↑ 1.87 9.61E-04 
Hlx ↑ 2.89 6.04E-03 184727158 - 184728438 ↑ 2.65 1.56E-15 
Hmha1 ↑ 1.87 6.04E-03 80013034 - 80016328 ↑ 2.47 1.46E-08 
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Hr ↑ 1.73 4.39E-02 70556254 - 70557093 ↑ 4.01 3.60E-32 
Hspa12b ↑ 1.86 9.45E-03 131144410 - 131145548 ↑ 1.31 1.73E-07 
Hspb2 ↑ 2.08 2.61E-02 50751198 - 50752439 ↑ 0.96 1.52E-03 
Ift172 ↑ 1.11 4.82E-02 31251204 - 31254190 ↑ 0.59 1.93E-02 
Igfbp6 ↑ 1.36 4.88E-02 102144457 - 102146515 ↑ 4.41 1.12E-28 
Igsf8 ↑ 1.45 2.61E-02 172317128 - 172319710 ↑ 0.84 2.90E-03 
Il3ra ↑ 1.37 2.61E-02 14348533 - 14351571 ↑ 1.15 4.56E-02 
Il4ra ↑ 2.13 4.75E-02 125576094 - 125576787 ↑ 0.97 7.90E-04 
Inha ↑ 1.86 2.30E-02 75509225 - 75510231 ↑ 0.78 3.16E-02 
Inpp4a ↑ 1.83 3.13E-02 37357599 - 37358365 ↑ 0.92 4.39E-03 
Insl3 ↑ 1.81 6.04E-03 71683606 - 71686499 ↑ 2.53 3.40E-06 
Ints1 ↑ 1.54 1.36E-02 139756700 - 139760883 ↑ 1.57 2.61E-04 
Ipo13 ↑ 1.42 2.61E-02 117900366 - 117901879 ↑ 1.53 3.01E-07 
Irf5 ↑ 1.57 3.60E-02 29535360 - 29536310 ↑ 0.83 2.68E-03 
Islr ↑ 1.50 4.74E-02 58156645 - 58158564 ↑ 2.16 1.36E-14 
Jag2 ↑ 1.43 1.69E-02 112919364 - 112921979 ↑ 1.55 1.46E-03 
Jak3 ↑ 1.81 6.04E-03 71683606 - 71686499 ↑ 1.04 1.43E-02 
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Kcnb1 ↑ 1.31 4.55E-02 167103828 - 167106903 ↑ 2.48 4.21E-13 
Kcnip3 ↑ 2.32 2.20E-02 127510479 - 127511233 ↑ 1.11 2.87E-02 
Kcnk6 ↑ 2.03 1.36E-02 29224919 - 29226072 ↑ 1.07 3.65E-03 
Kcnq4 ↑ 1.68 4.79E-02 120711111 - 120712013 ↑ 1.96 9.23E-07 
Kif6 ↑ 2.62 2.61E-02 49830654 - 49831250 ↑ 0.86 3.01E-02 
Klc3 ↑ 1.61 3.45E-02 19392593 - 19396052 ↑ 1.58 5.76E-03 
Klhl18 ↑ 1.12 3.67E-02 110426577 - 110429397 ↑ 0.82 4.54E-03 
Klhl26 ↑ 1.65 4.67E-02 70450800 - 70453197 ↑ 0.81 2.19E-02 
Leng9 ↑ 1.96 3.67E-02 4151167 - 4152089 ↑ 1.68 2.06E-05 
Lgi4 ↑ 1.58 2.74E-02 31066612 - 31068126 ↑ 4.18 4.87E-19 
Lgr6 ↑ 2.43 1.02E-02 134986885 - 134988243 ↑ 2.43 8.81E-17 
Lhx6 ↑ 2.50 1.36E-03 36090262 - 36091972 ↑ 1.33 2.92E-04 
Lingo3 ↑ 1.74 3.74E-02 80833655 - 80836518 ↑ 2.28 3.77E-09 
Lmna ↑ 1.27 4.95E-02 88483038 - 88485480 ↑ 1.51 5.81E-05 
Lrg1 ↑ 1.88 3.35E-02 56123056 - 56125215 ↑ 5.00 3.68E-55 
Lrp1 ↑ 1.68 3.16E-02 127594590 - 127595717 ↑ 1.96 3.21E-08 
Lrp3 ↑ 1.48 4.33E-02 35202132 - 35205838 ↑ 1.86 2.63E-07 
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Lrrc14 ↑ 1.13 4.67E-02 76712854 - 76714915 ↑ 0.98 5.36E-04 
Lrrn4cl ↑ 1.70 2.23E-02 8851645 - 8852674 ↑ 1.74 2.39E-04 
Ltbp4 ↑ 2.28 2.61E-02 27329343 - 27330499 ↑ 2.02 1.34E-05 
Lysmd1 ↑ 1.54 2.44E-02 95138879 - 95141161 ↑ 1.51 1.28E-02 
Macrod1 ↑ 1.49 2.20E-02 7094765 - 7097602 ↑ 1.79 6.04E-11 
Maml2 ↑ 1.90 2.99E-02 13641092 - 13641763 ↑ 0.81 2.01E-02 
Map3k14 ↑ 1.42 3.32E-02 103229857 - 103232232 ↑ 1.66 5.96E-05 
Map3k6 ↑ 2.05 9.97E-03 133250744 - 133252158 ↑ 2.31 2.84E-16 
Mapkapk3 ↑ 1.58 3.34E-02 107263251 - 107264228 ↑ 0.88 2.86E-03 
Mast3 ↑ 1.48 3.55E-02 70779080 - 70781823 ↑ 0.84 1.36E-02 
Mcf2l ↑ 1.18 4.04E-02 13000444 - 13004454 ↑ 2.87 6.76E-25 
Megf8 ↑ 1.67 1.72E-02 25337346 - 25338865 ↑ 0.74 1.13E-02 
Mfsd12 ↑ 1.74 3.67E-02 81362408 - 81364394 ↑ 0.68 3.99E-02 
Mgll ↑ 1.46 3.35E-02 88822787 - 88823769 ↑ 2.08 2.12E-12 
Mir208b ↑ 1.94 3.58E-02 54978527 - 54979854 ↑ 2.85 2.19E-08 
Mn1 ↑ 1.73 1.69E-02 111418980 - 111421997 ↑ 1.37 3.56E-05 
Mon1a ↑ 1.51 3.29E-02 107900797 - 107903266 ↑ 1.31 4.60E-03 
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Mri1 ↑ 1.46 3.69E-02 84253835 - 84255149 ↑ 0.73 2.53E-02 
Mrpl34 ↑ 1.68 1.05E-02 71460614 - 71462721 ↑ 0.86 1.05E-03 
Mrps28 ↑ 1.58 4.82E-02 8881829 - 8882995 ↑ 0.67 6.64E-03 
Mrps6 ↑ 1.53 2.47E-02 92060796 - 92062119 ↑ 0.78 3.35E-03 
Mrvi1 ↑ 3.21 5.96E-03 110923076 - 110923802 ↑ 1.63 9.07E-09 
Msx1 ↑ 1.80 4.07E-02 37820909 - 37822016 ↑ 2.41 3.14E-11 
Mvp ↑ 1.49 3.15E-02 127001072 - 127002125 ↑ 1.81 9.76E-06 
Mxra8 ↑ 1.49 4.30E-02 155841408 - 155843078 ↑ 0.60 3.17E-02 
Myh11 ↑ 1.41 4.81E-02 14200357 - 14201353 ↑ 2.32 2.61E-17 
Myh14 ↑ 1.78 6.22E-03 44629695 - 44632638 ↑ 5.52 1.45E-61 
Myh6 ↑ 1.72 3.33E-02 54959588 - 54961529 ↑ 1.84 3.09E-05 
Myo10 ↑ 1.28 3.27E-02 25779454 - 25782156 ↑ 1.19 5.63E-04 
Myo18b ↑ 1.71 2.62E-02 112879074 - 112880299 ↑ 1.03 1.20E-04 
Myo1d ↑ 1.46 4.12E-02 80489627 - 80491772 ↑ 0.71 1.79E-02 
Myo5c ↑ 1.37 4.70E-02 75293796 - 75295062 ↑ 1.93 3.05E-06 
Mypop ↑ 1.69 4.79E-02 18987590 - 18988344 ↑ 1.59 2.08E-03 
Nacc2 ↑ 1.53 3.99E-02 26059829 - 26060817 ↑ 1.19 6.74E-05 
Chapter 7 
 
 
216 
Naif1 ↑ 1.60 4.67E-02 32452481 - 32453336 ↑ 0.89 1.28E-02 
Ncf4 ↑ 1.78 4.59E-02 78250081 - 78251187 ↑ 1.14 2.29E-02 
Nckipsd ↑ 1.34 2.81E-02 108813724 - 108815970 ↑ 0.94 1.13E-02 
Ncor2 ↑ 1.63 4.50E-02 125028100 - 125029563 ↑ 1.28 2.06E-04 
Ndufaf2 ↑ 1.77 4.78E-02 108062158 - 108062761 ↑ 0.92 6.47E-04 
Nfix ↑ 2.31 6.22E-03 84785098 - 84786543 ↑ 1.94 8.28E-09 
Nfkb2 ↑ 1.29 3.23E-02 46309430 - 46313711 ↑ 0.89 1.01E-02 
Nfkbie ↑ 2.13 2.45E-02 45558957 - 45559719 ↑ 0.98 4.11E-02 
Ng23 ↑ 1.24 4.79E-02 35030396 - 35032291 ↑ 3.34 2.31E-13 
Nlgn2 ↑ 1.67 2.61E-02 69823847 - 69826349 ↑ 1.04 1.27E-03 
Nod1 ↑ 1.72 1.41E-02 54942824 - 54945174 ↑ 2.05 8.89E-14 
Nod2 ↑ 1.57 2.39E-02 88663461 - 88665842 ↑ 3.09 1.02E-07 
Notch1 ↑ 1.67 1.98E-02 26464579 - 26465962 ↑ 0.69 3.66E-02 
Notch4 ↑ 1.88 3.35E-02 34566957 - 34567807 ↑ 1.33 2.66E-07 
Npr1 ↑ 2.31 4.78E-02 90464375 - 90465207 ↑ 0.87 1.81E-03 
Npr2 ↑ 1.88 1.63E-02 43632112 - 43633215 ↑ 1.28 3.96E-08 
Nr2f1 ↑ 1.97 2.46E-02 78194390 - 78196105 ↑ 2.37 4.00E-08 
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Osbp2 ↑ 1.70 3.41E-02 3862859 - 3863730 ↑ 1.10 2.35E-03 
Osgin1 ↑ 1.60 4.51E-02 119444619 - 119445849 ↑ 3.48 9.52E-08 
Otud7b ↑ 1.30 3.97E-02 96154484 - 96155879 ↑ 0.58 4.02E-02 
P2ry2 ↑ 1.47 3.52E-02 100997662 - 100999384 ↑ 1.79 1.59E-11 
Palm ↑ 1.28 4.78E-02 79818628 - 79821266 ↑ 0.93 3.40E-02 
Papln ↑ 1.46 1.67E-02 83773583 - 83779594 ↑ 1.73 4.48E-05 
Pbxip1 ↑ 1.46 4.78E-02 89432141 - 89433846 ↑ 0.59 1.99E-02 
Pcsk6 ↑ 2.10 4.86E-02 65871200 - 65871865 ↑ 1.55 8.21E-09 
Pde2a ↑ 1.44 4.40E-02 101504016 - 101505555 ↑ 1.01 1.20E-04 
Pdss2 ↑ 2.13 3.83E-02 43303465 - 43304210 ↑ 0.80 4.28E-03 
Pear1 ↑ 2.06 6.89E-03 87756120 - 87757146 ↑ 1.21 1.71E-04 
Peli2 ↑ 1.30 3.81E-02 48255615 - 48257024 ↑ 0.77 1.72E-02 
Per3 ↑ 1.41 3.60E-02 151011911 - 151014065 ↑ 1.57 2.67E-07 
Phc3 ↑ 1.71 3.97E-02 30948304 - 30948991 ↑ 0.70 3.62E-02 
Phldb1 ↑ 1.93 3.08E-02 44733265 - 44734109 ↑ 1.67 2.07E-09 
Phospho1 ↑ 2.11 3.37E-03 95830140 - 95831709 ↑ 1.84 1.88E-11 
Pitpnm2 ↑ 1.44 4.67E-02 124120169 - 124124457 ↑ 0.70 8.56E-03 
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Plec ↑ 1.91 2.99E-02 76205330 - 76206319 ↑ 1.16 1.23E-03 
Plekha6 ↑ 1.55 4.48E-02 133293353 - 133294301 ↑ 1.87 3.30E-13 
Plekhg5 ↑ 2.41 1.36E-03 152107318 - 152108849 ↑ 1.19 4.52E-04 
Plxdc2 ↑ 2.48 4.75E-02 16586295 - 16586847 ↑ 2.12 4.55E-11 
Pmepa1 ↑ 1.61 3.35E-02 173234133 - 173235416 ↑ 1.54 9.21E-11 
Podn ↑ 1.22 4.77E-02 108020699 - 108022954 ↑ 4.08 3.86E-22 
Polrmt ↑ 1.52 3.41E-02 79734717 - 79742099 ↑ 1.16 3.68E-04 
Ppargc1b ↑ 1.49 4.81E-02 61307050 - 61308172 ↑ 1.68 5.94E-06 
Ppp1r10 ↑ 1.55 3.82E-02 35930029 - 35932186 ↑ 1.72 2.64E-07 
Ppp1r3c ↑ 1.95 4.32E-02 36731165 - 36731830 ↑ 2.15 8.03E-16 
Psd ↑ 1.29 3.23E-02 46309430 - 46313711 ↑ 1.84 9.99E-04 
Psmb8 ↑ 1.98 2.20E-02 34196368 - 34197296 ↑ 2.08 1.13E-08 
Ptch2 ↑ 1.35 4.25E-02 117107836 - 117111873 ↑ 1.08 4.30E-02 
Ptgir ↑ 1.59 4.98E-02 16906565 - 16907934 ↑ 2.09 7.00E-04 
Rab6b ↑ 1.38 3.59E-02 103118970 - 103120332 ↑ 1.68 6.72E-09 
Ralbp1 ↑ 1.14 4.75E-02 65848552 - 65851402 ↑ 1.19 1.43E-06 
Rap1gap ↑ 1.48 4.39E-02 137719871 - 137720952 ↑ 1.89 2.68E-05 
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Rarg ↑ 2.14 4.83E-02 102249686 - 102250299 ↑ 1.70 4.78E-07 
Relb ↑ 3.39 6.89E-03 19619260 - 19620102 ↑ 0.89 1.01E-02 
Rfx1 ↑ 1.41 4.15E-02 84094363 - 84098192 ↑ 0.83 3.25E-02 
Rgl3 ↑ 1.43 3.35E-02 21990931 - 21992404 ↑ 1.73 3.29E-04 
Rps6ka4 ↑ 1.57 1.75E-02 6829671 - 6832708 ↑ 0.81 1.32E-02 
Rusc2 ↑ 1.52 2.61E-02 43414409 - 43417141 ↑ 1.15 7.05E-04 
Rxrg ↑ 1.33 4.66E-02 167631802 - 167632993 ↑ 5.33 2.46E-66 
Safb2 ↑ 1.54 3.93E-02 56565671 - 56567317 ↑ 1.36 1.06E-06 
Sall4 ↑ 1.28 3.60E-02 168754073 - 168757130 ↑ 1.35 1.92E-03 
Sbk1 ↑ 1.58 2.61E-02 126290775 - 126293217 ↑ 1.29 1.90E-05 
Scara5 ↑ 1.87 3.52E-02 65730174 - 65731429 ↑ 1.30 1.63E-04 
Scarf2 ↑ 2.48 2.17E-03 17802131 - 17804955 ↑ 1.32 1.16E-03 
Scube2 ↑ 2.10 4.80E-02 109837913 - 109838588 ↑ 1.06 1.60E-04 
Sdccag8 ↑ 1.55 4.69E-02 177017866 - 177018686 ↑ 0.97 1.97E-03 
Sema6b ↑ 1.88 3.35E-02 56123056 - 56125215 ↑ 2.27 1.82E-05 
Sgca ↑ 1.73 4.94E-02 94963049 - 94963630 ↑ 1.78 1.44E-08 
Sgta ↑ 1.33 4.82E-02 81043791 - 81045761 ↑ 0.67 4.58E-02 
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Sh3tc1 ↑ 1.70 4.67E-03 35705494 - 35708182 ↑ 0.81 2.20E-02 
Shank3 ↑ 2.60 4.67E-03 89556952 - 89558524 ↑ 1.61 1.88E-08 
Sipa1 ↑ 1.53 8.76E-03 5653761 - 5656625 ↑ 1.14 4.59E-04 
Slc25a29 ↑ 1.30 4.95E-02 108825446 - 108828040 ↑ 3.37 1.72E-16 
Slc39a3 ↑ 1.84 2.30E-02 81030517 - 81032070 ↑ 1.63 4.54E-07 
Slc45a3 ↑ 1.99 2.30E-02 131981009 - 131981843 ↑ 1.11 1.35E-02 
Slc7a10 ↑ 1.48 4.33E-02 35202132 - 35205838 ↑ 1.93 1.93E-04 
Slco3a1 ↑ 3.10 6.04E-03 74421951 - 74422723 ↑ 2.05 1.87E-17 
Smcr7 ↑ 1.40 3.96E-02 60730159 - 60732094 ↑ 2.10 2.99E-16 
Solh ↑ 1.60 2.72E-02 25958845 - 25961076 ↑ 1.49 1.03E-02 
Sorl1 ↑ 1.96 3.18E-02 41979093 - 41979796 ↑ 1.24 1.23E-03 
Spef1 ↑ 1.48 3.99E-02 131170987 - 131173103 ↑ 1.23 2.20E-05 
Speg ↑ 1.47 3.35E-02 75405935 - 75407470 ↑ 1.52 1.13E-08 
Sstr3 ↑ 2.05 3.88E-02 78543835 - 78544755 ↑ 2.78 3.94E-08 
St3gal3 ↑ 1.16 3.58E-02 118096582 - 118098689 ↑ 0.81 3.99E-03 
Stab1 ↑ 1.35 3.88E-02 31139464 - 31142361 ↑ 0.87 8.86E-03 
Stap2 ↑ 1.40 4.39E-02 55999044 - 56001363 ↑ 1.45 8.56E-08 
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Stard8 ↑ 2.13 2.61E-02 99072348 - 99073231 ↑ 1.17 1.81E-05 
Stk11 ↑ 1.60 4.12E-02 80129310 - 80133513 ↑ 1.20 6.97E-05 
Stoml1 ↑ 1.48 3.84E-02 58259800 - 58260562 ↑ 1.17 2.39E-04 
Taf1c ↑ 1.10 4.69E-02 119600176 - 119603791 ↑ 1.96 2.49E-07 
Taf3 ↑ 1.46 4.02E-02 9930279 - 9931159 ↑ 1.39 1.42E-05 
Tap1 ↑ 1.98 2.20E-02 34196368 - 34197296 ↑ 0.88 3.19E-02 
Tap2 ↑ 1.74 3.77E-02 34214944 - 34215755 ↑ 0.90 1.61E-02 
Tbc1d2 ↑ 1.29 4.60E-02 46606251 - 46607428 ↑ 1.26 1.47E-02 
Tbx3 ↑ 2.33 4.19E-03 119680061 - 119681185 ↑ 0.70 3.10E-02 
Tbxa2r ↑ 1.92 2.72E-02 81332045 - 81333506 ↑ 1.66 1.06E-04 
Tcap ↑ 2.69 2.01E-02 98383882 - 98384795 ↑ 3.79 1.05E-18 
Tcf15 ↑ 1.58 3.59E-02 152140278 - 152141332 ↑ 1.94 1.62E-06 
Tecpr1 ↑ 1.42 3.55E-02 144205843 - 144207095 ↑ 1.99 1.02E-13 
Tecr ↑ 2.63 8.51E-03 83573567 - 83574196 ↑ 1.13 1.77E-04 
Tesc ↑ 1.47 3.67E-02 118060928 - 118061955 ↑ 4.17 1.64E-39 
Tmem104 ↑ 1.84 3.66E-02 115242983 - 115244469 ↑ 0.97 1.57E-02 
Tmem200b ↑ 1.55 3.56E-02 131922232 - 131923460 ↑ 1.50 1.02E-02 
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Tmub1 ↑ 1.63 4.15E-02 24445489 - 24446363 ↑ 0.95 3.77E-02 
Tnfaip2 ↑ 2.17 2.14E-02 111444844 - 111446519 ↑ 2.55 1.21E-17 
Tnfaip8l2 ↑ 1.54 2.44E-02 95138879 - 95141161 ↑ 3.15 3.86E-08 
Tnni3 ↑ 1.49 2.82E-02 4526667 - 4527949 ↑ 2.07 1.53E-06 
Tnrc6b ↑ 1.68 3.73E-02 80876028 - 80876967 ↑ 1.21 1.16E-03 
Tnrc6c ↑ 1.16 4.12E-02 117757887 - 117761940 ↑ 1.46 2.04E-07 
Tnxb ↑ 2.12 2.50E-02 34670273 - 34673576 ↑ 1.99 2.05E-08 
Tppp3 ↑ 1.34 4.39E-02 105472175 - 105473374 ↑ 1.95 5.43E-07 
Traf1 ↑ 1.67 1.38E-02 34943457 - 34944493 ↑ 1.70 2.43E-03 
Trim11 ↑ 1.60 3.73E-02 58989998 - 58991076 ↑ 0.61 2.76E-02 
Trim56 ↑ 1.30 3.38E-02 137112677 - 137114840 ↑ 0.72 2.59E-02 
Trim72 ↑ 2.12 2.15E-02 128009711 - 128010714 ↑ 4.13 1.25E-46 
Trpv4 ↑ 2.37 2.74E-02 114630265 - 114631025 ↑ 2.74 2.91E-10 
Tshz3 ↑ 3.16 4.99E-03 36695045 - 36695782 ↑ 1.13 1.25E-02 
Ttc28 ↑ 1.33 3.67E-02 111269978 - 111271874 ↑ 0.60 4.29E-02 
Ttc7 ↑ 1.84 4.01E-02 87311949 - 87312805 ↑ 1.45 2.69E-04 
Tyrobp ↑ 2.30 4.19E-02 30414242 - 30414800 ↑ 1.52 9.99E-07 
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Ubxn10 ↑ 1.35 2.29E-02 138719194 - 138722070 ↑ 2.25 1.46E-08 
Ucp3 ↑ 1.32 4.17E-02 100479196 - 100481533 ↑ 3.63 5.47E-18 
Ulk4 ↑ 1.73 4.79E-02 121154949 - 121155696 ↑ 0.76 6.23E-03 
Unc13a ↑ 1.85 2.61E-02 71662276 - 71663908 ↑ 0.97 4.93E-04 
Unc93b1 ↑ 1.33 4.19E-02 3942187 - 3944517 ↑ 1.32 2.97E-06 
Ush1c ↑ 1.77 4.93E-02 46208528 - 46209358 ↑ 1.09 3.55E-03 
Ushbp1 ↑ 1.60 2.26E-02 71386905 - 71388152 ↑ 2.35 5.39E-13 
Vav1 ↑ 2.25 1.52E-02 57278825 - 57279692 ↑ 1.16 2.85E-03 
Vegfb ↑ 1.69 3.52E-02 6985122 - 6985876 ↑ 0.88 2.91E-03 
Vps18 ↑ 1.39 3.87E-02 119296487 - 119298278 ↑ 1.08 3.22E-02 
Vwf ↑ 1.30 2.67E-02 125641811 - 125643512 ↑ 1.04 2.08E-03 
Wdr81 ↑ 1.63 9.83E-03 75443611 - 75446317 ↑ 0.91 1.68E-02 
Wdtc1 ↑ 2.87 3.93E-02 133294094 - 133294565 ↑ 0.70 2.13E-02 
Wfs1 ↑ 1.46 3.24E-02 36966382 - 36968901 ↑ 1.93 1.69E-16 
Wipf3 ↑ 2.69 4.64E-02 54485559 - 54486263 ↑ 1.69 1.79E-10 
Zbtb48 ↑ 1.32 3.52E-02 152019157 - 152022502 ↑ 1.19 4.62E-03 
Zbtb7a ↑ 1.56 4.32E-02 81143558 - 81145675 ↑ 1.27 2.21E-03 
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Zc3h18 ↑ 1.41 4.72E-02 122402949 - 122403746 ↑ 0.75 3.10E-02 
Zdhhc1 ↑ 1.34 4.39E-02 105472175 - 105473374 ↑ 0.86 2.36E-02 
Zfhx3 ↑ 1.40 1.05E-02 108954613 - 108957252 ↑ 1.46 3.41E-05 
Zfp629 ↑ 1.66 3.74E-02 127610585 - 127612444 ↑ 1.20 1.69E-06 
Zfp641 ↑ 1.81 4.07E-02 98288346 - 98289173 ↑ 0.84 1.41E-02 
Zfp652 ↑ 2.11 3.37E-03 95830140 - 95831709 ↑ 1.35 9.56E-08 
Zfp668 ↑ 1.44 3.27E-02 127865867 - 127868548 ↑ 0.96 2.40E-02 
Zfp775 ↑ 1.77 2.32E-02 48619171 - 48621394 ↑ 1.74 4.40E-08 
Zfp787 ↑ 1.79 1.79E-02 6131469 - 6133450 ↑ 1.17 1.65E-05 
Zfyve21 ↑ 1.66 4.15E-02 111810494 - 111811422 ↑ 0.69 1.17E-02 
Zmynd8 ↑ 1.39 4.62E-02 165889339 - 165890943 ↑ 0.63 1.78E-02 
Bnip2 ↓ -2.17 2.81E-02 69997546 - 69998309 ↑ 0.92 4.85E-04 
C1qtnf7 ↓ -2.81 1.40E-02 43555085 - 43555778 ↑ 1.07 1.86E-03 
Cmya5 ↓ -2.07 4.67E-02 93145841 - 93146925 ↑ 1.82 1.02E-09 
D9Ertd402e ↓ -1.91 4.52E-02 122808301 - 122808996 ↑ 2.23 7.75E-16 
Derl2 ↓ -1.73 2.14E-02 71020535 - 71021954 ↑ 0.97 4.79E-04 
Dnajc21 ↓ -1.33 4.39E-02 10466438 - 10468104 ↑ 0.66 3.26E-02 
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Dnm3 ↓ -2.39 3.59E-02 162018394 - 162019194 ↑ 2.01 9.05E-08 
Dst ↓ -1.83 4.81E-02 34054081 - 34054715 ↑ 1.71 3.10E-05 
Ebf1 ↓ -1.92 3.97E-02 44627615 - 44628511 ↑ 2.09 2.51E-05 
Egfr ↓ -1.80 4.39E-02 16886677 - 16887318 ↑ 0.95 1.29E-02 
Frmd6 ↓ -1.88 2.81E-02 70872447 - 70873246 ↑ 0.64 1.43E-02 
Gpatch2 ↓ -1.70 4.39E-02 187220824 - 187221949 ↑ 0.82 1.14E-02 
Grm1 ↓ -1.95 4.78E-02 10809589 - 10810388 ↑ 5.83 5.71E-20 
Hadha ↓ -1.33 4.15E-02 30140414 - 30141494 ↑ 1.58 4.16E-06 
Immp2l ↓ -1.96 4.55E-02 41580807 - 41581481 ↑ 1.68 4.27E-09 
Klf7 ↓ -2.66 2.55E-02 64117428 - 64118155 ↑ 1.00 4.54E-04 
Klf9 ↓ -2.24 1.28E-02 23150327 - 23151006 ↑ 2.76 2.64E-26 
Max ↓ -1.33 3.73E-02 76955993 - 76957657 ↑ 1.12 1.00E-05 
Mbnl2 ↓ -2.16 4.01E-02 120302265 - 120302906 ↑ 0.72 1.65E-02 
Mfn1 ↓ -2.13 2.36E-02 32532277 - 32533052 ↑ 0.69 2.12E-02 
Nceh1 ↓ -1.84 4.03E-02 27187439 - 27188208 ↑ 1.30 8.30E-07 
Neat1 ↓ -2.42 1.90E-03 5843466 - 5844277 ↑ 3.39 2.11E-18 
Pik3r1 ↓ -2.05 2.78E-02 101713227 - 101713992 ↑ 1.05 2.09E-03 
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Ppap2a ↓ -2.05 3.90E-02 112802901 - 112803453 ↑ 1.04 5.02E-05 
Ppap2b ↓ -2.54 3.32E-02 105159954 - 105160823 ↑ 1.19 8.10E-07 
Prune2 ↓ -2.13 3.23E-02 17078101 - 17078805 ↑ 1.63 1.25E-05 
Ptprr ↓ -1.93 3.93E-02 116049566 - 116050157 ↑ 2.36 3.51E-05 
Rcan2 ↓ -3.04 2.20E-02 43968520 - 43969005 ↑ 0.67 1.47E-02 
Ryr2 ↓ -1.65 4.82E-02 11751798 - 11752652 ↑ 1.16 9.93E-03 
Sgcd ↓ -1.73 4.80E-02 47203138 - 47203703 ↑ 1.30 6.17E-05 
Srgn ↓ -1.77 3.73E-02 62506139 - 62506905 ↑ 1.53 2.87E-07 
Tcf4 ↓ -2.05 3.61E-02 69581499 - 69582257 ↑ 1.84 7.86E-12 
Upf2 ↓ -1.70 4.66E-02 6010546 - 6011377 ↑ 0.86 1.10E-02 
Zbtb16 ↓ -1.87 4.96E-02 48734322 - 48734883 ↑ 1.89 1.31E-06 
Zfp703 ↓ -2.00 4.49E-02 26974168 - 26974914 ↑ 1.70 8.84E-07 
Zfp827 ↓ -2.11 2.13E-02 79126106 - 79126995 ↑ 0.83 4.72E-03 
1110018J18Rik ↓ -1.81 3.20E-02 64309872 - 64310578 ↓ -1.10 1.72E-04 
Bmpr1a ↓ -1.71 3.39E-02 34435613 - 34437154 ↓ -0.91 2.69E-03 
Cetn3 ↓ -1.60 4.79E-02 81782190 - 81782787 ↓ -0.86 4.78E-03 
Chic2 ↓ -1.94 4.69E-02 75019723 - 75020325 ↓ -0.81 5.39E-03 
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Dcaf13 ↓ -2.45 4.04E-02 39139987 - 39140604 ↓ -0.56 4.79E-02 
Diap3 ↓ -2.46 3.48E-02 86963147 - 86963860 ↓ -2.89 2.56E-12 
Fam151b ↓ -2.76 1.74E-02 92486922 - 92487525 ↓ -1.13 1.42E-02 
Fam48a ↓ -2.05 3.88E-02 54707950 - 54708490 ↓ -1.10 3.62E-03 
Herc3 ↓ -2.05 3.74E-02 58834199 - 58834857 ↓ -1.42 5.68E-07 
Herpud2 ↓ -1.61 4.80E-02 25135646 - 25136712 ↓ -0.65 2.10E-02 
Kif26b ↓ -2.35 3.55E-02 178702892 - 178703541 ↓ -2.91 7.69E-13 
Lass6 ↓ -2.11 4.39E-02 68866458 - 68867045 ↓ -1.61 8.41E-07 
Map4k3 ↓ -1.76 4.77E-02 80630120 - 80630734 ↓ -0.78 1.24E-02 
Mapk1ip1l ↓ -1.56 4.12E-02 47302783 - 47303676 ↓ -1.23 5.62E-05 
Nudt21 ↓ -2.56 6.32E-03 94028763 - 94029608 ↓ -0.81 3.32E-02 
Orc5 ↓ -1.92 2.79E-02 22547464 - 22548312 ↓ -0.75 1.33E-02 
Pam ↓ -2.15 3.62E-02 97900281 - 97901054 ↓ -1.58 1.46E-07 
Parg ↓ -2.42 4.88E-02 32213077 - 32213570 ↓ -1.16 2.84E-04 
Pdcl ↓ -1.72 4.66E-02 37351660 - 37352545 ↓ -0.96 1.68E-03 
Pias2 ↓ -2.69 2.16E-02 77144877 - 77145549 ↓ -1.03 5.98E-05 
Pitrm1 ↓ -1.17 4.82E-02 6549449 - 6551096 ↓ -0.69 4.88E-03 
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Ptpn9 ↓ -1.89 4.07E-02 57048831 - 57049518 ↓ -1.51 1.66E-08 
Rad21 ↓ -2.52 4.39E-02 51962496 - 51963121 ↓ -1.83 4.68E-14 
Scfd1 ↓ -1.96 4.82E-02 51431523 - 51432144 ↓ -1.00 1.20E-03 
Sowahc ↓ -2.07 3.67E-02 59225878 - 59226582 ↓ -1.89 1.44E-04 
Sri ↓ -2.03 3.96E-02 8059823 - 8060539 ↓ -0.72 7.17E-03 
St6galnac3 ↓ -2.08 3.62E-02 153310189 - 153310858 ↓ -1.16 4.32E-02 
Thsd4 ↓ -1.46 4.85E-02 60466595 - 60467605 ↓ -1.05 5.35E-03 
Zdhhc6 ↓ -1.75 4.67E-02 55313676 - 55315273 ↓ -0.65 2.55E-02 
Zfpm2 ↓ -2.01 4.76E-02 41080783 - 41081495 ↓ -1.39 5.44E-05 
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7.2. Comparison of PCM1 staining and sorting protocol (from Chapter 5). 
 Year 
  
2009 2011 2012 2014 2015 2015 2015 
 Lab and 
reference 
 
  
Bergmann 
(Bergmann 
et al., 
2009) 
Bergmann 
(Bergmann 
et al., 
2011) 
Bergmann 
(Bergmann 
and 
Jovinge, 
2012) 
Hein 
(Gilsbach 
et al., 2014) 
Hein 
(Preissl et 
al., 2015a) 
Bergmann 
(Bergmann 
et al., 
2015) 
Bergmann 
(Alkass et 
al., 2015) 
Note 
  
TnnT, TnnI 
TnnT, 
TnnI, 
PCM1 
PCM1 
Method 
Refer 
2011 
Bergmann 
refer 2014 
Hein 
Human 
(more 
similar to 
2011) 
mouse, 
refer 2015 
human 
Buffer 
1. 
Lysis 
Buffer 
0.32 M sucrose √ √ √ √ - √ √ 
10 mM Tris-HCl 
(pH √ 8) 
√ √ √ √ √ √ √ 
5 mM CaCl2 √ √ √ √ √ √ √ 
5 mM 
magnesium 
3mM 3mM √ 3mM 3mM √ √ 
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acetate 
2.0 mM EDTA √ √ √ √ √ √ √ 
0.5 mM EGTA √ √ √ √ √ √ √ 
1 mM DTT √ √ √ √ √ √ √ 
proteinase 
inhibitor 
√ NA NA NA √ NA NA 
2. 
Sucrose 
buffer 
2.1 M sucrose 
(2.1 & 2.2 
M only has 
different in 
sucrose) 
√ √ √ 1M √ √ 
10 mM Tris-HCl 
(pH √ 8) 
√ √ √ √ √ √ √ 
5 mM 
magnesium 
acetate 
3mM 3mM √ 3mM 3mM √ √ 
1 mM DTT √ √ √ √ - - - 
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3. 
Nuclei 
storage 
buffer 
(NSB 
plus) 
0.44 M sucrose 0.43M 0.43M √ 0.43M 
use staining 
buffer 
(PBS+ 
5%BSA+ 
0.2% Igepal 
CA-630) 
√ √ 
10 mM Tris-HCl 
(pH √ 7.2) 
√ √ √ √ √ √ 
70 mM KCl √ √ √ √ √ √ 
10 mM MgCl2 2mM 2mM √ 2mM √ √ 
1.5 mM 
spermine 
- - √ - √ √ 
5mM EGTA √ √ - √ - - 
Isolation 
protocol 
1 tissur amount 10g NA 1g NA NA 8-10g NA 
2 
50 ml Falcon 
tube filled with 
15 ml of lysis 
buffer 
200mL 200mL √ 
2011 
Bergmann 
protocol 
3mL no vol NA 
3 
blend with speed 
9, 10 min 
√ √ - - √ - 
4 Homogenize at 20000rpm, 20000rpm, √ NA √ √ 
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24,000 rpm for 
10 sec. 
8s 10s 
5 
Add 15 ml of 
lysis buffer to 
dilute the 
homogenate to 
30 ml. 
add triton 
x-100 to 
0.2%, no 
add more 
lysis 
- √ 
3mL + 0.4% 
Triton-X 
no add 
more lysis 
buffer 
NA 
6 
Perform 8 
strokes use a 
glass douncer. 
√ √ √ - √ √ 
7 
Filter: 70 μm 
nylon mesh cell 
strainer. 
100->70 
um strainer 
100->70 
um strainer 
100->70 
um strainer 
40um 
100->60 
um strainer 
100->60 
um 
strainer 
8 
1000 x g, 10 
min, 4 °C 
divide 6 
tube, 8min 
700g, 8min 700g 
2mL (with 
0.2% 
Triton-X) 
then spin, 
5min 
700g 600g 
9 resuspense √ no vol √ no vol, 1M no vol no vol 
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30mL 2.1M 
sucrose buffer 
sucrose 
10 
layer on 10mL 
2.2M sucrose 
√ 
same vol, 
2.1M 
√ 
no vol, 1M 
sucrose 
same vol, 
2.1M 
same vol, 
2.1M 
11 30000g, 1h, 4 °C √ √ 13000g 1000g, 5min 13000g 13000g 
12 
1 ml of nuclei 
storage buffer 
1.5mL 1.5mL √ 
0.5mL 
staining 
buffer 
no vol no vol 
FACS 
13 
Primary Ab, 
4 °C, ON 
at least 
30mins 
NA √ 30min NA √ √ 
 
PCM1 (Sigma), 
1:100 
- (1:1000) (1:500) (1:1000) (1:1000) 
Santa, 
1:200 
Santa, 
1:200 
 
TnnT (Thermo), 
1:100 
- 
direct 
conjugate 
A488 
- - - - - 
 
TnnT (Abcam 
Ab10214), 1:100 
- - - - - - 
 
TnnT (Abcam √ - - - - - 
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Ab10224), 1:800 
 
TnnI (Millipore 
MAB3152), 
1:800 
√ - - - - - 
14 
add double vol 
of primary Ab 
NA 
no vol, (at 
least 1 
time) 
NA NA NA NA 
15 
1000 x g, 10 
min, 4 °C 
NA 700g NA NA 700g NA 
16 
secondary Ab 
1:500, 4 °C, 1h 
NA 
A488, 
1:1000 
A488/ 
A647, 
1:1000 (not 
sure direct 
conjugation) 
1:1000 (not 
sure direct 
conjugation) 
PE, Santa, 
1:100 
A488, no 
dilution 
17 
add double vol 
of primary Ab 
NA 
no vol, (at 
least 1 
time) 
NA NA NA NA 
18 1000 x g, 10 NA NA 700g NA NA 700g NA 
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min, 4 °C 
19 
nuclei fix in BD 
fix/Perm 
20mins, 4 °C 
before sort 
- - - - - NA √ 
20 1500g, 15mins NA NA √ NA NA 1200g NA 
Nuclei 
marker 
Nuclei 
marker 
Hoechst for ploidy NA 
DRAQ5, 
1:500 
7-AAD, 
1:500 
DRAQ7, 
1:200 
DRAQ5, 
1:1000 
Hoechst 
DAPI - NA - (1:1000) (1:1000) - - 
  
DRAQ5 
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All we have to decide 
is what to do with the time that is given us. 
Gandalf in The Lord of the Ring. 
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